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 Leishmaniasis and Human African trypanosomiasis are tropical diseases caused by 
kinetoplastid parasites that together affect over 12 million people, with an estimated 400 
million at risk worldwide.  Both are potentially fatal, yet the current treatments available 
are expensive and many have toxic side effects.  Emerging resistance to many current 
drugs is also a concern; novel therapeutic agents are therefore urgently required. 
 
 One novel target for drug discovery previously identified in the group is 
sphingolipid synthesis.  Sphingolipids are ubiquitous biomolecules found in nature and 
are both structural membrane components and signalling molecules.  Inositol 
phosphorylceramide synthase (IPCS) is an essential enzyme involved in kinetoplastid 
sphingolipid synthesis that has no mammalian equivalent, making it an attractive drug 
target.  Whilst specific inhibitors of the fungal IPCS are known, they are unsuitable as 
pharmaceuticals.  The overall aim of this project was to identify novel inhibitors of this 
enzyme that could be further investigated as potential antikinetoplastid drugs. 
 
 The first stage involved the construction of Saccharomyces cerevisiae strains as 
expression systems of the kinetoplastid IPCS enzymes.  The strain complemented with 
the Leishmania major enzyme was subsequently used in the development and 
optimisation of a robust high throughput screening (HTS)-compatible assay.  This was 
used to screen the 1.8 million compound library stored at the GlaxoSmithKline research 
site in Tres Cantos in what is believed to be the largest screening project undertaken by 
an academic group to date.  500 compounds were identified as selective inhibitors of the 
L. major IPCS enzyme, and 216 of these were selected for additional investigation. 
 
 Further compound triage was achieved by means of a screening process involving 
multiple in cellulo assays against both Leishmania parasites and mammalian cells.  Six 
compounds demonstrating both high potency and selectivity were identified.  Following 
additional biochemical testing, the two most potent compounds were found to share a 
common benzazepane chemical structure.  Investigation of analogues of these 
compounds permitted the identification of preliminary structure-activity relationship 
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1.1 Thesis Synopsis 
 
 The aim of this work is to identify novel small molecule inhibitors of the inositol 
phosphorylceramide synthase (IPCS) enzyme from trypanosomatid parasites, with a 
particular focus on Leishmania major.  This enzyme represents a promising drug target 
against the diseases caused by these parasites.  This chapter presents a review of the 
areas of work central to this project, beginning with an overview of the diseases 
leishmaniasis and human African trypanosomiasis, which are caused by trypanosomatid 
parasites.  The structure and function of sphingolipids will subsequently be summarised, 
along with the differences in metabolism observed between different kingdoms; these 
differences form the basis of this project.  Finally, the process of drug discovery by high 
throughput screening (HTS) will be discussed.  
 
 Chapter 2 reports the construction and testing of yeast strains engineered to produce 
the trypanosomatid IPCS enzymes, whilst the development and implementation of the 
HTS-compatible assay is covered in chapter 3.  Chapter 4 reports the identification of a 
lead compound family following further screening, with structure-activity relationships 
(SARs) being explored in chapter 5.  Conclusions and future work are discussed in 
chapter 6, whilst materials and methods are described in chapter 7. 
 
1.2 Neglected Tropical Diseases 
 
 The neglected tropical diseases (NTDs) are a group of infections which currently 
affect more than 1 billion people globally,
1
 with the majority of those affected living in 
developing countries characterised by poverty, poor sanitation and a lack of education 
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and appropriate medical care.
2, 3
  It is estimated that NTDs cause in the region of 
500,000 deaths per annum,
4
 as well as being responsible for approximately 48 million 
disability-adjusted life years lost each year.
5
  NTDs have also been linked to an 
increased susceptibility to the human immunodeficiency virus (HIV), with widespread 




 Of the diverse group of NTDs, 17 have been prioritised by the World Health 
Organisation (WHO); these diseases are endemic in 149 countries and cost developing 
economies billions of dollars each year.
1
  These 17 diseases are collectively caused by 
four distinct types of infective pathogen; helminth worms, viruses, bacteria and 
protozoa.  In this last group, the three diseases – leishmaniasis (Leishmania spp.), 
human African trypanosomiasis (HAT, Trypanosoma brucei) and American 
trypanosomiasis (Chagas disease, Trypanosoma cruzi) – are caused specifically by 
trypanosomatid parasites. 
 
 Trypanosomatids belong to the phylogenetic class Kinetoplastida, a group of 
single-cell, flagellated parasites that are distinguished by the presence of a region 
containing a large mass of mitochondrial DNA, termed the kinetoplast, in their single 
mitochondrion.
7
  There are two separate orders within the Kinetoplastida class (Figure 
1–1): Trypanosomatidae, which are characterised by possessing only a single flagellum 
and a small kinetoplast; and Bodonidae, which are biflagellate and possess a larger 
kinetoplast.
8
  Another feature of the trypanosomatid parasites is that they are dixenous 



































1.2.1.1 Introduction and Clinical Manifestations 
 
 There are more than 30 known species of Leishmania; these can be classified into 3 
distinct subgenera (Figure 1–1).  L. (Leishmania) spp. and L. (Viannia) spp. differ 
slightly in their colonisation of the insect host, whilst L. (Sauroleishmania) spp. infect 
reptile rather than mammalian hosts.
10
  In total, 20 species are known to be pathogenic 
to humans; these are distributed across 98 countries on 5 continents (Figure 1–2)
11, 12
 
and in total 310 million people are currently at risk of infection.  It is estimated that 
there are approximately 1.3 million new cases annually, although less than half of these 
are officially recorded with data from Africa being especially sparse.
13
  There are three 
distinct forms of leishmaniasis, with the clinical manifestations differing according to 

















Figure 1–1: The taxonomy of Kinetoplastida (for clarity, the only species 
of Leishmania shown are those of major medical importance to humans) 
 




 Cutaneous leishmaniasis (CL) is the most common and least severe form of 
leishmaniasis and is predominantly caused by the Old World species L. aethiopica,      
L. major and L. tropica in the Eastern hemisphere, and by the New World species        
L. braziliensis and L. mexicana in the Western hemisphere.
14
  The disease first presents, 
often after two weeks to two months, as a papule at the site of infection which is 
commonly the exposed skin of the face, arms or legs.  This then evolves to form a 
nodular plaque before progressing to a large, ulcerative lesion;
15
 although this is usually 
painless, it can become uncomfortable if it is located close to a joint or if it becomes 
infected.  It is not uncommon for satellite papules or lesions, as well as subcutaneous 
a 
b 
Figure 1–2: The global distribution of (a) cutaneous leishmaniasis (reproduced from WHO
11
 
with permission) and (b) visceral leishmaniasis (reproduced from WHO
12
 with permission) 
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induration, to develop around the site of the primary lesion.
16
  The majority of cases of 
CL regress and cure spontaneously, although this often takes in excess of 12 months.  
As a result, patients are often left with permanent scarring which, whilst not generally 
debilitating, can be highly disfiguring. 
 
 Mucocutaneous leishmaniasis (MCL) is predominantly a disease associated with 
New World species of Leishmania with the majority of cases occurring in Brazil, 
Bolivia and Peru; however, cases due to the Old World species L. donovani, L. infantum 
and L. major have also been reported.
17
  The disease usually manifests several years 
after the presentation of the primary lesions of CL as an infection of the mucosal 
membranes.  The progression of the disease is slow in comparison to CL, with the 
mucosal lesions developing over a period of several years.
18
  Eventually these lesions 
can lead to the destruction of the mucosa and cartilage of the mouth, nose and throat 
which can, in some cases, be fatal if left untreated.
14
  Even if treated successfully, 





 Visceral leishmaniasis (VL), also known as kala-azar, is the most severe form of 
the disease and is usually fatal within 2 years if left untreated.
20
  The primary causative 
agents of the disease are L. donovani, which is prevalent in Africa and the Indian 
subcontinent, and L. infantum, which is responsible for cases in Mediterranean regions 
and the New World.
21
  New World cases of VL were historically attributed to               
L. chagasi, but this species is now known to be L. infantum and the names are used 
synonymously.
22
  Visible symptoms include prolonged fever and drastic weight loss, 
although the major damage occurs internally.  Enlargement of the liver and spleen 
(hepatomegaly and splenomegaly respectively) and pancytopenia are the major clinical 
characterisations.
23
  Gastrointestinal bleeding and liver or heart failure are the most 
common causes of death in patients,
21
 with the disease presenting an estimated annual 
death toll of 40,000–50,000.
24
  Even if treated successfully, a common outcome of VL 
caused by L. donovani is the development of the chronic disease post-kala-azar dermal 
leishmaniasis (PKDL), which manifests as a maculopapular and nodular rash.  The 
disease acts as a reservoir for Leishmania parasites and usually requires an additional 
course of treatment.
25
  In addition, VL is the form of the disease most closely associated 
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1.2.1.2. Life Cycle 
 
 The life cycle of the Leishmania species is shown in Figure 1–3.
27
  It can be 
described as both dixenous, meaning the life cycle is split between two different host 
species, and dimorphic, with the parasite exhibiting morphologically distinct forms in 
the different hosts.  The cycle can proceed anthroponotically (utilising only human 



















 The cycle begins with the transfer of metacyclic (infective or stationary phase) 
promastigote parasites to the human host (1) via a bite from a female phlebotomine 
sandfly, the genus of which is dependent on the geographical location.  Old World 
leishmaniasis in the Eastern hemisphere is spread by sandflies of the genus 
Phlebotomus whilst the New World disease in the Western hemisphere (primarily in 
South America although cases have been reported as far north as Texas) is transmitted 
by sandflies of the genus Lutzomyia.
10, 29
  The parasites are passed into the bloodstream 
along with saliva and promastigote secretory gel, which synergistically recruit 
Figure 1–3: The life cycle of Leishmania spp. (reproduced from CDC
27
 with permission) 
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macrophages to the site of infection.
30
  Promastigotes are subsequently phagocytosed by 
the recruited macrophages and skin dendritic cells (2)
31
 and, within 72 hours, undergo 
metamorphosis to the amastigote form (3) induced by the increase in temperature and 
acidity (in comparison to the sandfly midgut).
32, 33
  The amastigote form, which is the 
cause of the disease in humans, is smaller and more ovoid in shape with a severely 
diminished flagellum.  This flagellum is non-motile and is thought instead to be 
involved in host-parasite signalling.
34
  Intramacrophage amastigotes proliferate by 
binary fission, eventually resulting in macrophage rupture and the release of amastigote 
parasites, leaving them free to infect other cells (4). 
 
 Infected macrophages and free parasites can also be ingested by a sandfly during 
the taking of a blood meal (5, 6).  The decrease in temperature and increase in pH in the 
sandfly midgut (or hindgut in the case of L. (Viannia) spp.) triggers the transformation 
of amastigotes into flagellated procyclic (non-infective or log phase) promastigotes,
10
 
which are able to adhere to the midgut epithelial cells and rapidly proliferate (7).
35
  
Once stationary phase has been achieved procyclic promastigotes differentiate to 
metacyclic promastigotes (metacyclogenesis), which have an elongated body and longer 
flagellum.  The metacyclic promastigotes subsequently migrate via osmotaxis to the 
proboscis (8) in preparation for transmission to a mammalian host during the sandfly’s 
next blood meal. 
 
1.2.1.3. Currently Available Treatments 
 
 The preferred treatment for leishmaniasis depends primarily on the form of the 
disease contracted and the identity of the infective species,
36
 with several possible 
therapies (both single drug treatments and drug combinations) available.  The most 

















1.2.1.3.1. Pentavalent Antimonials  
 
 Trivalent antimonial compounds were first reported for the treatment of CL and VL 
in 1912 and 1915 respectively.
37, 38






















































































Figure 1–4: The structures of currently used antileishmanial drugs 
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toxicity and in 1922 a superior pentavalent antimonial named urea stibamine was first 
utilised by Brahmachari as a chemotherapeutic agent against VL.
39
  Further progress 
over the next couple of decades resulted in the discovery of sodium stibogluconate (1) 
in 1945 and later meglumine antimoniate (2) which have been the primary treatments 
for both CL and VL for over 60 years.
40
   
 
 Despite being the preferred front line drug for the majority of Leishmania 
infections, pentavalent antimonials display an extremely poor safety profile.  Common 
side effects range in intensity from headaches and joint or muscle pain to pancreatitis 
and cardiotoxicity that may be fatal.
41, 42
  Both drugs also require intravenous 
administration at a dosage of 20 mg of Sb(V)/kg/day for 20 days and treatment is 




 The mode of action of pentavalent antimonial drugs has been extensively studied 
but is still not thoroughly understood; there are, however, two proposed mechanisms.  
The first is a prodrug model and suggests that Sb(V) is biologically reduced to Sb(III), 
and this is the species that exhibits antileishmanial activity.
40
  This reduction has been 
observed to be stage specific (which would explain the observation that amastigotes are 
more sensitive to Sb(V) than promatigotes) with parasite susceptibility to Sb(V) 
correlating with the level of Sb(V) reducing activity.
44
  The second proposed mode of 
action suggests that Sb(V) possesses intrinsic biological activity; sodium stibogluconate 





 As with many antimicrobials, one of the major challenges facing pentavalent 
antimonials is resistance.  The current recommended dosage is now much greater than 
in historic cases (up to the 1970s, a dosage of 10 mg of Sb(V)/kg/day for 10 days was 
utilised)
40
 and in the year 2000 it was observed that up to 60% of cases in India did not 
respond to pentavalent antimonial treatment due to resistance.
46
  Multiple studies of 
antimonial resistance have suggested the mechanisms to be multifactoral, meaning it is 











 Pentamidine (3) was first reported as a treatment for VL in India in 1949.
48
  
Typically administered as a formulation, treatment requires intramuscular or 
intravenous injection at a dosage of 4 mg/kg/day for pentamidine methanesulphonate or 
7 mg/kg/day for pentamidine isethionate.
49
  There are a number of side effects, the most 
serious of which is the irreversible condition diabetes mellitus type 1.
50
  Other side 





 The mode of action of pentamidine is not fully understood, although the 
mitochondrion is known to be involved.  This is demonstrated by the observation that 
resistant Leishmania parasites show a reduction in pentamidine accumulation in the 
mitochondrion compared to wild types due to an increase in drug efflux.
52
  The drug has 
also been shown to bind preferentially to the kinetoplast DNA due to the high adenine-




 As mentioned above, pentamidine, like the pentavalent antimonials, faces problems 
due to resistance.  In the 1990s, pentamidine was abandoned as the second line 
treatment for VL in India due to the declining response, high costs and numerous side 
effects.
53, 54
  However, the drug remains the first line treatment for CL caused by          
L. guyanensis in French Guiana, where a single injection of pentamidine isethionate 




1.2.1.3.3. Amphotericin B 
 
 Amphotericin B (AmB, 4) is a polyene antibiotic first isolated from Streptomyces 
nodosus in 1955,
56, 57
 and was first used to treat patients with VL in Brazil in 1963.
58
  
Treatment requires intravenous injection, and the drug is usually administered as a 
complex with deoxycholate.  Due to the multiple side effects (which include fever, renal 
failure and potentially fatal cardiovascular issues)
59
 AmB has historically been used as a 
second line treatment for leishmaniasis; however, increased resistance to pentavalent 
antimonials and pentamidine resulted in the adoption of AmB as the first line treatment 
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against VL in India in the 1990s.
60
  AmB deoxycholate is highly efficacious, displaying 




 AmB can also be administered as a liposomal formulation.  This exhibits milder 
side effects than AmB deoxycholate due to an increased uptake of the drug by the 
reticuloendothelial system; this formulation targets the drug to the cells harbouring the 
parasite and reduces renal uptake of the drug, resulting in lower levels of 
nephrotoxicity.
53, 62
  When it first came onto the market the high cost of this formulation 
precluded its use in the majority of countries where it was needed the most, meaning the 
cheaper but more toxic AmB deoxycholate was still generally used.
63
  An agreement 
made in 2005 between the WHO and the manufacturer, however, has lowered the cost 




 AmB functions by binding ergosterol, the predominant sterol component in 
Leishmania plasma membranes,
65
 for which it has a higher affinity than the cholesterol 
that is predominant in mammalian membranes.
66
  This initially results in the formation 
of non-aqueous pores which cause an increase in permeability of the cell membrane for 
monovalent cations, resulting in uneven ionic distribution.
67
  At larger concentrations of 
AmB aqueous pores form and allow greater movement of ions, protons and salts across 
the membrane, resulting in osmotic lysis.
68
  It has also been reported that the interaction 
of AmB with sterols in macrophage membranes actively prevents the entry of 





 In comparison to the other antileishmanial drugs, there has been little evidence over 
the years to suggest Leishmania resistance.  However, in 2012 an AmB-resistant clinical 
isolate of L. donovani was identified and was observed to have membranes completely 
devoid of ergosterol.
69
  This, along with the increased usage of liposomal formulations 
of AmB that have longer half lives, means that the increase of AmB resistance in the 












 Paromomycin (5) is an aminoglycoside first isolated in the 1950s from 
Streptomyces krestomuceticus,
70
 and has been used to treat CL since the 1960s and VL 
since 1990.
71, 72
  Whilst CL can be treated by topical application of creams containing 
paramomycin,
73
 when treating VL the drug must be administered parenterally at a 
dosage of 11 mg/kg/day for 21 days.
74
  Compared to other antileishmanials 
paromomycin exhibits few side effects, the most common of which are injection site 




 The mode of action of paromomycin is thought to be complex.  It has been shown 
to bind to the parasite ribosome and drastically increase the levels of misreading of 
mRNA during protein synthesis, whilst mammalian systems are affected at a much 
lower level;
75
 this could result in the formation of defective proteins which could 
hinder, or be actively detrimental to, parasite survival.  The drug has also been shown to 




 Paromomycin has not been as widely utilised as the other major antileishmanials 
and hence widespread resistance has not yet been observed, although clinical isolates of 
L. aethiopica from patients given the drug showed decreased sensitivity in vitro 
following treatment.
78
  This acquired, or secondary, resistance is of concern for patients 
with VL/HIV co-infection due to the high relapse rate.
70







 The final drug of choice for treating leishmaniasis is the phospholipid-like 
compound miltefosine (6), which was originally developed to prevent the spread of 
breast cancer.
80
  However, in 1996 it was shown to possess antileishmanial activity and 
in 2002 was first orally-available drug approved to treat VL in India.
54, 81
  A dosage of 
100 mg/kg/day for 28 days results in cure rates up to 94%,
82
 whilst a dosage of           
2.5 mg/kg/day for 28 days can be used to treat CL, although the effectiveness is species 
dependent.
83
  The most common side effects of the drug are gastrointestinal symptoms 
such as nausea, vomiting, abdominal pain and diarrhoea, and less frequent effects 
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include hepatotoxicity and nephrotoxicity.
84
  Miltefosine is also teratogenic and 




 As with many of the antileishmanials, the mode of action of miltefosine is not fully 
understood.  Evidence of apoptosis-like cell death, including nuclear condensation and 
DNA fragmentation, has been observed in both promastigotes and amastigotes in 
response to the drug; however, the mechanism by which it achieves this remains 
unclear.
86
  Another hypothesis suggests that miltefosine inhibits the synthesis of 
phosphatidylcholine (PC), an integral membrane component that is also involved in cell 
signalling.
84
  Other suggestions for possible effects include perturbation of lipid 




  As with paromomycin, resistance to miltefosine can easily be induced by drug 
pressure in vitro, but clinical cases are rare.
88
  However, it is possible for susceptibility 
to decrease during treatment, especially in HIV co-infection cases where relapse 
occurs.
89
  The long half life of miltefosine also encourages resistance and this fact, 
combined with the expense of treatment, suggests that miltefosine may be short lived as 
an effective antileishmanial drug.
90
   
 
1.2.1.3.6. Additional Treatments 
 
 Whilst the treatments described above are by far the most commonly utilised 
therapies against leishmaniasis, there are several additional drugs that are used on a 
smaller scale.  These include, but are not limited to: ketoconazole, an orally available 
antifungal agent primarily used in the treatment of CL;
91
 sitamaquine, an orally 
available compound that showed high efficacy against VL in recent clinical trials;
92
 
dapsone, an orally available drug originally used to treat leprosy and repurposed for 
CL;
93
 and imiquimod, a topically-applied drug that is highly effective when used as part 
of a combination therapy against antimonial-resistant CL.
94
   
 
 To date, however, there is no singular ‘wonder drug’ for the treatment of 
leishmaniasis, with all of those discussed above either displaying critical levels of 
human toxicity or being inaccessible, either geographically or financially, to those who 
most require them.  Although numerous drug targets in various Leishmania species have 
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been proposed, there have been relatively few medicinal chemistry campaigns to 
investigate these further;
54
 for example, the Drugs for Neglected Diseases initiative 
(DNDi) is only investigating 3 new compounds as potential preclinical candidates 
whilst the rest of the projects are based on using new combinations of currently 
available drugs.
95
  Whilst this approach may produce improved treatment regimens in 
the short term, the long term aim is to produce novel drugs which better fit the proposed 
target product profiles (TPPs) that have been published by the DNDi.  These are lists of 
essential and desirable attributes for novel drugs, with requirements including oral 
administration (or topical for CL), a short (< 14 day) treatment schedule, zero fatalities 
from the treatment itself and activity against multiple species.
96, 97
  No current drug 
comes close to meeting most of these criteria and this fact, combined with the 
expanding emergence of resistance and lack of suitable vaccines,
98
 highlights the urgent 
necessity for novel, potent antileishmanial drugs. 
 
1.2.2 Human African Trypanosomiasis 
 
1.2.2.1 Introduction and Clinical Manifestations 
 
 Trypanosoma brucei, the causative agent of HAT (also known as African sleeping 
sickness), was first discovered by Bruce in 1894 and subsequently named in his honour 
in 1899.
99
   Later work identified two distinct subspecies that are geographically 
isolated; T. brucei gambiense is prevalent in central and Western Africa,
100
 whilst          
T. brucei rhodesiense is dominant in Eastern and Southern Africa (Figure 1–5).
101
  More 
than 60 million people are at risk of infection in 36 sub-Saharan African countries, with 
actual numbers of cases varying drastically over the years.
102
  The disease was brought 
under control in the 1960s; however, this was followed by an epidemic that lasted until 
the late 1990s, and at the height of this it was estimated that up to 300,000 new cases 
arose each year.  This trend was reversed in the early 21
st
 century, and in 2009 the 
number of reported cases dropped below 10,000 for the first time in 50 years.  Even 
fewer cases are reported today, although not all cases are documented and it is estimated 










 The disease manifests in two forms depending on the infective species.  T. brucei 
gambiense, which is responsible for more than 98% of cases, results in a chronic illness 
which may be a- or pauci-symptomatic for months or even years, whilst T. brucei 
rhodesiense causes acute illness with more than 80% of untreated cases resulting in 
death within 6 months of infection.
104
  Both forms of the disease are ultimately fatal if 
left untreated; however, cases where infected individuals have remained asymptomatic 




 Despite their differing rates of progression, both diseases are clinically presented in 
the same two recognised stages.  The first, known as the early or hemolymphatic stage, 
usually occurs 1–3 weeks after infection and entails fatigue, malaise, headaches, 
arthralgia and weight loss as the parasites invade the lymph and systemic organs.  In 
addition, fever and vomiting may also occur and frequently result in the disease being 
misdiagnosed as malaria.
106
  If left untreated, the parasites will eventually cross the 
blood-brain barrier (BBB) and invade the central nervous system, marking the onset of 
the late (or encephalitic) stage of the disease.  This results in a broad spectrum of 
symptoms including: psychiatric disturbances ranging from mild conditions, such as 
a b 
Figure 1–5: The distribution of HAT caused by (a) T. brucei gambiense 
(reproduced from WHO
100
 with permission) and (b) T. brucei 
rhodesiense (reproduced from WHO
101
 with permission) 
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lassitude and irritability, to violence and hallucinations; loss of motor function 
including, in many cases, the ability to walk and talk; and sensory involvement such as 
pruritus and hyperaesthesia, with the latter being particularly common in European 
sufferers.
102, 107, 108
  Finally, the patient descends into the characteristic sleep 
disturbances that give the disease its name.  This is accompanied by seizures, cerebral 
oedema, coma, systemic organ failure and eventually death.    
 
1.2.2.2. Life Cycle 
 
 The life cycle of T. brucei gambiense and T. brucei rhodesiense is shown in Figure 
1–6.
109
  As with Leishmania spp., the life cycle is dixenous involving both an insect and 
mammalian host.  Due to the chronic nature of the disease caused by T. brucei 
gambiense the main reservoir of the parasites is likely to be human, whereas T. brucei 
rhodesiense requires a bovid reservoir because of the acute nature of the infection.
110




 As with Leishmania spp., the cycle begins with the transfer of metacyclic 
trypomastigote parasites to the human victim via a bite from an insect vector (1) which, 
in this case, is a tsetse fly of the genus Glossina.  More than 20 species of Glossina are 
responsible for disease transmission; these species have adapted to a wide range of 
Figure 1–6: The life cycle of T. brucei gambiense and T. brucei 
rhodesiense (reproduced from CDC
109
 with permission) 
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habitats which accounts for the highly endemic nature of the disease.
111
  In addition, the 
disease can be transmitted in a handful of other ways such as a prick from a 




 Following the bite, the inoculated metacyclic trypomastigotes transform into long 
slender bloodstream form (LS-BSF) trypomastigotes (2).  Unlike Leishmania spp., the 
parasites circulate freely in the bloodstream and lymph and are able to evade clearance 
by the host immune system by switching between variant surface glycoproteins.
112
  LS-
BSF trypomastigotes divide rapidly by binary fission (3); upon reaching a certain 
density the accumulation of a differentiation inducing factor produced by the parasites 
stimulates differentiation to short stumpy bloodstream form (SS-BSF) trypomastigotes 
(4).
113, 114
  SS-BSF trypomastigotes have a short half life (estimated between 24 and 72 
hours) and are non-proliferative in the mammalian host; instead, they are pre-adapted 
for the vector midgut and, following a blood meal by a tsetse fly (5), it is the SS-BSF 
trypomastigotes that continue the life cycle.
115
  
    
 In the tsetse fly midgut, the SS-BSF trypomastigotes transform into procyclic 
trypomastigotes which subsequently divide by binary fission (6).  Following midgut 
colonisation, which takes up to 6 days, the procyclic trypomastigotes migrate through 
the foregut and proboscis to reach the salivary glands; they also transform into an 
adherent epimastigote form during this time (7).
116
  Epimastigotes subsequently divide 
and multiply in the salivary gland before transforming into a detached metacyclic form 




1.2.2.3. Currently Available Treatments 
 
 The drug of choice for the treatment of HAT depends on both the infective 
subspecies and the stage of the disease, with those effective in the encephalitic stage 
being required to cross the BBB.  The number of drugs approved for HAT is therefore 
very limited, with those currently in use shown in Figure 1–7 (with pentamidine, also 










 Pentamidine (3) was first developed and used to treat HAT in the 1930s.
118
  To this 
day it remains the drug of choice against hemolymphatic stagec T. brucei gambiense 
infections,
119
 but it shows only limited efficacy against T. brucei rhodesiense infections 
and is completely ineffective against encephalitic stage disease.
120
  Administered either 
intramuscularly or intravenously at the same dosage as against Leishmania infections, a 
course of 7–10 treatments results in cure rates up to 94% with the same side effects 
being observed.
121, 122















































 Figure 1–7: The structures of currently used antitrypanosomal drugs 
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 As discussed in section 1.2.1.3.2, the mode of activity of pentamidine is not fully 
understood.  However, it has been observed that T. brucei parasites possess a number of 
transporters with a high affinity for pentamidine, allowing accumulation of the drug to 
very high intracellular levels resulting in selective toxicity for the parasite over 
mammalian cells.
123
  Unlike Leishmania infections, resistance of T. brucei to 
pentamidine is extremely rare in the field,
120
 although overuse as a chemoprophylactic  






 Suramin (7), first used to treat HAT in 1922, is perhaps the oldest antimicrobial 
drug still in use today.
125
  It is the first line treatment for hemolymphatic stage T. brucei 
rhodesiense infections and is typically administered at a dosage of 20 mg/kg (up to a 
maximum of 1 g per treatment) by slow intravenous infusion every 5–7 days for 4 
weeks.
122, 126
  Although it is effective against T. brucei gambiense infections, suramin is 
generally avoided due to the high risk of co-infection with Onchocerca volvulus (the 
causative agent of onchocerciasis, or ‘river blindness’) against which it has high activity 
and can lead to severe adverse reactions including shock.
127
  It is also unable to cross 
the BBB so cannot be used to treat encephalitic stage disease.  Side effects from 





 Due to the multiple negative charges on suramin at physiological pH it is able to 
bind to numerous serum proteins, including low-density lipoprotein (LDL), which 
facilitate its uptake into the parasites by endocytosis.
125
  Accumulation of the drug is 
relatively slow, but at high enough concentrations there are a number of enzymes which 
have been reported to be inhibited by suramin including certain kinases, acid 
phosphatase and phospholipase A1.
128
  Perhaps key, however, are the numerous 
glycolytic enzymes located in the trypanosome glycosome.  Many of these carry a high 
positive charge and have been shown to be sensitive to micromolar levels of suramin,
129
 
whilst homologous enzymes from other organisms, including mammals, are less 
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 As with pentamidine, field resistance to suramin is rare.  One possible reason for 
this is that LDL is essential for parasite proliferation and therefore its uptake into the 
parasites (and hence the uptake of suramin) cannot be drastically reduced if they are to 
remain viable.
130
  Despite this, clinical instances of decreased suramin sensitivity have 
been reported,
131
 and resistance can be readily selected for in the laboratory.
132




 Melarsoprol (8) is an organoarsenical compound which has been used in the 
treatment of HAT since 1949.
133
  Whilst active against both stages of the disease in both 
T. brucei subspecies it is typically only used to treat the encephalitic stage due to its 
high toxicity, and it remains the only treatment available for late stage T. brucei 
rhodesiense infections.
134
  Historically the drug was administered intravenously as a 
series of three or four daily injections (at a dosage of up to 3.6 mg/kg per injection, 
although this varied between countries) followed by a rest period of 7–10 days, repeated 
up to four times; however, more recent studies have shown that a treatment regime of 
10 daily injections at a dosage of 2.2 mg/kg produces comparable cure rates.
135, 136
  
Melarsoprol is the most toxic of the antitrypanosomal drugs with a myriad of side 
effects including fever, vomiting, abdominal pain, polyneuropathy and 
thrombocytopaenia;
137
 by far the most dangerous, however, is encephalopathy which 




 The mechanism by which melarsoprol kills trypanosomes is not fully understood, 
although it has been observed that the drug rapidly metabolises in the body to form 
melarsen oxide, which is thought to be the species responsible for trypanocidal 
activity.
139
  One observation is that the drug has the ability to interact with thiol groups 
and disulphide bonds in proteins, which could lead to a loss of function; this would 
explain the acute toxicity to the patient’s own cells.
63, 140
  Another is that melarsen oxide 
reacts with trypanothione to form a stable adduct which inhibits trypanothione 




 In addition to its high toxicity, melarsoprol also exhibits a high treatment failure 
rate in comparison to the two aforementioned trypanocidal drugs.  During the first 50 
years of its use melarsoprol treatment was unsuccessful in 5–8% of cases, but over the 
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last 15 years this figure has risen alarmingly.
142
  This is particularly evident in the 
Democratic Republic of Congo, where the failure rate reached 20% in 2003 rising to 
57% in recent years, casting doubt on the future use of melarsoprol as a trypanocidal 
drug.
143, 144
     
 
1.2.2.3.4. Eflornithine  
 
 Eflornithine (9) was originally developed as an anticancer drug but was observed to 
be active against trypanosomes in vivo in 1980, and was first utilised in the field the 
following year.
145
  The drug is an irreversible inhibitor of ornithine decarboxylase, 
which is an integral enzyme in polyamine biosynthesis.  Inactivation of the enzyme 
results in arrested trypanosome division and transformation to the metacyclic form, 
which the immune system is capable of eliminating.
146
  However, this mode of action 
means that eflornithine is only effective against T. brucei gambiense given that the 
target enzyme has a very high turnover rate in T. brucei rhodesiense (as it also does in 
mammals).
147
   
 
 Although its primary use is as a safer alternative to melarsoprol for encephalitic 
stage disease, eflornithine still displays a variety of frequent side effects including fever, 
gastrointestinal symptoms, pneumonia, seizures and depression of bone marrow 
function.
148
  The major drawback of eflornithine, however, is that it has a half life of 
only 3–4 hours, meaning it has to be administered intravenously at intervals of 6 hours 
for 14 days.  Additionally, the required dose is extremely high (100 mg/kg in each 
injection for adults, or 150 mg/kg for children), hence the overall cost of treatment – 
both the drug price and extended hospitalisation – makes it inaccessible to many 
people.
149
   
 
1.2.2.3.5. Nifurtimox  
 
 Nifurtimox (10) was marketed in the 1960s as a treatment for Chagas disease 
(caused by the kinetoplastid parasite T. cruzi) and was first utilised as a treatment for 
arseno-resistant T. brucei in the 1980s.
150
  Its mechanism of action involves the 
reduction of the nitrofuran to produce free radicals which subsequently bind to, and 
disrupt, proteins and DNA.
151
  Although the drug shows limited efficacy as a 





 it is much more widely utilised in nifurtimox-eflornithine combination 
therapy (NECT) for the treatment of encephalitic stage disease caused by T. brucei 
gambiense.   
 
 NECT therapy was approved for use in 2009 and involves a treatment regime of 
intravenous eflornithine (200 mg/kg) every 12 hours for 7 days combined with oral 
nifurtimox (5 mg/kg) every 8 hours for 10 days.
153
  Although hospitalisation is still 
required, the burden on the patient is reduced by the increased dosing frequency and 
shorter total treatment time; furthermore, the treatment cost is roughly half that of 
eflornithine monotherapy.
154
  In addition, whilst some side effects (nausea, dizziness 
and tremors) were more common with NECT, the treatment displayed a more 
favourable overall safety profile with the incidence of major adverse effects being 
halved.
155, 156
  Finally, the prospect of resistance emerging is much reduced for a 





 Despite the encouraging development of NECT, however, it is far from a perfect 
treatment.  A TPP proposed by the DNDi, including requirements such as oral 
bioavailability, multi-target activity and activity against both T. brucei subspecies, 
highlights the large gap between currently available HAT drugs and what is perceived 
to be ideal.
158
  Ongoing efforts include novel combination testing and repurposing from 
the Malaria Box,
159
 and it is crucial that additional drug discovery programmes for HAT 
continue the search for potent, non-toxic drugs against both hemolymphatic and 
encephalitic stage disease. 
 
1.2.3 Towards New Antikinetoplastid Drugs 
 
 Historically, drug discovery efforts for tropical diseases have been 
underwhelming, hence the term ‘neglected’.  Between 1975 and 1999, only 1.1% of 
new chemical entities were for NTDs despite them being accountable for 11.5% of 
global disease burden.
160
  The situation failed to improve over the next decade; whilst 
4% of new therapeutic products registered between 2000 and 2011 were for neglected 
tropical diseases, these were predominantly new indications or formulations.  Only 1% 
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of the new chemical entities registered during this time period were for NTDs, and 




A major step forwards was made in January 2012 with the launch of the London 
Declaration on NTDs.
162
  This declaration, with 22 original endorsers, committed to 
working towards eliminating five diseases (including HAT) and controlling another five 
(including VL) by 2020, and diverges from the classical viewpoint that drug discovery 
and development is the sole responsibility of pharmaceutical companies and instead 
requires collaborations such as product development partnerships and public-private 
partnerships.
163
  Thanks to this new initiative, the future of drug discovery for NTDs 
looks brighter than it has in years; however, in order to achieve this goal, new druggable 




 Sphingolipids are a class of natural molecules first identified in 1884 by 
Thudichum, who isolated three related compounds from human brain tissue.
164
  This 
category of compounds is now known to encompass thousands of structurally diverse 
molecules, and one of the major challenges in the field is keeping up with the rapid 
growth in understanding and knowledge.
165
   
 
1.3.1 Structural Features 
 
 The sphingolipid family has a common core structure that is distinguishable from 
other classes of lipids by the presence of an amide bond which links the amine group of 
a sphingoid base backbone to the acyl group of a fatty acid (Figure 1–8).  Sphingoid 
bases are aliphatic amino alcohols that are structurally similar to sphingosine (11) but 
may differ by a number of factors including alkyl chain length, saturation and 
modifications such as hydroxyl or methyl groups situated at various positions along the 
chain.
166
  Mammals predominantly produce sphingosine along with dihydrosphingosine 
(12, also called sphinganine) and, to a lesser extent, phytosphingosine (13) (which is the 
predominant sphingolipid found in plants and fungi)
167
 although smaller quantities of 
different chain length homologues are also produced.
168
  Sphingoid bases are readily   
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 Sphingolipids can be categorised into several major classes.  Simple sphingolipids 
include sphingoid bases and ceramides as discussed above along with basic derivatives 
such as ceramide-1-phosphates.  Complex sphingolipids (Figure 1–10) are extremely 
varied in nature and comprise molecules in which head groups are attached via 
phosphodiester linkages (phosphosphingolipids) or glycosidic bonds 
(glycosphingolipids, which can be either simple cerebrosides or complex 
gangliosides).
170
  Some aquatic organisms produce sphingolipids containing phosphono 
linkages or 1-arsenate groups,
171
 whilst certain bacteria have been shown to produce 
sulphonosphingolipids.
172













Figure 1–8: The core structure of a sphingolipid.  R
1
 is usually a 
saturated or monounsaturated alkyl chain, R
2
 is typically a hydrogen 
or polar hear group and R
3
 is classically a saturated alkyl chain   
 
Figure 1–9: The predominant sphingoid bases 
































Sphingosine (11) Dihydrosphingosine (12) Phytosphingosine (13) 
Ceramide (14) Dihydroceramide (15) Phytoceramide (16) 
















1.3.2 Biological Functions 
 
 Sphingolipids are essential and ubiquitous components of eukaryotic membranes,
173
 
although they have also been identified in some prokaryotes
174
 and a marine virus.
175
  
The acyl chains of sphingolipids tend to be fully saturated, unlike the unsaturated chains 
generally observed with other membrane lipids; as a result, sphingolipids are able to 
pack tightly together and increase the structural stability of the membrane.
176
  In 
addition, this packing of sphingolipids, both together and with sterols (thought to be due 
to the hydrogen bonding ability of the amide functionality),
177
 allows the formation of 
compact zones of condensed bilayer.
178
  This results in phase separation between the 
sphingolipid- and sterol-rich microdomains, known as lipid rafts, and the more 















































































Figure 1–10: Structures of representative examples of the various classes of 




 are alkyl chains.  (a) ceramide-1-
phosphate; (b) phosphosphingolipid; (c) cerebroside glycosphingolipid when  
R
3
 = H or ganglioside glycosphingolipid when R
3
 = mono- or polysaccharide; 
(d) phosphonosphingolipid; (e) arsenosphingolipid and (f) sulphonosphingolipid 
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 It has been proposed that lipid rafts form in the trans-Golgi apparatus and are able 
to traffic apical and basolateral proteins into separate vesicles for transport to the correct 
localisation in polarised epithelial cells.
180
  This phenomenon was also observed in 
neurons, with proteins being sorted to either the axonal or dendritic localisation.
181
  
Lipid rafts have also been implicated in T-cell receptor signalling,
182
 as well as the 





 Simple sphingolipids have also been observed to possess roles as signalling 
molecules (second messengers) in cells.  For example, ceramide has been identified as 
an initiator of both apoptosis and autophagy,
185, 186
 and sphingosylphosphorylcholine as 
a stimulator of calcium mobilisation in various cell types.
187
  This activity is facilitated 
by the fact that many sphingolipids are uncharged at physiological pH and so are freely 
able to cross membranes.
188
   
 
1.3.3 Biosynthetic Pathway 
 
 The biosynthesis of sphingolipids is complex and involves an intricate network of 
interconnected pathways with ceramide, involved in both anabolism and catabolism, 
acting as a metabolic hub.
189
  Given that sphingolipids are essential cellular 
components, the biosynthetic pathway is largely conserved across organisms.  However, 
it is the mammalian pathway that is the most extensively studied, and an overview is 
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Figure 1–11: An overview of mammalian sphingolipid metabolism (adapted from Bartke and 
Hannun
189
 with permission).  Bioactive sphingolipids are outlined in red, whilst those outlined 
in blue are predominantly membrane components.  Enzyme abbreviations are as follows: SPT, 
serine palmitoyltransferase; KDS, 3-keto-dihydrosphingosine reductase; CerS, ceramide 
synthase; CDase, ceramidase; DES, dihydroceramide desaturase; SK, sphingosine kinase; 
SPPase, sphingosine-1-phosphate phosphatase; S1P lyase, sphingosine-1-phosphate lyase; 
CK, ceramide kinase; C1PP, ceramide-1-phosphate phosphatase; GCT, galactosylceramide 
transferase; β-GCase, β-galactosylceramidase; GCS, glucosylceramide synthase; GCase, 




 Sphingolipid biosynthesis is compartmentalised between the endoplasmic reticulum 
(ER), where synthesis commences, and the Golgi apparatus, where the majority of 
ceramide metabolism occurs.
190
  Synthesis begins in the ER with the condensation of   
L-serine and palmitoyl coenzyme A (CoA) to form 3-keto-dihydrosphingosine; this is 
the rate-limiting step of sphingolipid synthesis.
191










Further lipid metabolism 
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subsequently reduced to dihydrosphingosine.  These first two metabolic steps (Figure 
1–12) are highly conserved across eukaryotes.   
 
 Following dihydrosphingosine formation, the metabolic pathways begin to diverge.  
In animals, dihydrosphingosine is acylated to dihydroceramide before being desaturated 
to form ceramide.  In higher plants and fungi, however, dihydrosphingosine is first 
hydroxylated to form phytosphingosine before being subsequently acylated to form 
phytoceramide (Figure 1–13).
192, 193
  The products of this synthesis are subsequently 
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Figure 1–12: Eukaryotic biosynthesis of dihydrosphingosine 
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Figure 1–13: Divergent metabolism of dihydrosphingosine in different organisms 
 
 
   
 Once transported to the Golgi apparatus ceramide (or phytoceramide) can be 
utilised in a variety of metabolic processes as shown in Figure 1–11.  However, the 
predominant metabolic process is organism-dependent.  Mammalian cells possess a 
sphingomyelin synthase (SMS) enzyme which converts ceramide to sphingomyelin; this 
is the predominant sphingolipid in animals, forming up to 22% of cellular 
membranes.
194, 195
  In contrast, higher plants and fungi produce inositol 
phosphorylceramide (IPC) as their prevalent complex sphingolipid using an IPC 
synthase (IPCS) enzyme.
196
  Finally, kinetoplastid parasites form a distinct group and 
convert ceramide to IPC, also using an IPCS (Figure 1–14).
197
































































1.3.4 IPCS as a Drug Target 
 
 Due to the high levels of conservation across kingdoms in the early stages of 
sphingolipid synthesis, inhibitors that target enzymes early on in the pathway do not 
make suitable drugs as they also result in host toxicity.
198
  However, given the fact that 
mammals produce SMS rather than IPCS this enzyme represents an attractive 
pharmaceutical target.  This concept was first demonstrated in yeast in the 1990s.  The 
model yeast Saccharomyces cerevisiae was observed to be susceptible to aureobasidin 
































































































































Figure 1–14: Divergent metabolism of ceramide in different organisms 
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Subsequent studies on an AbA-resistant strain of S. cerevisiae identified a single 
upregulated gene, which was named AUR1, which was responsible for the conference of 
resistance.  Subsequent depletion or deletion of this gene resulted in abnormal 
morphology and a loss of viability.
200, 201
  It was later shown that the AUR1 gene 
complemented the IPCS defect present in sphingolipid compensatory yeast strains 
(which produce glycerophospholipids to compensate for the lack of sphingolipids), 
hence confirming the identity of the AUR1 protein as an IPCS.
202
   
 
 IPCS homologues were later identified in multiple fungal species by polymerase 
chain reaction (PCR) amplification from genomic DNA libraries using degenerate 
primers;
203
 this resulted in the identification of four conserved domains, two of which 
were similar to domains present in the lipid phosphate phosphatase (LPP) family.
204
  
Two additional inhibitors of the fungal IPCS were also subsequently identified; 
rustmicin (18)
205
 and khafrefungin (19)
206
 (Figure 1–15).  However, neither of these 
compounds nor AbA display a favourable pharmacokinetic profile and their highly 
complex structures present a significant challenge to medicinal chemistry efforts.
207
  A 
recently published three-step method of modifying AbA resulted in the synthesis of a 
number of compounds which displayed either comparable or slightly improved activity 
over AbA against two different fungal species;
208
 other than this, however, attempts at 
improving the activities of these compounds have been unsuccessful.  
 
 The identification of IPCS in yeast also inadvertently led to the discovery of the 
mammalian SMS family of enzymes in the early 2000s.  Having noted that IPC was the 
fungal equivalent of SMS, Huitema et al. employed a bioinformatics approach to search 
for mammalian proteins of unknown function possessing a conserved sequence motif 
(H(YFWH)X2D(VLI)X2(GA)X3(GSTA)) shared by LPPs and the IPCS homologues.  
They identified a family of enzymes containing four highly conserved domains, named 
D1−D4; D3 and D4 contained the similar sequences shared by LPPs and the IPCS 
homologues.
209
  Despite these regions of similarity in the sequences, it is still 
acknowledged that IPCS represents an attractive pharmaceutical target; computational 
systems biology has confirmed this to be the case in Leishmania.
210
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Figure 1–15: Known inhibitors of the fungal IPCS 
  
1.3.5 The Kinetoplastid IPCS  
 
 The kinetoplastid IPCS enzymes were identified by Denny et al. in 2006, again by 
searching the relevant genome databases for the conserved motif given above.
196
  All 
the orthologues displayed two regions that were conserved relative to animal SMSs and 
similar to AUR1.
203, 209
  These regions contain the catalytic triad of His220, His264 and 
Asp268 (numbered for the L. major enzyme) and are located in the luminal domains of 
D3 and D4 (the conserved regions proposed by Huitema et al. for SMS)
209
 of IPCS, 
which is predicted to contain six transmembrane helices (Figure 1–16).
211
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Figure 1–16: (a) The predicted topology of kinetoplastid IPCS (adapted from Goren 
et al.
211
 with permission) with the domains proposed by Huitema et al.
209
 for SMS 
shown in red and (b) the alignment of highly conserved regions from human SMS, 
L. major IPCS and T. brucei brucei sphingolipid synthases (SLSs).  Stars indicated 




   
 The enzyme has been shown to proceed via a double-displacement mechanism 
(Figure 1–17).
212
  Based on this model, functions for the three amino acids of the 
catalytic triad have been proposed.  In the first step, His264 and Asp268 are thought to 
operate as a charge relay system which facilitates nucleophilic attack by His264 on the 
electrophilic phosphorus in the phosphatidylinositol (PI) substrate.
213
  His220 is 
postulated to facilitate nucleophilic attack of the ceramide on the phosphorus in the 
second step, whilst a conserved arginine (Arg262 in the L. major enzyme) is believed to 
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Figure 1–17: The double-displacement mechanism of IPCS.  In the first 
step, the phosphorylinositol group is transferred to the reactive histidine 
(His264 for L. major) with the release of diacylglycerol.  In the second step, 
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Figure 1–18: The proposed mechanism of action of L. major 
IPCS (adapted from Mina et al.
214
 with permission) 
Step 1 Step 2 
 
 As can be seen from the mechanism, in addition to regulating the production levels 
of the essential sphingolipid IPC, this synthetic step also plays a part in controlling the 
cellular levels of ceramide and diacylglycerol (DAG).  This is a crucial observation 
given that DAG is a mitogenic factor and hence is essential for cell growth,
215
 whilst 
ceramide (as noted in section 1.3.2) induces apoptosis.
185
  Therefore, compounds which 
inhibit IPCS would reduce parasite viability by affecting the levels of three different 
biomolecules and hence should ideally be highly effective and selective pharmaceutical 
compounds.  The potential for selectivity between closely related IPCS enzymes from 
different species has already been established; in the case of AbA, inhibitory activity 
against L. amazonensis IPCS
216
 and T. brucei sphingolipid synthase (SLS) isoform 4 
has been described, whilst the L. major IPCS is insensitive.
217
  As discussed above, 
however, the only known inhibitors of the fungal IPCS are not suitable drug candidates 
and hence small molecule inhibitors of this drug target, ideally based on novel chemical 
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1.4 Introduction to High Throughput Screening and Drug Discovery 
 
 The mounting public demand to identify cures for worldwide diseases (including 
those aforementioned), as well as the development of drug resistance in many infective 
species,
218, 219
 has resulted in high pressure being placed on the pharmaceutical industry 
to produce new drugs at a rapid rate.  The drug discovery process, however, is far from 




 The first stage is the identification of a biological target involved in the disease or 
pathway of interest.  Following this, compounds are tested against this target to uncover 
some with activity; these compounds have the potential to become drugs and are hence 
known as leads.  Lead optimisation (a process undertaken to increase factors such as 
solubility and bioavailability) and preclinical studies in animal models to assess 
biological activity and safety can then last up to five years.  Phase I clinical trials (first 
time in man), where the leads are tested in healthy human volunteers to determine safety 
and dosage, generally take about a year whilst phase II trials, which evaluate efficacy 
and adverse effects in patient volunteers, normally last for two years.  Any long term 
adverse effects are identified in phase III, which monitors patient volunteers over a 




 Following this process it can be some years before the drug is registered and 
approved meaning that, on average, it takes around 12 to 15 years to progress a lead 
compound to the clinic.  The attrition rate of compounds during this period is 
significant; according to a recent study, over 92% of small molecule drugs that entered 
phase I clinical trials did not reach approval.
222
  As a result, the identification of a large 
number of high quality leads is of paramount importance for the drug discovery process 
to be successful, and in the 1990s many pharmaceutical companies began to turn to high 
throughput screening (HTS) for this stage in the campaign.
223
  It is a process that allows 
large libraries of compounds, ranging from several thousand to a few million, to be 
tested both rapidly and relatively inexpensively, hence it has the capacity to produce 
large numbers of potential lead compounds to be progressed further through the drug 
discovery pipeline.  
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1.4.1 Evolution of HTS 
 
 As with all highly advanced technology, HTS has a very modest background.  The 
foundations were laid in 1950 when Takatsky fashioned the first microtitre plate out of 
Lucite (a synthetic polymer of methyl methacrylate) in order to provide an easier 
method of performing low volume serial dilutions.
224
  His 72-well invention was well 
received and by the mid 1950s a moulded plastic version had been commercialised in 
the United States by Liner, making it a standard piece of equipment for use in 
immunoassays.
225
  This prompted the development of plate readers throughout the 
1970s, although these were specific to the biochemical industry.  The platform was 
launched into the standard research laboratory setting following the construction of the 
laboratory plate reader by BioTek in 1981.
226
  This incited an even larger surge in 
microplate manufacture, and by the mid 1990s the necessity for standardisation of 
microplate dimensions across manufacturers had been noted.
227
  This was eventually 
finalised in 2004 by the Society for Biomolecular Screening (now the Society for 





 and outside flange
230
 dimensions in addition to well positions for 




 The first reported attempts at developing HTS assays date to the late 1970s where 
continuous flow and automation techniques were used to screen blood metabolite 
levels.
232, 233
  These initial assays highlighted many of the problems still associated with 
HTS such as reagent variability, day-to-day variance of results and the need to carefully 
validate the assay prior to use.  Despite this, assays such as these paved the way for 
increasingly high throughput experiments, although it was not until the 1990s when 
standard automatic instrumentation and a choice of plate formats were introduced that 




 Since that time, HTS has continued to adapt and evolve as required, primarily in the 
pharmaceutical industry where it has found a niche in drug discovery.  As compound 
libraries grew so did the need for miniaturisation; each well in a 96-well plate typically 
has an optimal working volume of roughly 200 µl (dependent on well shape), resulting 
in overly high reagent costs when working with large numbers of compounds.  As a 
result, very few assays carried out in 96-well format are now considered high 
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throughput, with that label mostly being reserved for those run in 384-well and 1,536-
well plates; these typically utilise volumes of 50–70 µl and 5–10 µl respectively.
234, 235
  
With 1,536-well plates it is possible to screen in excess of 100,000 compounds per day, 




 Increasing technological advancement has also resulted in increased availability to 
the extent that HTS has recently branched out into the academic environment.
237
  For 
example, the University of Dundee has compiled a library of more than 57,000 
compounds as a screening tool in drug discovery for neglected diseases;
238
 this has been 
successfully utilised to identify small molecule inhibitors of the N-myristoyltransferase 
from T. brucei.
239
  Another principle academic use is the identification of chemical 




 To date, the major drawback of HTS is that the results obtained using in vitro 
assays typically correlate poorly with those obtained in in vivo studies, usually due to 
issues such as off-target toxicity and poor biodistribution.
241
  In the past, HTS on animal 
models has not been practical given the sheer expense and animal numbers that would 
be required.  Recently, however, it was reported that HTS using zebrafish embryos, 
which can survive in 50 µl of water in 384-well plates, is a possibility;
242
 this has since 
been achieved by a number of research groups in 96-well plates.
243, 244
  Given the close 
genetic and physiological similarities between zebrafish and humans,
245
 it is predicted 
that screening using this model will greatly reduce attrition rates throughout the drug 
discovery process and increase the number of effective compounds that successfully 
make it to market. 
 
1.4.2 Stages of HTS 
 
 The HTS process encompasses several stages (Figure 1–19), none of which holds a 
greater importance than any other.  Consequently, unless the proper time and attention 
is spent on each stage of the HTS process the screen will undoubtedly end in failure.  As 
a result, HTS is a highly multidisciplinary process encompassing biologists and 
biochemists, technology experts, IT personnel and medicinal chemists, all of whom are 
essential for the screen to be successful and produce the much desired lead compounds.   
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Figure 1–19: The stages of HTS 
 
1.4.2.1 Target Identification 
 
 The selection of an appropriate target for HTS involves the consideration of a 
number of factors, of which the three most important are: how well the target has been 
linked to the disease (target validity); how facile it would be to utilise or develop a 
screening assay for the target (assayability); and whether the target is likely to be able to 
interact with chemically tractable small molecules in a potent and selective fashion to 
produce a measurable response (druggability).
246
  The major issue with target validity is 
that there is an inverse correlation between this factor and the novelty of the target.  
Targets that have been well-studied and have established links to a particular disease 
may well have been previously screened for inhibitors (and hence potential leads could 
already be patented by another company), whilst highly novel targets are often poorly 
correlated to disease.
247
  The majority of pharmaceutical companies which are large 
enough to have several projects ongoing will normally study a range of targets which 
span the risk scale. 
  
 On the other hand, if a target is highly validated there is a strong chance that a 
successful assay format has already been established, or if not, that an existing protocol 
can be readily modified.  Novel targets may require an entirely new assay format to be 
developed, and the difficulty of this task cannot be predicted prior to commencing the 
next stage of HTS.
248
  However, if the screen can be implemented successfully then 





HTS Implementation and Data Analysis 
Assay Validation 
Assay Development 
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 Druggability assessment of targets is theoretical, with predictions being made using 
available structural data.
249-251
  When tested against known protein/ligand combinations, 
programmes are capable of identifying binding sites with greater than 80% accuracy.
252
  
However, predicting druggability of non-protein targets or proteins for which structural 
information is lacking, such as many membrane proteins,
253
 is not possible by these 
methods; in these cases, druggability usually has to be estimated based on similarity to 




 Overall, target selection involves balancing the pros and cons of the above range of 
factors.  ‘Perfect’ targets that satisfy all the criteria for a high quality, successful screen 
are rare to the point of being non-existent, thus distributing the risk among the various 
factors is of paramount importance at this stage of the screening campaign. 
 
1.4.2.2 Assay Development 
 
 In a typical HTS campaign there is usually not one assay developed and utilised but 
two.  The primary assay is employed during the initial screen against the compound 
library whilst a second assay, or ‘counter screen’, is used as a follow-up to validate 
compounds that act via the desired biological pathway.  This is to ensure that any false 
positives (F+, compounds which produce the same effect via other mechanisms) are 




 In order to achieve this validation primary and secondary assays are typically 
orthogonal, using either different methodologies or altering the way in which target 
activity is detected and read.  The most common way of achieving this is to develop 
both a biochemical and a cell-based (phenotypic) assay.  These assays study the target 
in different environments and hence utilise contrasting methods of activity detection; 
using a combination of both therefore ensures that only worthwhile hits will be taken 
forward for additional investigation. 
 
1.4.2.2.1 Biochemical Assay  
 
 A biochemical assay is defined as one in which the target of interest is isolated 
from cells and screened in vitro in an entirely artificial environment.  During the early 
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1990s, when HTS was established as a component of the drug discovery process, this 
was by far the preferred format due to the technical difficulties involved in running 
phenotypic assays on a high throughput scale.
247
  However, these initial biochemical 
assays were themselves far from technically simple. 
 
 The majority of assay formats utilised complex separation-based techniques, such 
as radiofiltration, as a means of detecting target activity.  This was a technique 
originally developed to measure serum immunoglobulin levels
254
 before it was adapted 
for screening purposes such as the search for drugs against human gastric cancer.
255
  
This technique subsequently evolved into the enzyme-linked immunosorbent assay 
(ELISA) which superseded the use of radioactive species and is still used today.
256
  
However, these assay formats are typically both time consuming and labour intensive as 
several washes have to be conducted between each step, limiting them to being 
performed in 96-well plates at a comparatively low throughput rate. 
 
 The majority of modern assays instead utilise a simple, homogenous format 
commonly referred to as ‘mix and read’.  The term was first coined by Toney et al. 
upon their development of an assay for measuring insulin levels in plasma samples that 
did not rely on the complex separation steps of the previously used ELISA assay but 
instead only required the mixing of the components in the well.
257
  Not only does this 
cut down on labour and cost, but the potential to use 384-well and 1,536-well plates 
dramatically increases throughput.
258
  For these assays, the majority of detection 
methods are optical and include absorbance, luminescence and fluorescence.  Of these, 
fluorescence is the most widely used as it is highly sensitive, permitting the use of very 
small volumes.
259
  This sensitivity, though, is also the biggest drawback as the potential 
for compound interference, either due to compound insolubility or intrinsic 
fluorescence, is high and can therefore give rise to F+ results.
260
  The main strategy for 
combating this effect is to avoid short excitation wavelengths (below 400 nm) as this is 
the range at which many small molecule library compounds, such as heterocyclic 
aromatics and compounds with low levels of conjugation, are also excited, resulting in 
intrinsic fluorescence in the 400−495 nm region.
261
  This can be achieved using a red-
shifted fluorophore as demonstrated by Simeonov et al., who screened a library of 
71,391 compounds using 8 different fluorophores with a range of excitation and 
emission values.  Whilst 3,643 compounds (5.1%) produced intrinsic fluorescence when 
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the blue-fluorescent fluorophore AlexaFluor 350 was used, no compounds produced 





 The major advantage of most biochemical assays is the certainty that the effect 
measured is due to the target and not to a different mechanism or pathway; however, 
there are multiple disadvantages.  The production and purification of the required 
protein is often a very time-consuming step and, in many cases, the yields obtained do 
not provide adequate material for a large HTS campaign,
263, 264
 limiting the screening 
process to smaller libraries.  In addition, many small-molecule library compounds are 
capable of forming aggregates which interfere with protein function, resulting in F+ 
results; this was demonstrated by McGovern et al., who studied 45 reported inhibitors 
identified by screening and observed that 35 also inhibited unrelated proteins by 
forming aggregate particles large enough to be observed under a microscope.
265
  With 
respect to screening for new antileishmanials, the major issue is that amastigotes are 
intracellular parasites localised inside macrophages, hence hit compounds identified in 
vitro often lose efficacy in cellulo due to the fact they are required to cross multiple 
membranes and remain stable in an acidic environment.
266
  A study in 2011 eventually 
suggested that an overreliance on target-based drug discovery was responsible for the 
high attrition rates and low productivity observed in the pharmaceutical sector over the 
previous decade;
267
 consequently, biochemical assays are now predominantly used as a 
secondary assay for confirming target specificity, whilst phenotypic assays form the 
majority of primary screening campaigns. 
 
1.4.2.2.2 Phenotypic Assay  
 
 Phenotypic assays were virtually non-existent in the HTS world until 1996, when 
Schroeder and Neagle reported the construction of a fluorescent imaging plate reader 
(FLIPR).
268
  This instrument was pioneering in the fact that it was capable of reading all 
the wells in a 96-well plate simultaneously, hence allowing transient signals in cells in 
response to different conditions to be quantified.  Early assays included investigating G-
protein coupled receptor (GPCR) activation by measuring the resulting increase in 
intracellular calcium
269
 and the characterisation of potassium channels by measuring 
changes in membrane potential.
270
  Since that time, phenotypic assays using FLIPR 
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technology have increased rapidly in popularity, resulting in the development of FLIPR 
machines for use with 384-well and 1,536-well plate formats.
234, 271
   
 
 Phenotypic assays can be classified as either target-blind or target-directed.  The 
former simply involves the testing of compounds against the target cells of interest and 
monitoring cell viability.  This type of screen has, in the past, been of particular 
importance in the discovery of anticancer agents;
272-274
 more recently, target-blind 
phenotypic screening has led to advances in drug discovery for infectious tropical 
diseases.  The Malaria Box, compiled in 2013, is a collection of 400 compounds active 
against Plasmodium falciparum parasites that is now available to researchers free of 
charge.
275
  In addition, three antikinetoplastid compound collections (Leish-Box, 
Chagas-Box and HAT-Box) have recently been identified by target-blind phenotypic 
screening and have been provided as an open access resource to, hopefully, further 
progress research in this area.
276
   
 
 The principal advantage of utilising this type of screen is that compounds are tested 
in a cellular context.  As a result, if test compounds act on targets that form part of 
pathways requiring several additional components to elicit a response, hit compounds 
will be identified that may have been overlooked using a biochemical format.
277
  In 
addition, the requirement for the production of purified target protein is negated.  This 
type of screening does, however, have one major disadvantage; no information about 
the target or mode of action is known, hence the investigation of structure-activity 
relationships (SARs) during the lead optimisation stage can prove more challenging and 
may require the development of an additional assay.
278
  Another downside is that 
protozoan parasites and mammalian cells can often be difficult, expensive and time-
consuming to culture. 
 
 The second type of phenotypic assay is cell-based target-directed, which attempts to 
screen a known target in a cellular context.  Perhaps the most prolific use of this type of 
assay has been in GPCR drug discovery, with a wide variety of assays utilising different 
technologies to measure different cellular events having been developed over the 
years.
279
  The majority of these assays require some form of cellular engineering or 
labelling and a wide variety of purpose designed cell lines are now commercially 
available for use in these assays.
280
  Genetic manipulation of protozoan parasites for 
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NTD drug discovery, however, is relatively challenging, and therefore the target of 
interest is instead engineered into a different organism, or vehicle, for study.  The 
simplest organisms to manipulate are bacteria; for example, Escherichia coli was 
successfully utilised as a vehicle by Eakin et al. in a screen for inhibitors of parasite 
enzymes involved in purine salvaging.
281
  A major drawback of using bacteria is that 
their cellular machinery for folding proteins is different to that of eukaryotes and 
misfolding can often occur.
282
  As a result, yeast (most commonly S. cerevisiae and 
Schizosaccharomyces pombe), which is highly tractable, is gaining increasing 
recognition as a potential vehicle for HTS.
283
     
 
 The most common use of yeast cell-based screening relies upon the substitution of 
an essential yeast gene with a functional orthologue from the organism of interest.  This 





proteins.  However, the first, and so far only, account of yeast-based HTS for NTD drug 
discovery was published by Bilsland et al. in 2013, whereby they co-expressed the 
essential dihydrofolate reductase genes from different species with different fluorescent 
proteins.  The fluorescence output could therefore be measured as an indicator of 
growth, and hence inhibition by test compounds.
287
   
 
 Although less common, yeast can also be utilised in different assay formats.  One 
of these is a lethal expression platform, whereby the introduction of a foreign protein 
results in growth impairment.  This was successfully demonstrated by Kurtz et al., who 
over-expressed an ion-channel forming protein from the influenza virus in S. cerevisiae 
resulting in reduced growth, which was corrected in the presence of enzyme 
inhibitors.
288
  In addition, yeast can also be used as a transactivation platform, whereby 
modulation of foreign protein activity affects the levels of secondary messenger 
substrates or products which therefore leads to an altered phenotype.  An assay of this 
type was developed by Middendorp et al. in their investigation of human β-secretase, an 
enzyme thought to be associated with Alzheimer’s disease.  They engineered a yeast 
strain in which the gene for histidine was under the control of a GAL promoter and      
β-secretase was responsible for the activation of invertase, an enzyme that catalyses the 
hydrolysis of sucrose to glucose.  Glucose subsequently repressed the GAL promoter 
and prevented the production of histidine, meaning the yeast was non-viable on medium 
lacking this amino acid.  On the other hand, in the presence of a β-secretase inhibitor no 
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 The main advantage of cell-based target-directed screening is that the identity of the 
target is known, which makes the progression of hit compounds to the next stage of the 
drug discovery pipeline much more rapid.  Furthermore, yeast-based screening provides 
several additional advantages including: straightforward genetic engineering, especially 
with respect to protozoan parasites; low cost of culture; and rapid growth rate.
290
  One 
disadvantage of utilising either type of phenotypic assay is that hit compounds which do 
not cross the plasma membrane will not be identified, even though a simple resynthesis 
might solve the problem; this issue is exacerbated in yeast which has the additional 
barrier of the cell wall.  In addition, the target in yeast is tested in its non-native 
environment which could affect protein function and interaction.  As each assay format 
has its pros and cons, it is therefore necessary to take all of these into consideration 
when selecting the most suitable format for each individual HTS campaign. 
 
1.4.2.2.3 Assay Optimisation 
 
 Once the appropriate assay format has been selected it must be carefully optimised 
for several parameters, the primary one being cost.  The need to lower cost was the 
driving force behind the miniaturisation process from 96-well plates down to 384-well 
and 1,536-well plate formats.  However, it has been observed that reagent costs may not 
decrease linearly with the reduction in assay volume as proportionally more material is 
required in order to obtain the same signal and data quality.  For example, in a 
comparison of different assay formats for Kinase assays, Klumpp et al. observed that 
for luminescence assays, the total volume was reduced eight-fold in 1,536-well format 
compared to 384-well format but the amount of luminescence reagent could only be 
reduced four-fold.  In contrast, with fluorescence resonance energy transfer (FRET) 
assays and fluorescence polarisation assays the reduction in reagent required was 




 As HTS deals with large numbers of samples, the time required to run the assay on 
a day-to-day basis is another key factor.  Assays that require either a long setup period 
or exhibit a slow plate readout rate are highly disfavoured as they result in equipment 





  It is also essential to determine the tolerance of the assay to the solvent the 
test compounds are delivered in, which is usually dimethyl sulphoxide (DMSO).  This 
solvent is utilised in the assay as a negative control, so during assay development it is 
necessary to check whether different concentrations of the solvent affect the readout;
293
 
this is particularly important for phenotypic assays as many organic solvents have 
damaging effects on cell membranes and are therefore toxic.
294
  For biochemical assays, 
buffer composition, pH and concentration is critical and must closely resemble the 
natural environment of the target to ensure it behaves as expected.
247
  Finally, running 
the assay at the optimum temperature will decrease the time required to obtain a signal 
of sufficient quality. 
 
 Overall, assay development is generally the longest part of the HTS campaign 
given the sheer number of variables to consider.  The process can take anywhere from a 
few weeks (if a similar screen has been conducted before and only a few modifications 
are needed) to several months (if an entirely new screening format is required for a 
novel target).  A few trial plates at the selected conditions are tested using a known 
inhibitor to ensure signal to noise ratio is high enough before progressing to the next 
stage. 
 
1.4.2.3 Assay Validation 
 
 The purpose of validation is to assess how the optimised assay will perform under 
high throughput conditions.  This includes obtaining predictions of hit rate, F+ and false 
negative (F−) rates as well as determining robustness and day-to-day reproducibility of 
the assay. 
 
 In order to achieve this, a representative sample from the compound library to be 
screened is selected at random.  The size of this sample is typically between 1% and 5% 
of the total library size; any smaller would reduce the usefulness of validation in 
predicting the factors mentioned above, whilst any larger would result in a large waste 
of material should any major problems be identified.
247
  These compounds are 
subsequently dispensed into triplicate sets of plates, with some wells being reserved for 
the solvent negative control and a known inhibitor as a positive control.  Each set is then 
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 The first check performed upon undertaking assay validation is that there are no 
technical problems, such as issues with setup, robotics or plate readers, involved in 
running the assay.  One such issue was flagged by Maddox et al. during their screen for 
novel upregulators of the heat shock protein 70 promoter, where a linear trend between 
the order of plate preparation and the signal to noise ratio was observed.  Further 
investigation revealed that the time the plates were left at room temperature after setup 
but prior to incubation correlated proportionally with an elevation of background levels 





 Upon obtaining numerical results from validation, computational analysis is then 
required to determine whether the assay is suitable to progress to the primary HTS 
screen.  Primarily, the data allows an estimation of the hit rate for the assay.  In order to 
be classed as a hit the compound must show a percentage activity above the 
statistically-defined threshold which is calculated as shown in equation 1.1.
297
  The 
ideal hit rate in a primary HTS is about 1%; anything much higher than this will result 
in many potentially valid compounds having to be discarded at the next step of the 
screening campaign.  One method of reducing a high hit rate is to lower the 
concentration of test compounds so as to remove those of lower potency; this technique 
was successfully employed by Urban et al. in a screen for chaperones of 
glucocerebrosidase, a protein which, when mutated, causes Gaucher’s disease.  Their 
initial screen produced too many compounds for them to investigate further, but they 
were able to reduce their hit rate from 4.3% to 0.7% by lowering the compound 
concentration from 76.7 µM to 15.3 µM.
298
  Significantly high hit rates (> 10%) are 
indicative of a problem with the assay, such as an excessive solvent concentration or 
elevated temperature affecting the target. 
     
 Another important statistical value calculated is the Z-prime factor (Z′), the formula 
for which is given in equation 1.2.
299
  This replaced the previously utilised signal to 
noise ratio which, whilst measuring the difference between positive and negative 
samples, does not take result variability into account.  Z′, on the other hand, is 
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where: SD  =  standard deviation 
 M =  mean 
 C1 =  negative control 




Figure 1–20: Idealised Gaussian distributions of the data and separation bands typically 
observed in an assay (adapted from Zhang et al.
299
 with permission).  Abbreviations are as 
in equation 1.2.  The variability is 3SD (from the standard threshold calculation, equation 
1.1) and encompasses 99.7% of the data points.  The greatest separation and highest Z’ will 
occur when the difference between the means is large and the standard deviation is small 
calculated using both the means and standard deviations of the samples so is a much 
more accurate measure of assay robustness.  It is essentially a measure of positive and 
negative population separation, as shown in Figure 1–20.  In order to obtain the most 
reliable Z′, a large number of control wells would ideally be spaced randomly around a 
test plate to ensure the values obtained were independent of each other.  In practice, this 
is not feasible; dispensing compounds, either manually or robotically, into random wells 
rather than a common layout would drastically decrease throughput.  In addition, the 
larger the number of control wells, the fewer wells available for test compounds.  As a 
result, two columns per plate are typically reserved – one each for the positive and 
negative controls – and these are preferably centralised to avoid edge-related bias.  
Whilst Z′ > 0.5 was originally considered very good,
299
 0.5 is now generally considered 
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Figure 1–21: Compound attrition through the HTS cascade 
 Finally, running the validation plates in triplicate allows an estimation of the F+ 
and F− rates for the assay.  Compounds which produce a positive result in one plate and 
negative in the other two are F+, with compounds that produce a negative result in one 
plate and positive in two being F−.  Of the two, the F− rate is more important; following 
primary HTS, compounds which are F+ can be identified and discarded after the 
confirmation screen, whilst compounds which are F− will be lost in the primary screen 
and have no chance of being recovered.  Therefore, whilst the F+ rate can reach as high 





1.4.2.4 HTS Implementation and Data Analysis 
 
 Following a successful validation the primary screen can finally be undertaken.  
Given the difficulties that often arise during target selection and assay development, the 
screen itself is often the easiest part of the whole HTS campaign although it involves 
several stages and can still be extremely time consuming (Figure 1–21).  The most 
difficult task is ensuring consistency across the entire time period of the screen, so it is 
preferable that all reagents used are from the same batch and all biological material used 
originates from the same source.  The throughput rate is dependent on the technical 
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 Despite the care taken, there is a possibility that systematic errors will be observed 
in the HTS results.
304, 305
  Common causes of this include plate positional effects in 
either dispensation or reading (where certain rows or columns exhibit consistently high 
or low values in comparison to the rest of the plate)
306
 and uneven temperature or 
evaporation effects across the plate.
307
  The latter has become an increasingly common 
occurrence as assays have miniaturised; the loss of 1 µl of moisture from a 5 µl assay in 
a 1,536-well plate has a much more pronounced effect than the loss of the same volume 
from a 50 µl assay in a 384-well plate. 
 
 Compounds which are identified as hits are then screened again, in the same format 
as the primary HTS, in duplicate.  This step is termed confirmation and is used for two 
purposes: to identify and eliminate any compounds which were F+ in the first screen (as 
described in section 1.4.2.3); and to obtain average percentage activities for compounds 
which are true hits.
247
  Alternatively, an orthogonal secondary screen can be used at the 
confirmation stage to validate the hits from the primary screen, before active 
compounds are progressed to the next stage which is called dose response.  Here, 
compounds are screened in duplicate at a range of concentrations (these vary between 
screens and pharmaceutical companies but generally range from ~100 µM to ~1 nM) in 
order to calculate their half maximal inhibitory concentration (IC50).
308
  This stage may 
be carried out used either the primary or secondary assay, although the biochemical 
assay is generally utilised given that it is directly testing the response of the target. 
 
 The final phase of the HTS implementation process is a cytotoxicity assay.  This 
involves screening the hit compounds against human cells in order to check for off-
target toxicity.
309
  The cells used are usually HepG2 hepatoma cells given that the liver 
is the organ most commonly damaged by drugs; a study in 2003 showed that drug-
induced liver injury accounted for more than 50% of cases of acute liver failure in the 
United States,
310
 with more than 600 drugs being linked to hepatotoxicity.
311
  
Compounds which are active in this assay are therefore instantly discarded as they are 
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1.4.2.5 Lead Selection 
 
 Depending on the numbers of compounds which are inactive in the cytotoxicity 
assay, some or all of them are given lead status.  These may not necessarily be the 
compounds which produce the highest response; compounds with slightly less activity 
but more favourable pharmacokinetic profiles will be given priority as these are more 
likely to eventually make better drugs, as was demonstrated by Lipinski et al. in 
1997.
312
  The group studied over 2,000 drugs and drug candidates in clinical trials and 
found that the best oral drugs, which tended to be membrane permeable and hence 
readily absorbed by the body, tended to have properties which fell within certain limits.  
These guidelines are referred to as ‘the rule of 5’ and cover molecular weight (< 500), 
LogP  (< 5), number of H-bond donors (< 5) and number of H-bond acceptors (< 10).
312
  
These criteria are commonly used as a measure of drug-likeness, and any screening hits 
that match (or are close to) these criteria will certainly be considered for lead status. 
 
 It is, however, important to note the distinction between drug-like and lead-like 
candidate compounds.  As discussed above, the former display properties common 
among approved drugs; this does not, however, mean that they are amenable to a lead 
optimisation campaign.  In contrast, lead-like compounds tend to be smaller with 
simpler chemical structures, which facilitates subsequent modification, whilst retaining 
the other favourable physiochemical properties.
313
  Lead optimisation is therefore 
generally faster and more cost effective for these compounds.  As a result, an assortment 
of both drug-like and lead-like compounds may be delivered to the medicinal chemists 




 In summary, HTS is a process which allows large libraries of compounds, ranging 
from several thousand to a few million, to be tested against a particular biological target 
or system.  It is therefore of paramount importance to many drug discovery campaigns, 
allowing the acquisition of large amounts of data in a timescale that would have been 
inconceivable just a few decades ago.  Despite this, its usefulness has been called into 
question by many groups given the low number of clinical successes that have resulted 
from this particular method.
314-316
  On the other hand, strong proponents of HTS argue 
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that the high number of lead compounds identified by this method is sufficient proof 




 Irrespective of personal opinion, HTS continues to be the method of choice for the 
lead generation stage of many current drug discovery campaigns.  As such, the field is 
continually advancing both in terms of technological developments and increasing the 
quality and diversity of chemical libraries.
319
  Consequently, it can be predicted that 
HTS will continue to play a vital role in drug discovery for many years to come.    
 
1.5 Project Aims 
   
1.5.1 Previous Work 
 
 Building on the discovery of the kinetoplastid IPCS enzymes by Denny et al., work 
in the group subsequently focussed on constructing a yeast expression system to 
produce the L. major IPCS (LmjIPCS).  This was achieved by bringing the yeast AUR1 
enzyme under the control of a GAL promoter which was repressed in the presence of 
glucose, meaning that the yeast was reliant on the expression of the LmjIPCS from an 
added plasmid.  Following this, further work revolved around formatting an assay to 
screen the enzyme biochemically, which was subsequently used to screen a synthesised 
library of substrate analogues.  The expression system was also successfully formatted 
for isoform 4 of the T. brucei sphingolipid synthase enzyme (TbSLS4) and plant 
orthologues.
212, 217, 320, 321
   
 
 However, doubt was later cast on the expression system by Sevova et al., who 
observed that TbSLS4 was capable of synthesising sphingomyelin and ethanolamine 
phosphorylceramide but not IPC.
322
  They suggested that this could be due to leaky 
expression from the GAL promoter, which would result in some AUR1 being produced 
and hence IPC product being observed.  This therefore threw the results obtained thus 
far in the group into question.  In addition, the biochemical assay developed is only 
suitable for low throughput screening in 96-well plate format due to the numerous 
manual separation steps that are involved. 
 
 





 With the above limitations in mind, the aims of the project were as follows: 
 
1. To establish a new system to produce the LmjIPCS and T. brucei orthologues 
(referred to as sphingolipid synthases (SLSs) given that they are multifunctional)
211
 
that would eliminate the potential for leaky expression of AUR1 and hence confirm 
whether they are functional orthologues of the yeast enzyme.   
2. To design, develop and implement a novel assay utilising the constructed strains to 
screen the 1.8 million compound collection at GlaxoSmithKline (GSK) in order to 
identify novel small molecule inhibitors. 
3. To perform secondary screening (both biochemical and in cellulo against parasites) 
in order to determine whether any of the compounds selected were suitable for lead 
development. 
4. To explore SARs for this lead series in order to ascertain whether the efficacy of 
the lead compound(s) could be enhanced in order to produce the best possible 
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 As discussed in section 1.5, Sevova et al. disputed the previously utilised 
expression system, citing the potential for leaky expression of the yeast AUR1 
protein.
322
  In order to address this claim, a novel expression system was required.  
Rather than keeping AUR1 expression under promoter control, the removal of the 
AUR1 coding sequence entirely would result in yeast completely dependent on a 
kinetoplastid SLS for growth.  This would therefore completely eliminate the possibility 
of leaky expression of AUR1.  Further characterisation of the kinetoplastid SLSs would 
hence be possible and would either confirm or disprove the results previously published. 
 
2.2 Construction of Complemented Mutant Yeast Strains 
 
 L. major contains a single IPCS enzyme, the gene sequence for which is located in 
the TriTrypDB genome database with the accession number LmjF.35.4990.  With much 
of the previous work in the group centring around LmjIPCS, this enzyme was the 
primary focus.  The TbSLS4 enzyme also required investigation as, as discussed in 
section 1.5.1, the ability of this enzyme to function as an IPCS was questioned in the 
literature.  This enzyme was therefore investigated along with T. brucei sphingolipid 
synthase isoform 1 (TbSLS1) in order to confirm this activity.  The gene sequences for 
TbSLS1 and TbSLS4 are located in the TriTrypDB database 
(http://www.tritrypdb.org/tritrypdb/) for the T. brucei Lister 427 strain with the 
accession numbers Tb427tmp.211.1030 and Tb427tmp.211.1000 respectively. 
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 The coding sequences were cloned into multiple cloning site (MCS) 2 in the pESC-
LEU (pEL) plasmid vector (Figure 2–1),
323
 bringing the enzymes under the control of a 
GAL promoter.  The plasmids were amplified in E. coli before being purified and used 











strain.  This is a strain in which the genomic AUR1 has been knocked out and replaced 
by the TRP1 gene encoding tryptophan, with the AUR1 gene, encoding the essential 
IPCS, being reintroduced on a plasmid.  A kind gift from Prof. T. Dunn, this strain had 
previously been utilised to confirm the function of the Arabidopsis thaliana protein 
ERH1 as an IPCS.
324
  In addition to the three kinetoplastid SLSs, the S. cerevisiae strain 
was also transformed with pEL.ScAUR1
+
 as a control.  The transformants were grown 
on permissive SGR medium; this contained galactose to induce expression of the IPCSs 
and raffinose to act as a carbon source, and lacked tryptophan and leucine in order to 
select for successful transformants.     
 




 plasmid, the successful 
transformants were subsequently grown on medium containing 5-fluoroorotic acid 
(5FOA).  In cells maintaining the aforementioned plasmid the gene product of URA3, 
the enzyme orotidine 5′-phosphate decarboxylase, coverts 5FOA to fluorouracil, a toxic 
analogue of uracil, resulting in cell death (Figure 2–2).
325




Figure 2–1: The structure of the pEL plasmid.
323
  The genes for ampicillin 
resistance and LEU2 are selectable markers for E. coli growth and S. cerevisiae 
growth respectively.  The two MCSs are under the control of GAL promoters, so 
are active in the presence of galactose and repressed in the presence of glucose 




 The yeast transformed with pEL.LmjIPCS
+
 (α-Lmj) was able to grow on 5FOA 
medium, and a successful plasmid shuffle was confirmed by colony polymerase chain 
reaction (PCR) (Figure 2–3 (a)).  Confirmation of L. major IPCS as a functional 
homologue of AUR1 was subsequently achieved using a complementation assay, in 
which α-Lmj and the control strain complemented with pEL.ScAUR1
+
  (α-AUR1) were 
streaked on both permissive and non-permissive medium (Figure 2–3 (b)).  The 
complemented yeast strains were only capable of growth on permissive medium, 
verifying that not only are they functionally homologous, but that a functioning IPCS 
enzyme is essential for yeast growth.  This was confirmed by Dr N. Wansadhipathi-





 The yeast transformed with pEL.TbSLS1
+
 (α-Tb1) or pEL.TbSLS4
+
 (α-Tb4) both 
plasmid shuffled successfully, as confirmed by colony PCR (Figure 2–4 (a)).  When the 
strains were tested in the complementation assay they exhibited the same growth pattern 
as both the previously tested α-Lmj and the α-AUR1 control (Figure 2–4 (b)).  As the 
engineered yeast strains are fully dependent on the T. brucei SLS enzymes in the 
absence of endogenous AUR1, this strongly suggests that TbSLS1 and TbSLS4 are 
functional homologues of AUR1 and are capable of synthesising IPC.   
 
 The results obtained thus far are in accord with those previously observed in the 
group.  However, in addition to questioning the expression system, Sevova et al. also 
reported that the TbSLS enzymes were insensitive to the fungal IPCS inhibitor AbA 
(17, Figure 1–15).
322
  This contradicts the group’s study in which TbSLS4 was observed 
to be sensitive to AbA.
217


















Figure 2–2: The conversion of 5FOA to fluorouracil by orotidine 5′-phosphate decarboxylase 














SD –W –L AUR1 
LmjIPCS 
SGR –W –L AUR1 
LmjIPCS 
Figure 2–3: (a) Colony PCR of the plasmid shuffled strains, using primers designed to amplify 
fragments of the inserted coding sequences.  A refers to the α-AUR1 strain and AUR1-specific 
primers and L refers to the α-Lmj strain and LmjIPCS-specific primers.  No PCR product is 
observed when the α-Lmj strain is cycled with AUR1-specific primers, indicating that the 









 and the control pEL.ScAUR1
+
.  No growth was observed on glucose-containing 
medium (SD) due to the repression of expression from the GAL promoter.  Both strains 






















































SD –W –L AUR1 
TbSLS1 TbSLS4 
AUR1 SGR –W –L 
TbSLS1 TbSLS4 
Figure 2–4: (a) Colony PCR of the plasmid shuffled strains, using primers designed to amplify 
fragments of the inserted coding sequences.  A refers to the α-AUR1 strain and AUR1-specific 
primers, 1 refers to the α-Tb1 strain and TbSLS1-specific primers and 4 refers to the α-Tb4 
strain and TbSLS4-specific primers.  No PCR product is observed when the α-Tb1 or α-Tb4 
strains are cycled with AUR1-specific primers, indicating that the plasmid shuffle was 











 and the control pEL.ScAUR1
+
.  No growth was observed on glucose-containing 
medium (SD) due to the repression of expression from the GAL promoter.  All strains 
displayed growth on galactose-containing medium (SGR) as this induces expression 
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a c b d 
Figure 2–5: Diffusion assay of (a) AUR1, (b) LmjIPCS, (c) TbSLS1 and (d) 
TbSLS4.  AUR1 and TbSLS4 demonstrate sensitivity to 100 µM AbA as can be 
seen by the formation of clearance zones, whilst LmjIPCS and TbSLS1 do not 
2.3 Sensitivity of Kinetoplastid SLSs to AbA 
 
2.3.1 Diffusion Assay  
 
 The sensitivity of the complemented yeast strains to 100 µM AbA was first tested 
in a diffusion assay.  This involved embedding the yeast in permissive medium 
solidified with agarose before applying the inhibitor as a solution in DMSO.  This was 
able to diffuse through the agarose and, if active, produce a clearance zone around the 
point of application where the yeast would be unable to grow. 
 
 The results are shown in Figure 2–5.  As expected, α-AUR1 exhibited sensitivity to 
AbA whilst α-Lmj did not, a result which mimics those obtained previously in the 
group.
212
  Notably, the TbSLS strains demonstrated differential sensitivity to AbA with 
α-Tb1 being insensitive and α-Tb4 being sensitive.  This difference is an extremely 
interesting observation given the high homology between the two coding sequences 
(90% identity) and protein sequences (86% identity) and hence a secondary, orthogonal 
assay was required in order to confirm this result. 
 
2.3.2 Biochemical Assay  
 
 In order to verify the results obtained in the diffusion assay, the sensitivities of the 
kinetoplastid SLSs were investigated biochemically.  This necessitated the production 
of microsomal membrane material, which was undertaken according to the established 





  However, low yields of below 0.05% were consistently obtained, which 
were far lower than those previously reported.  Increasing the number of vortexing 
cycles and the mass of glass beads used resulted in marginal improvements.  The crucial 
factor for increasing the yield was found to be the size of the glass beads; the maximum 
yield obtained using 212−300 µm beads was 0.08% whilst yields up to 0.45% were 
obtained using 425−600 µm beads; this therefore suggests that larger beads led to 
increased disruption of the yeast cells.   
 
 With the microsomal membranes in hand, the sensitivities of the kinetoplastid SLSs 
to 1 µM AbA were tested using the established high-performance thin layer 
chromatography (HPTLC) assay.
320
  This protocol involved the incubation of the crude 
microsomal membrane fractions (in the absence of additional PI) with NBD-C6-
ceramide, a fluorescent analogue of ceramide, in the presence of an inhibitor.  The 
turnover of this commercially available substrate to the fluorescent product NBD-C6-
IPC, as shown in Figure 2–6, was determined by separating the components of the 
reaction mixture on a HPTLC plate and visualising using a fluorescence scanner.  NBD-
C6-ceramide has an Rf of 0.96 whilst NBD-C6-IPC has an Rf of 0.57, resulting in well-




 The results, shown in Figure 2–7, validate what was observed in the diffusion 
assay, confirming the differential sensitivity of the two TbSLS enzymes to AbA.  This 
observation is even more significant in this assay due to the lower concentration used 
for testing.  Unexpectedly, however, only a single product was observed for TbSLS4.  
Whilst a single product is the expected case for L. major, the SLS enzymes of T. brucei 
have previously been shown to be multifunctional; TbSLS1 synthesises both IPC and 
sphingomyelin, and different studies suggest that TbSLS4 is capable of synthesising 
IPC, sphingomyelin and ethanolamine phosphorylceramide.
211, 217
  Whilst a faint band 
for sphingomyelin can be seen for TbSLS1, IPC is the only band observed for TbSLS4.  
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No explanation can be offered for this observation, although it is possible that additional 




 Although the reason for the observed differential sensitivity has not yet been 
determined, there are a few potential explanations.  One possibility is that the 
kinetoplastid SLSs interact differently with KEI1, an AUR1 accessory protein identified 
by Sato et al.
327
  Mutant S. cerevisiae lacking the KEI1 protein showed decreased IPC 
production and hypersensitivity to AbA, demonstrating its essentiality in the correct 
functioning of IPCS.  The ability of KEI1 to interact with IPCSs of different origins 
could therefore affect the activity observed, with poor interaction resulting in reduced 
activity and increased sensitivity.  Alternatively, slight differences in the protein 
sequences could be responsible.  As can be seen in Figure 2–8, whilst the TbSLS protein 
sequences are highly conserved there are a couple of regions where the sequences differ.  
The first of these regions is a putative transmembrane domain, and therefore unlikely to 
be involved.  The other is at the cytosolic C-terminus and is therefore more capable of 




Figure 2–7: HPTLC assay of (a) AUR1, (b) LmjIPCS, (c) TbSLS1 and (d) TbSLS4 in the 
presence (+) or absence (−) of 1 µM AbA.  AUR1 and TbSLS4 demonstrate sensitivity to 
AbA, as can be seen by the lack of NBD-C6-IPC formation, whilst LmjIPCS and TbSLS1 do 
not.  The apparent differences in the Rf of NBD-C6-IPC is likely due to the high volatility of 
chloroform and hence slight variations in the solvent system used to run the HPTLC plates 
 




 One additional possibility is that enzyme function is being affected by small 
variations in protein sequence.  The alignment of the amino acid sequence for TbSLS4 
determined in-house with those from Goren et al.,
211
 the TriTrypDB database 
(http://www.tritrypdb.org/tritrypdb/) and the UniProt archive (http://www.uniprot.org/) 
is shown in Figure 2–9 and demonstrates a lack of sequence consensus.  Whilst this may 
be explained for UniProt sequence due to the source strain being different (T. brucei 
TREU927 rather than Lister 427) there are still eight positions where amino acid 
identity differs between the other three sequences.  Notably, there is also a deletion in 
the Durham sequence compared to the other three, and this along with seven of the ten 






Figure 2–8: Alignment of the four TbSLS coding sequences with the conserved domains 
proposed by Huitema et al.
209









 This could be significant given that there is still debate as to where AbA binds to 
the IPCS enzyme.  In an investigation of the yeast AUR1 enzyme, Aeed et al. observed 
conflicting results; synthetic compounds based on fragments of AbA showed 
competitive inhibition, suggesting binding in the active site, whereas AbA showed non-
competitive inhibition against an AbA-resistant AUR1 mutant.
328
  This resistance was 
due to the mutation of a single amino acid (F158Y) that is considerably removed from 
the residues of the catalytic triad, and whilst it is possible that this mutation results in a 
conformation shift that prevents AbA binding in the active site, it is equally possible 
that this residue is involved in AbA binding.  Interestingly, mutation of the 
neighbouring amino acid (H157Y) also generates a resistant enzyme,
200
 which might 
support the theory that AbA binding is distant from the active site.  The C-terminal 
region, which is a large cytosolic domain (and hence more accessible than the active site 
in the Golgi lumen), might therefore present a possible binding site in the kinetoplastid 
IPCS enzymes.   
 
Figure 2–9: Alignment of the TbSLS4 coding sequences with the 
conserved domains proposed by Huitema et al.
209
 for SMS shown in red, 
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 Furthermore, the C-terminus has been shown to be essential for IPCS function; 
Nagiec et al. demonstrated that a frame-shift mutation of AUR1 resulting in deletion of 
the C-terminus led to a loss of IPCS activity.
202
  It is therefore possible that some 
residues in this region may be essential for activity and, given that the TbSLS enzymes 
are multifunctional, it could be hypothesised that one or more of the mutations in the 
Durham sequence may be responsible for the apparent lack of sphingomyelin synthase 
activity demonstrated by TbSLS4.  Further investigation, such as site-directed 
mutagenesis to identify the key residues responsible for IPC and sphingomyelin 
synthase activity as well as AbA sensitivity, would be required to fully investigate this 




 The work described in this chapter involved the construction of yeast strains 
complemented with kinetoplastid SLS enzymes.  LmjIPCS, TbSLS1 and TbSLS4 were 
all shown to be capable of synthesising IPC, and whilst LmjIPCS and TbSLS1 were 
insensitive to AbA, TbSLS4 was found to be sensitive.  This supports the previous work 
undertaken in the group and is evidence that selective inhibition of related kinetoplastid 
SLSs is achievable. 
 
 Having constructed and validated the complemented strains, attention turned to the 
second aim of the project, which was to develop and implement a HTS-compatible 
assay.  Neither of the assays utilised thus far are suitable; both are low throughput and 
quantification of the results is possible but imprecise.  The 96-well plate format 
biochemical assay is also unsuitable due to the numerous manual handling steps 
required.
320
  A miniaturised cell-based assay using the constructed strains was therefore 
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 With the engineered yeast constructs in hand, the next step was to establish a HTS-
compatible assay in order to screen the 1.8 million compound library held at the GSK 
facilities located in Tres Cantos, Spain.  As discussed in section 1.4.2.2.3, a number of 
factors had to be considered when designing the assay, with cost and time being the 
major issues.  As a result, the assay was required to be quick and easy to run, 
maximising the use of automation and minimising the number of reagents and 
components involved. 
 
 Of the three strains constructed, α-Lmj was selected to be used in the screen for two 
reasons.  Firstly, whilst the number of HAT cases has decreased by 76% since 2000, the 
number of cases of leishmaniasis has increased exponentially and consequently is it 
considered by the WHO, and therefore also by GSK, to be a greater priority.
1
  Secondly, 
Leishmania spp. possess only a single IPCS enzyme.  T. brucei has four and, whilst 
RNA interference studies have shown that inhibiting gene expression of all four 
isoforms results in arrested division and some cell death,
217
 it is not known whether the 
enzymes are redundant and therefore if the parasites could continue to divide and grow 
with up to three isoforms inhibited.  HTS against TbSLS would therefore have to be 
undertaken against all four isoforms in order to identify common inhibitors; this would 
be extremely time consuming, making α-Lmj the obvious choice. 
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3.2 Yeast Multiplexing Assay 
 
3.2.1 Assay Rationale 
 
 The first assay format proposed was a novel multiplexing assay in which the 
growth of two different yeast strains in the same well could be compared by engineering 
the strains to produce different, complimentary fluorescent proteins.  If, for example,   
α-Lmj produced green fluorescent protein (GFP) and α-AUR1 produced red fluorescent 
protein (RFP), the overall fluorescence readout from the wells containing test 
compounds would indicate which, if either, of the two strains was growing and hence 
which SLS had been inhibited (Figure 3–1).  An assay of this type would also allow 
compounds that act via off-target effects to be identified. 
 
 This strategy was possible due to the presence of two MCSs in the pEL plasmid 
vector, as shown in Figure 2–1.  With the required SLS already present in MCS 2, the 
gene for the required fluorescent protein could be cloned into the vacant MCS 1 which 
would place it under the control of the GAL promoter.  As a result, growing in medium 
containing galactose to induce SLS expression would also result in the same level of 
expression of the fluorescent protein, hence fluorescence levels should correlate with 























Figure 3–1: Graphical representation of the potential well readouts of the proposed 
multiplexing assay.  If the test compound inhibits both AUR1 and LmjIPCS or is a general 
antifungal (1), growth of both strains will be low and low fluorescence will be detected.  If 
only LmjIPCS is inhibited (2) the readout at red fluorescence wavelength (580−590 nm) would 
be much higher than at the green wavelength (505−510 nm), and vice versa if only AUR1 is 
inhibited (3).  If the compound is inactive (4) both fluorescence readouts will be high 
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3.2.2 Construction of Mutant Yeast Strains Expressing Fluorescent Proteins 
 





 plasmids.  Further work on the construction of 
fluorescent strains was undertaken at Tres Cantos by Dr J. Mina, who successfully 





 plasmids.  These plasmids were used to transform S. cerevisiae as 





 plasmid was not undertaken.   
 
3.2.3 Confocal Microscopy of Fluorescent Yeast Strains 
 
 The fluorescence profiles of the yeast strains were checked prior to further assay 
development by diluting the samples to produce a single cell layer on the bottom of the 
wells in a test plate, which was then analysed by confocal microscopy.  Very low 
proportions of cell populations proved to be fluorescent, with tRFP being the only 
fluorescent protein that was detectably expressed in more than 10% of cells (Figure     
3–2).  This low and variable fluorescence output made accurate comparison of the 
growth of two different strains in the same well unfeasible.  Consequently, although an 
assay of this type has since been reported,
287
 it was concluded that this assay format was 
not robust enough for HTS and the reason for the low fluorescence was not determined 



























Fluorescent Protein Expressed 
a b 
Figure 3–2: (a) The % of the cell population expressing the various fluorescent 
proteins and (b) the microscopic image of a monolayer of cells expressing eGFP.  Low 
and uneven fluorescence readouts show that this was not a suitable option for HTS 
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3.3 Fluorescein Production Assay 
 
3.3.1 Assay Rationale 
 
 Given that the multiplex assay format based on fluorescent protein expression was 
non-viable for HTS, an alternative format was required.  It was subsequently proposed 
that the production of the extracellular enzyme exo-β-glucanase by S. cerevisiae could 
be exploited as a measure of growth.  Whilst the intrinsic function of this enzyme is 
modification of the cell wall in preparation for budding, it is also capable of hydrolysing 
the commercially available, non-fluorescent substrate fluorescein di-(β-D-





 Although low levels of exo-β-glucanase are maintained throughout the cell cycle, it 
is thought that the enzyme is synthesised discontinuously with production limited to the 
G2 phase in order to prepare for budding and cell division.
330
  Therefore, in terms of a 
library screening assay, a compound which inhibits the SLS would prevent growth, 
resulting in little exo-β-glucanase production and hence low levels of fluorescence.  On 
the contrary, an inactive compound would have no effect on growth and as a result   
exo-β-glucanase levels would increase as the yeast divides and grows, causing a 
subsequent increase in FDGlu hydrolysis. 
 
3.3.2 Optimisation of Assay Parameters 
 
 FDGlu assays have been utilised in the past by GSK,
331, 332
 so it was hoped that 
adaptation of the assay for screening the α-Lmj yeast would prove straightforward.  This 
adaptation process comprised the optimisation of several parameters, the primary one 
being the constitution of the assay mixture.  This included the composition of the 
Figure 3–3: The hydrolysis of FDGlu to fluorescein by exo-β-glucanase 
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culture medium, the starting yeast culture concentration required to give sufficient 
growth and the concentration of FDGlu required to produce adequate fluorescence.  The 
necessity for a buffer and identity of a suitable positive control compound were also 
investigated. 
 
3.3.2.1 Galactose Concentration 
 
 As perhaps the simplest condition to study, the concentration of galactose in the 
culture medium was the first parameter to be investigated.  Whilst galactose is required 
for the induction of expression of the SLS gene and hence is essential for the growth of 
the yeast, raffinose results in faster growth and hence is preferred as the primary carbon 
source.
333
  The concentration of galactose therefore only needs to be high enough to 
induce expression. 
 
 In addition to investigating different galactose concentrations using glucose as a 
negative control, target validation was also permitted by the use of three test 
compounds.  AbA (17, Figure 1–15), which has been shown to be inactive against 
LmjIPCS, should inhibit growth of α-AUR1 but not α-Lmj whilst two general 
antifungals AmB (4, Figure 1–4) and cycloheximide (20) (Figure 3–4) should prevent 
the growth of either yeast strain. 
 
 
 Various conditions were tested in a matrix assay in a 96-well plate (Appendix A.1) 
against both α-Lmj and α-AUR1.  Compound concentration was decreased down rows 
A−F at a dilution factor of ¼; this resulted in a concentration range of 10 µM to 10 nM.  
Row G contained the DMSO vehicle control, and row H was a control row with no 







Figure 3–4: The structure of the general antifungal 
cycloheximide, which inhibits protein biosynthesis  
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factor of ½; this resulted in a concentration range of 10% to 0.08%.  Column 9 was a 
control column containing no galactose, and columns 10−12 were control columns 
containing increasing concentrations of glucose.  Monitoring of growth was achieved by 
measuring the optical density (OD) at 630 nm; whilst 600 nm is preferred, the imaging 
equipment utilised was only capable of reading ODs at set values, with 630 nm being 
the closest available option.   
 
 An initial experiment involved the setup of the assay using a starting yeast OD630 of 
0.02.  However, the readings after 24 hours (the maximum assay time permissible to 
achieve the required throughput rate) showed that growth of the yeast had been slow 
and no conclusions could be drawn.  The experiment was subsequently repeated using 
an increased starting yeast OD630 of 0.05.  Following this modification, 24 hours was 
sufficient to obtain adequate levels of growth for data interpretation and the results are 




























































































































































 AbA, as expected, displayed inhibition of growth of α-AUR1 but was ineffective 
against α-Lmj.  In addition, glucose inhibited the growth of both yeast strains, a result 
that correlated with the previously performed complementation assay (section 2.2).  





























































Figure 3–5: Growth of (a, c and e) α-Lmj and (b, d and f) α-AUR1 in the presence 
of (a and b) AbA, (c and d) AmB and (e and f) cycloheximide.  As expected, AmB 
and cycloheximide inhibited the growth of both yeast strains whilst AbA only 
affected α-AUR1.  Column and row labels refer to the plate design in Appendix A.1  
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the use of yeast as a vector for the screen.  Cycloheximide, which is an inhibitor of 
protein biosynthesis,
334
 displayed comparable activity against the two strains; AmB, 
however, appeared slightly more effective against α-Lmj than α-AUR1.  As AmB 
functions by sequestering sterols, this result suggests a difference in membrane 
composition between the two strains.  Therefore, whilst LmjIPCS is functionally 
homologous to AUR1, the two enzymes may not operate at the same rate; possible 
reasons for differences in protein activity are discussed in section 2.3.2.  
 
 Somewhat surprisingly, growth for both strains was high in raffinose only medium 
(column 9).  This highlights the leakiness of the GAL promoter when unrepressed.  
Another interesting observation was that for both α-Lmj and α-AUR1, growth began to 
decrease at concentrations of galactose greater than 0.31% (columns 1−5).  This could 
possibly be attributed to adverse osmotic effects (the loss of water from the yeast cells 
due to the highly concentrated media).  Alternatively, high galactose concentrations 
may result in the overexpression of IPCS.  This could impact yeast growth in a number 
of ways; for example, the Golgi membrane composition could be significantly affected, 
which may in turn have a detrimental effect on the structure or folding of other proteins.  
Another possibility is that IPCS overexpression could adversely affect sphingolipid 
homeostasis.  As discussed in section 1.3.3, ceramide is the central metabolic hub in 
sphingolipid metabolism;
189
 overproduction of IPC would therefore reduce intracellular 
ceramide levels and impact on the levels of other complex sphingolipids.  As a result, 
the galactose concentration of the culture medium was set at 0.1%. 
 
3.3.2.2 FDGlu and Culture Concentrations 
 
 Having established a suitable medium composition attention then turned to 
maximising the fluorescence output of the assay.  As was observed previously, starting 
culture concentration needed to be investigated in order to produce sufficient growth 
during the time period of the assay.  In addition, the concentration of FDGlu required to 
give sufficient fluorescence output also needed to be determined, and it was predicted 
that a high starting culture concentration would require a low FDGlu concentration and 
vice versa.  This, however, led to competing demands as FDGlu is expensive and its use 
would ideally be minimised.  In contrast, large scale yeast culture is relatively cheap but 
is time consuming and requires equipment designed to deal with high volumes. 
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 In order to account for these limitations, two potential methods of minimising the 
concentrations required were proposed.  The first was the possibility that adding FDGlu 
post-incubation rather than pre-incubation may decrease the concentration required due 
to the fact that the quantity of the exo-β-glucanase enzyme could have built up to high 
levels in the culture medium during the 24 hour incubation period.  Therefore, by 
adding the reagent when enzyme levels are high, less FDGlu may be required to 
produce a sufficient difference in fluorescence between positive and negatives samples. 
 
 The other consideration made was the fact that S. cerevisiae grows well under 
mildly acidic conditions and can produce small quantities of organic acids such as lactic 
acid, succinic acid and pyruvic acid in order to acidify the culture medium.
335
  
Fluorescein, however, fluoresces best at neutral pH and therefore addition of a buffer at 
pH 7.0 often results in an improved fluorescence readout.
336
  As a result, the addition of 
a neutral buffer such as phosphate buffer post-incubation may reduce the concentration 
of FDGlu required to obtain a sufficiently strong fluorescent signal.   
 
 In order to investigate these possibilities, a matrix assay was designed (Appendix 
A.2) to test a range of concentration combinations in low volume 384-well plates.  
Starting culture concentration was decreased down rows A−L at a dilution factor of ⅘; 
this resulted in a concentration range of OD600 0.125 to 0.011 (yeast OD was measured 
at 600 nm using a standard spectrophotometer).  FDGlu concentration was decreased 
across columns 1−12 at a dilution factor of ⅘; this resulted in a concentration range of 
20 µM to 1.7 µM.  The matrix was repeated in A13−L24 to produce a duplicate set of 
results in a single plate. 
 
 Two test plates were prepared using α-Lmj, one with FDGlu added and one without.  
Monitoring of the plate to which FDGlu was added post-incubation showed that 
fluorescence increase over a 1 hour period was negligible, suggesting that either the 
enzyme has a very low turnover rate or that levels do not build up in the culture medium 
during growth and therefore little enzyme is present.  The addition of a pH 7.0 
phosphate buffer, however, proved successful and resulted in the fluorescence readout 
from both plates increasing approximately tenfold.  The results following the addition of 
phosphate buffer (Figure 3–6) highlight the distinction between the differential 
additions of FDGlu. 




 From this experiment, it was clear that adding FDGlu post-incubation was not a 
valid option for HTS as, based on this evidence, a lengthy second incubation with 
FDGlu would be required which would add both time and complexity to running the 
assay.  On the contrary, the addition of phosphate buffer post-incubation proved highly 
successful resulting in a much higher fluorescence readout from the two plates, so this 
step was added to the assay protocol.  However, whilst the results show the basic overall 
pattern that would be expected (lower fluorescence at low starting culture and FDGlu 



































































































FDGlu Concentration / µM 
Figure 3–6: The fluorescence readouts following the addition of phosphate buffer 
in response to varying starting culture and FDGlu concentrations when FDGlu was 
added (a) pre-incubation and (b) post incubation, plotted on the same scale.  Each 





  3. Development of a HTS-Compatible Assay 
75 
 
conclusions in terms of optimal concentrations could be drawn given the general lack of 
trends down individual rows and columns and the high number of anomalous results.  
This was attributed to large errors due to the use of a manual multichannel pipette on 
such a small volume scale. 
 
 In order to improve upon the results obtained thus far, a repeat of the experiment 
was undertaken again in a low volume 384-well plate but using a higher volume to 
reduce the pipetting errors and a smaller range of conditions (Appendix A.3) to reduce 
the complexity of the assay.  Starting culture concentration was decreased down rows 
A−D at a dilution factor of ½; this resulted in a concentration range of OD600 0.125 to 
0.016.  Row E was a control row with no yeast cells.  FDGlu concentration was 
decreased across columns 1−4 at a dilution factor of ½; this resulted in a concentration 
range of 20 µM to 2.5 µM.  Column 5 was a control column with no FDGlu.  The 
matrix was repeated in A11−E15 to produce a duplicate set of results in a single plate 
and, following incubation, phosphate buffer was added and the fluorescence of the 
plates read.  The results are shown in Figure 3–7 and, unlike the previous experiment, 
they show excellent correlations between the concentrations of the two factors and the 













 As expected the highest readout was obtained from the highest FDGlu and culture 






















































FDGlu Concentration / µM 
Figure 3–7: The fluorescence readouts following the addition of phosphate 
buffer in response to varying starting culture and FDGlu concentrations.  Each 
column represents the average of the two fluorescence values that were obtained 
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(AFU)) was also achieved using other combinations of concentrations.  From this, it 
was decided that two sets of conditions would be tested further: an FDGlu concentration 
of 20 µM and a starting culture OD600 of 0.031; and an FDGlu concentration of 10 µM 
and a starting culture OD600 of 0.063. 
 
3.3.2.3 Z′ Optimisation 
 
 Having identified two combinations to test further, finalisation of the assay setup 
was undertaken in 1,536-well plates in order to mimic the format in which the HTS 
assay was to be run.  It was decided that the origin of the starting α-Lmj culture (either 
fresh or from frozen stocks) should be investigated.  Whilst it was predicted that fresh 
culture would exhibit superior growth to culture of frozen origin, adjusting the OD600 of 
the fresh culture to the correct value at the start of every assay would be both time 
consuming and increase the potential for contamination; it would therefore be beneficial 
to utilise previously prepared frozen aliquots of culture if at all possible.   
 
 In addition, the compound most suitable for use as a positive control needed to be 
identified.  AmB (4) and cycloheximide (20) both showed inhibition of growth during 
the experiments to determine the optimal galactose concentration, so were retested in 
this assay format.  Two additional compounds were also tested; both clemastine (21) 
and suloctidil (22) (Figure 3–8) were identified in a previous small scale screen as 
having high activity both in the biochemical assay and against L. major promastigotes, 
so it was predicted that both would show inhibition of yeast growth in this assay. 
 
 
 The combinations of conditions were tested in 1,536-well plates (Appendix A.4) 







Suloctidil (22) Clemastine (21) 
Figure 3–8: The structures of clemastine and suloctidil, which were 
both shown to be potent inhibitors of LmjIPCS in a previous screen 




























full rows, resulting in 192 data points.  A starting culture containing yeast at OD600 = 
0.031 and 20 µM FDGlu was used to fill rows A–L, whilst a starting culture containing 
yeast at OD600 = 0.063 and 10 µM FDGlu was used to fill rows Q–BB.  AmB or 
suloctidil was tested in rows E–H and U–X, whilst cycloheximide or clemastine was 
tested in rows I–L and Y–BB.  AmB and cycloheximide were tested at 10 µM, as this 
was shown to be effective in the assay to determine optimal galactose concentration, 
whilst suloctidil and clemastine, which were previously untested against yeast, were 
tested at 100 µM.  The DMSO vehicle was used a control for rows A–D and Q–T. 
 
 Upon plate reading, however, it was instantly obvious that there was a major issue 
with the assay setup.  Rather than the fluorescence readout being constant for each 
condition, the data obtained revealed a significant doming effect with high fluorescence 
values being obtained in the centre of the plate and a substantial decrease in 





 This doming effect was obviously a severe problem given that the very nature of 
the assay involved comparison of fluorescence values between different wells to 
determine the percentage inhibition of growth due to the effect of an added compound.  
Compounds are dispensed across the entire plate for a HTS assay and therefore an effect 
such as this would prevent the acquisition of any meaningful data; for example, 
compounds dispensed around the edges of the plate may appear active without 
possessing any inhibitory activity.  In addition, for this particular experiment, the 
Figure 3–9: The variation in fluorescence across row A (20/0.031, no test compound) 
and row Q (10/0.063, no test compound) in a plate for fresh culture.  20/0.031 refers to 
an FDGlu concentration of 20 µM and a starting culture OD600 of 0.031, whilst 10/0.063 
refers to an FDGlu concentration of 10 µM and a starting culture OD600 of 0.063  
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observation that 10 µM FDGlu and starting OD600 = 0.063 produced a higher 
fluorescence output could simply be due to the fact that this set of conditions was tested 
in rows Q−T along the centre of the plate, whilst 20 µM FDGlu and starting OD600 = 
0.031 was tested in rows A−D along the edge of the plate. 
 
 The explanation for this effect was increased evaporation during incubation from 
the wells around the edges of the plate in comparison to the wells in the centre.  A 
subsequent investigation into ways of reducing this evaporation showed that utilising a 
spare plate to cover the test plate rather than the provided lid significantly reduced this 
evaporation and resulted in constant fluorescence across the rows.  This was attributed 
to the fact that the lids used were generic and capable of covering any type of plate so 
did not produce an exact fit, whereas using a spare plate of the same type resulted in an 
improved fit hence reducing evaporation. 
 
 Having resolved the problem, the assay was subsequently repeated and comparison 
of sets of conditions at this stage was achieved by means of Z′ calculation with a value 
as close to 1.0 as possible being desirable (as discussed in section 1.4.2.3).  The results 
are shown in Figure 3–10.  Somewhat surprisingly, fresh and frozen cultures produced 
comparable fluorescence readouts suggesting that, providing numerous freeze-thaw 






























 The observation that clemastine appeared to be ineffective at inhibiting yeast 
growth was unanticipated.  Given that this compound demonstrated a high potency 
against the parasite promastigotes, this lack of inhibition could only be attributed to the 
differences between parasite and yeast biochemistry, either in terms of membrane 
composition and transport or compound metabolism.  This highlights one of the major 
drawbacks of the assay, as library compounds which may be highly active against the 
enzyme itself would not be identified if they were unable to cross the S. cerevisiae cell 
wall and plasma membrane. 
 
 The other three compounds tested all showed effective inhibition of yeast growth 
which translated into Z′ values sufficient for a high throughput screen.  As a result, the 
conditions selected were those that gave the highest Z′ value of 0.91.  These conditions 
were 10 µM FDGlu and a starting culture OD600 of 0.063 prepared from frozen yeast 
stocks using 10 µM cycloheximide as the positive control. 
 
3.3.3 Assay Validation 
 
 With assay optimisation complete, the next stage was to validate the assay against 































Culture Conditions / µM, OD600 
Figure 3–10: The calculated Z′ values using four test control compounds 
and different culture conditions.  20/0.031 refers to an FDGlu concentration 
of 20 µM and a starting culture OD600 of 0.031, whilst 10/0.063 refers to an 
FDGlu concentration of 10 µM and a starting culture OD600 of 0.063 
1.0 
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both α-Lmj and α-AUR1 to provide an initial appraisal of the specificity of the 
compounds for the two enzymes.  Given that the only difference between the two strains 
is the origin of the IPCS enzyme, compounds which inhibit the growth of the α-Lmj 
yeast but not the α-AUR1 yeast are highly likely to be specific for the LmjIPCS enzyme.  
Having no effect on the α-AUR1 yeast also suggests that compounds do not result in 
any significant off-target effects, which is a highly desirable criterion for a 
pharmaceutical compound. 
 
 The resulting Z′ values for each of the validation plates are shown in Figure 3–11. 
As discussed in section 1.4.2.3, the minimum Z′ for an assay to be approved is 0.5; for a 
screen requiring multiple test plates, this is the minimum mean Z′.  Some test plates 
may therefore be higher or lower than this value, but in order to ensure result reliability, 
the minimum Z′ threshold for an individual plate was set at 0.4. 
 
 One plate into which α-Lmj had been dispensed displayed a strong evaporation 
effect resulting in a Z′ less than the threshold and so had to be failed.  The Z′ values for 
the remaining plates were excellent with a mean of 0.82 for α-AUR1 and 0.68 for        
α-Lmj. 
 
 A numerical summary of the results is shown in Table 3–1.  As a result of the plate 
failure, data analysis for the α-Lmj culture could only be carried out on the 8,373 
compounds for which triplicate data was obtained.  The standard deviation and 











Figure 3–11: The Z′ values for each set of eight test plates for α-
AUR1 (red) and α-Lmj (blue).  Two columns (64 wells) of each 
control were tested per plate.  Figure provided by Dr E. Alvarez 
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Table 3−1: Validation results 
was calculated according to equation 3.1.  The larger variation in the data for α-Lmj 
resulted in a higher threshold, indicating that a higher inhibition had to be exhibited in 
order for compounds to be considered as active.  The F+ (compounds active in one of 
the three plates) rates were excellent in both cases, meaning few negative compounds 
would be incorrectly progressed to the next screening stage.  The F– (compounds active 
in two of the three plates) rates were acceptable but slightly higher than ideal given that 
F– compounds cannot be recovered further down the line.  No extreme false positives or 
negatives (inhibition values that differ in one plate compared to the other two by more 













 The measured hit rate was slightly higher for α-AUR1 than α-Lmj, a somewhat 
perturbing observation as it implies that more compounds were selective towards the 
yeast enzyme than LmjIPCS and therefore that few selective compounds would be 
identified in the primary screen.  However, further analysis showed that there were 
some compounds which were specific for LmjIPCS as they did not show inhibition of  
α-AUR1 growth.  Given that the validation collection is representative of the full 1.8 
million compound library, a reasonable number of selective compounds were therefore 
expected to be identified from the primary screen. 
 
  Descriptor α-AUR1 α -Lmj 
  Number of considered triplicates  9,766 8,373 
  Standard deviation / % inhibition 7.17 13.35 
  Statistical threshold / % inhibition 21.32 42.88 
  Hit rate / % 1.44 1.07  
  False positive rate / % 0.03 0.01 
  False negative rate / % 0.99 0.72 
  Extreme false positive rate / % 0.00 0.00 
  Extreme false negative rate / % 0.00 0.00 
(3.1) % inhibition = 100 × [(D −C1) / (C2 − C1)] 
where: D  =  data value 
 C1 =  mean negative control (DMSO) 
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 Whilst validation was successful and sufficient evidence of an effective assay to 
commence the high throughput screen, it was noted that both of the control fluorescence 
means differed greatly to those observed during the optimisation stages.  The DMSO 
control wells suffered a drop in fluorescence whilst an increase was observed in the 
cycloheximide control wells.  Despite these differences in fluorescence output the Z′ 
values were still excellent (as shown in Figure 3–11).  The reason for these variances, 
however, was unclear. 
 
3.3.4 Primary Screen 
 
 Following validation, the next step of the HTS process was the primary screen 
against α-Lmj.  Given the hit rate of 1.07% obtained against α-Lmj during validation, 
approximately 19,000 compounds were expected to be identified from the 1.8 million 
compound library.  Further screening steps against both α-Lmj and α-AUR1 would 
subsequently be required to differentiate between compounds that act on LmjIPCS and 
those that act via generic S. cerevisiae biochemical pathways. 
 
 The assay was commenced utilising the optimised conditions.  Following the 
reading of the first test-set of 53 plates, however, it was immediately apparent that the 
cycloheximide control mean had risen further, implying a reduction in growth 
inhibition.  This had a profound impact on the Z′ values and resulted in the majority of 
the plates in this test-set failing.  A fresh cycloheximide solution was found to reverse 
this effect, suggesting that the numerous freeze-thaws that were undertaken during the 
optimisation and validation process contributed towards an elevated rate of breakdown 
of the compound in solution.  The resulting action was to prepare a fresh solution on a 
weekly basis for the remainder of the screening process.  In addition, the drop in 
fluorescence in the DMSO control wells was found to be due to the microplates used in 
the assay; during optimisation microplates were sterilised in house whereas for 
validation and screening they were purchased pre-sterilised.  However, given that the Z′ 
values were still excellent, the decision was made to continue using the pre-sterilised 
plates in order to allow the throughput to remain as high as possible. 
 
 With these matters addressed, screening the remainder of the library was 
undertaken on an ultra-high throughput scale; on average, 120 plates (> 165,000 
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compounds) were tested per day.  Following reading, plates were visualised using the 
GSK-developed statistical online data analysis (SODA) software providing an output as 
shown in Figure 3–12.  The brighter the colour, the higher the inhibition of growth (the 
cycloheximide control mean was set to 100%). 
 
 The SODA software was also used to calculate the Z′ for each test plate.  Data from 
the plates that were above the Z′ threshold of 0.4 were uploaded to the ActivityBase 
software package (IDBS, Guildford, Surrey, UK) which is specifically designed for 
scientific data management.
337
  A total of 1,312 plates were tested in the initial screen 
with 67 (5%) of these failing.  The majority of these failed plates, which subsequently 
had to be retested, originated from the first test-set due to the problem with the 
cycloheximide solution, whilst very few plates failed during the remainder of the screen.  
The distribution of Z′ values for the primary screen is shown in Figure 3–13 with the 








Figure 3–12: An example plate from the primary screen.  The DMSO control is in columns 11 
and 12 and the cycloheximide control is in columns 35 and 36.  Wells with inhibited growth are 
coloured yellow, whilst wells showing no inhibition are red.  Figure provided by Dr E. Alvarez 





 Before the data could be analysed, further processing was required to remove the 
patterns that were observed in a non-negligible number of plates.  The majority of these 
were mild evaporation effects that were not significant enough to result in plate failure 
but still impacted on the numerical data obtained.  Dispensation effects, where 
individual tips dispensed a lesser or greater amount than required into blocks of four 
rows, were also sporadically observed.  In order to account for these effects the plate 
data were fed into a GSK-developed pattern recognition and fixing algorithm which 
subsequently corrected the affected data to diminish the effect of the pattern.  Two 















Figure 3–13: The distribution of Z′ values for the primary screen 
a 
b 
Figure 3–14: (a) The correction of a dispensation (positional) effect and (b) 
the correction of an evaporation effect in a 1,536-well test plate; the brighter 
the colour, the greater the effect.  Figures provided by Dr G. Colmenarejo 
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 Following this rectification, the % inhibition threshold was calculated for each test-
set (to avoid day to day variation) using equation 1.1.  This yielded 10,807 compounds 
that were statistical hits; however, this was far below the 19,000 compound estimate 
made following the screen of the validation set.  Further analysis of the data revealed 
that there were many compounds with favourable drug-like properties (within the ‘rule 
of 5’ limits as discussed in section 1.4.2.5) that were just below the calculated threshold.  
To investigate this, the threshold was recalculated for all the compounds in each test-set 
with a calculated LogP (cLogP) less than or equal to 3 and a molecular weight less than 
or equal to 300.  In every case the recalculated threshold was significantly lower than 
the original, in some cases by as much as 13% (Figure 3–15). 
 
 These results mirrored a trend observed in the pharmaceutical industry in the early 
to mid 2000s whereby increasingly lipophilic compounds, rather than more polar ones, 
were being identified by screening and progressed to lead optimisation and clinical 
trials only to result in failure.  This was observed in a study by Leeson and Springthorpe 
who noted that compounds in drug development programmes showed a mean cLogP 
value 1.5 log units greater than the mean for oral drugs launched between 1983 and 
2007.
338
  However, rising attrition rates indicated that this was not the best strategy to 
take and suggested that high polarity compounds were more promising as potential 























Threshold (cLogP ≤ 3, 
MW ≤ 300) 
Threshold (cLogP > 3, 
MW > 300) 
Figure 3–15: The difference between the calculated thresholds 
for small, polar compounds and large, non-polar compounds 
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 It was therefore necessary to rescue these small, polar compounds that would 
otherwise be lost from the screening process.  In order to achieve this, the test-sets were 
separated into the two groups of compounds (cLogP ≤ 3, MW ≤ 300 and cLogP > 3, 
MW > 300) and reanalysed using the recalculated thresholds shown in Figure 3–15.  
This resulted in the inclusion of many drug-like compounds that were classed as 
inactive using the overall thresholds, and the total number of compounds that were 
classified as hits using this method was 19,382.  However, larger compounds that were 
classed as hits using the overall threshold but were inactive using the slightly higher 
threshold for the cLogP > 3, MW > 300 group were also included so as not to discount 
potentially active compounds.  As a result, the total number of hit compounds arising 
from the primary screen was 19,669. 
 
3.3.5 Confirmation of Hits 
 
 With these compounds in hand, the next stage was to retest them in order to 
confirm their activity and discount the possibility that they were false positives.  An 
extra consideration to take into account was the fact that the next stage of the HTS 
process, the production of dose-response curves, can only be undertaken on a maximum 
of ~5,000 compounds.  As this assay format proved very robust and produced 
consistently high Z′ values, the probability that retesting alone would reduce the number 
of compounds from 19,669 to fewer than 5,000 was low.  The decision was therefore 
made to run this assay against both the α-Lmj and α-AUR1 strains in order to allow the 
removal of compounds which inhibited the growth of both strains.  This meant that 
compounds targeting both the LmjIPCS and the yeast AUR1 would be lost, but this 
number was predicted to be small given that the majority of compounds that affect both 
strains would likely be acting via off-target effects.   
 
 The confirmation assay was undertaken in duplicate for each strain, and example 
plate images are shown in Figure 3–16.  The majority of the tested compounds showed 
activity against α-Lmj (Figure 3–16 (a)), as would be expected given that they were all 
above the inhibition threshold in the primary screen.  Gratifyingly, whilst many 
compounds were also active against α-AUR1, there were many that displayed lower 
activity than against α-Lmj or were inactive altogether (Figure 3–16 (b)). 
 





 In order to select which compounds to progress to the dose-response stage, the 
separate inhibition thresholds for each strain were calculated and compounds that 
produced a response below the α-Lmj threshold were filtered out.  Of the remaining 
compounds, those that showed activity above the α-AUR1 threshold were also removed, 
leaving 3,573 compounds which demonstrated specificity for the LmjIPCS enzyme.  To 
these were added all the compounds which showed a response greater than 80% 
inhibition against α-Lmj regardless of the response against α-AUR1.  This step was 
performed to avoid highly potent compounds being lost due to the stringent filtering 







Figure 3–16: Example plates from the confirmation screen for (a) 10 µM against α-Lmj 
and (b) 10 µM against α-AUR1.  The DMSO control is in columns 11 and 12 and the 
cycloheximide control is in columns 35 and 36.  Wells with inhibited growth are coloured 
yellow, whilst wells showing no inhibition are red.  Figures provided by Dr E. Alvarez 
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3.3.6 Dose-Response Studies 
 
 The final stage of the high-throughput screen undertaken was the dose-response study, 
which involved testing the remaining compounds against both the α-Lmj and α-AUR1 
strains over a range of concentrations.  This would allow the determination of IC50 
values (the concentration of the compound required to give 50% inhibition) against both 
strains, hence providing a more comprehensive analysis of compound specificity.  The 
dose-response assay was undertaken in duplicate for each strain utilising a dilution 
factor of ⅓ for each compound; this resulted in a concentration range of 100 µM to     
1.7 nM with a total of 11 concentrations tested.  An example plate is shown in Figure   
3–17. 
  
 The results from this experiment were analysed using the ActivityBase software 
package (IDBS, Guildford, Surrey, UK) which was used to fit curves to the data 
(examples shown in Figure 3–18).  From these the pIC50 (−log10(IC50)) values for each 
compound were calculated against both α-Lmj and α-AUR1, and the resulting plot is 
shown in Figure 3–18 (c)).  Given that this is a log scale, a pIC50 of 4 corresponds to 
10
−4
 (100 µM), 5 corresponds to 10
−5
 (10 µM) and so on.  Therefore, in terms of the 
selectivity indices used to group compounds on the plot (with the corresponding 
numerical data in Table 3–2) a selectivity index (SI) of 1 indicates that a compound is 
10 times more potent against α-Lmj than α-AUR1.  Similarly, a SI of 2 indicates a 100-
fold difference in potency. 
Figure 3–17: An example plate from the dose-response screen.  Four compounds could 
be tested per row, two in the odd columns (1, 3, 5 ... 23 and 25, 27, 19 ... 47) and two in 
the even columns (2, 4, 6 ... 24 and 26, 28, 30 ... 48) with compound concentration 
decreasing from left to right.  The DMSO control is in columns 11 and 12 and the 
cycloheximide control is in columns 35 and 36.  Wells with inhibited growth are coloured 
yellow, whilst wells showing no inhibition are red.  Figure provided by Dr E. Alvarez 















  Selectivity Index (x) Number of Compounds 
x ≤ 0.0 508 
0.0 < x ≤ 0.5 765 
0.5 < x ≤ 1.0 1,308 
1.0 < x ≤ 1.5 1,085 
1.5 < x ≤ 2.0 397 
2.0 < x ≤ 2.5 77 
2.5 < x 26 
Table 3−2: The number of compounds per 




Figure 3–18: Example dose response curves for (a) a compound selective for 
LmjIPCS over AUR1 and (b) an unselective compound.  (c) A plot of the pIC50 
for AUR1 against the pIC50 for LmjIPCS for each compound, where x is the 
















pIC50 against LmjIPCS  
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 These data showed that, of the 4,166 compounds tested, there were 500 with a SI 
greater than 1.5 and 103 with a SI greater than 2.0.  These compounds were therefore 
highly active against the LmjIPCS enzyme yet showed little activity against the            
S. cerevisiae AUR1 enzyme and resulted in few off-target effects.  These numbers were 
unexpectedly high given the observations that were made during the validation screen of 
the HTS process (discussed in section 3.3.3), indicating that the screen was more 
fruitful than originally anticipated. 
 
 The compounds were subsequently clustered into structural families by Dr G. 
Colmenarejo (GSK Computational and Structural Chemistry group).  This was achieved 
using an in-house sphere exclusion algorithm as described by Butina.
339
  Briefly, the 
software first created a unique fingerprint for each compound by examining the location 
of each atom with respect to every other atom within 7 bonds.  The fingerprint for each 
molecule in the set was then compared to the fingerprint for every other molecule, and 
the compound with the largest number of neighbours was used to lead the first cluster.  
Any compounds with a similarity greater than 0.85 (where similarity is on a scale from 
0 to 1) were sorted into that cluster and removed from the list, excluding them from 
subsequent searches.  The compound with the next highest number of neighbours was 
subsequently selected and the process repeated until only compounds with no similarity 
to any other, named singletons, were remaining.  Two representatives from each cluster 
were selected at random for further testing along with all the singletons.  A total of 216 




 The work described in this chapter involved the development and optimisation of 
an assay that was suitable for HTS.  An assay format based on fluorescence output was 
selected over a multiplex assay and was subsequently used to screen GSK’s 1.8 million 
compound library.  A total of 216 compounds were ultimately selected for further 
investigation, which is described in the next chapter.  To the best of the author’s 
knowledge, this is the largest screening programme conducted by an academic group to 
date.   
 
 





Chapter 4  
 





 Having selected 216 compounds from the HTS campaign, the next stage of the 
project was to identify a small number of compounds or compound series to investigate 
further.  This aim necessitated the use of a number of assays not previously utilised in 
the project.  This ongoing screening project was undertaken with the support and 
assistance of GSK. 
 
4.2 L. major Promastigote Screening 
 
 The continued screening commenced with the testing of the 216 compounds against 
the promastigote stage (found in the insect vector) of the wild type, Friedlin virulent 
strain (FV1) L. major parasites.  All of the compounds selected for continued testing 
displayed a pIC50 of 5.0 or greater in the dose-response assay against LmjIPCS, which is 
equivalent to 50% inhibition of growth at 10 µM.  Testing against L. major 
promastigotes at 10 µM would therefore give an indication of how many compounds 
retain activity against parasites. 
 
 As with the HTS yeast assay, the parasite cytotoxicity assay was based on 
fluorescence and involved the incubation of L. major promastigote parasites with the 
test compounds prior to the addition of resazurin (trade name AlamarBlue
®
).  This is a 
blue, weakly fluorescent dye that is reduced in cellulo to the pink, highly fluorescent 
compound resorufin (Figure 4–1).
340
  The fluorescence output is therefore representative 
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of parasite viability, with a lower readout indicative of decreased growth and hence an 
effective antiparasitic compound. 
 
 The first iteration of the assay followed an established protocol,
320
 whereby 




 were incubated with the compounds (with 
the antileishmanial drug AmB (4, Figure 1–4) used as the positive control) for 24 hours 
prior to AlamarBlue
®
 addition.  However, the results between replicates were 
inconsistent and only 17 compounds repeatedly demonstrated inhibition above 50%.  
One possible explanation is that the number of cells per well between this assay and the 




 and the HTS 




.  The 10 fold increase in cells effectively 
reduces the relative concentrations of the test compounds and could explain why lower 
levels of inhibition were observed. 
 
 In order to address this, a lower starting concentration of parasites was required; 
this would, however, have to be accompanied by an increase in incubation time in order 
to maintain sufficient fluorescence readout.  The growth of various starting 
concentrations of parasites was subsequently examined over three different time periods 
(Appendix B) and, as predicted, reducing parasite concentration resulted in insufficient 
fluorescence output after 24 hours.  Whilst 48 hours resulted in a significant 
improvement, a 72 hour incubation period was selected in order to accurately mirror the 
protocol used for testing L. donovani axenic amastigotes (discussed later).
341
  On this 









 was selected for use in the assay. 
 
 Testing of the 216 compounds was repeated using the modified protocol and the 
results are shown in Figure 4–2.  Of the 216 compounds, 99 retained inhibitory activity 
greater than 50%, with 43 of these demonstrating complete inhibition.  117 compounds 
therefore showed a reduction in activity compared to the yeast dose-response assay, 
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with many appearing to have a mitogenic effect.  This could potentially be explained by 
differences in membrane composition between the two organisms, or by an increased 
rate of drug metabolism in L. major compared to yeast.  Alternatively, there could be a 
difference in the rate at which the organisms transport compounds out of the cell using 
drug efflux pumps. 
 
 These results were promising, with 99 compounds demonstrating significant 
antiparasitic activity.  However, whilst CL, of which L. major is a causative species, is 
more prevalent than VL, its non-fatal clinical manifestation means that it is less of a 
priority for drug discovery for GSK.  VL, on the other hand, has been targeted for 
control by 2020,
162
 and therefore compounds that have inhibitory activity against the 
IPCS from a species that causes VL, such as L. donovani,
21
 would be favoured for 
progression.  The following cell-based screening assays described in section 4.3 were 
carried out with the support of GSK at Tres Cantos. 
 
4.3 Compound Triage 
 
4.3.1 Primary Compound Triage 
 
4.3.1.1 L. donovani Axenic Amastigote Screening 
 
 Testing of the 216 compounds against L. donovani was initially undertaken in a 
dose-response assay against axenic amastigote parasites.  As discussed in section 
Figure 4–2: The inhibitory activities of the 216 compounds tested at 10 µM 
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1.2.1.2, amastigotes are the life cycle stage observed intracellularly in the mammalian 
host and are therefore more clinically relevant than the insect stage promastigotes.
33
  
Axenic testing was preferred at this stage due to the ease of assay implementation and 
the higher throughput achievable. 
 
 The assay was executed according to an established protocol,
341
 again relying on 
fluorescence resulting from resorufin production.  As with the L. major promastigote 




 parasites were incubated with the compounds for 72 hours 
prior to resazurin addition.  A dilution factor of ⅓ was used for each compound; this 
resulted in a concentration range of 50 µM to 0.85 nM with a total of 11 concentrations 
tested.  This allowed the determination of the ED50 (the concentration required to 
produce 50% inhibition of growth) and subsequently the pED50 (−log10(ED50)) for each 
compound.  The results (Figure 4–3) were promising; whilst 56 compounds were 
completely ineffective, 75 demonstrated a pED50 greater than or equal to 5.0 (equivalent 












 Of these 75 compounds, 51 showed inhibition greater than 50% at 10 µM against   
L. major.  This number was larger than expected as the difference in biochemistry 
between species,
342
 as well as between promastigotes and amastigotes, is significant.  
For example, the different forms utilise different energy sources; L. donovani 
promastigotes predominantly metabolise glucose whilst amastigotes utilise fatty acid 
metabolism,
343
 and one L. donovani glycolytic enzyme is only a pseudogene in             
L. major.
344













Figure 4–3: The pED50 values of the 216 compounds tested 




 axenic L. donovani amastigotes for 72 hours 
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intramacrophage environment, and compounds therefore have to remain stable in an 
acidic environment.  However, the IPCS coding sequence from L. donovani is very 
similar to L. major (93% identity) so the fact that so many compounds retained activity 
against two different Leishmania species was reassuring as it suggests that the target is 
valid in at least these two species.  In addition, it verifies that the assays used are 
effective at identifying inhibitors of highly related targets. 
 
4.3.1.2 HepG2 Cytotoxicity Screening 
 
 With the ultimate aim of identifying a compound series suitable for entry into in 
vivo proof of concept studies, the next stage of compound testing was a cytotoxicity 
assay to identify compounds with significant host toxicity.  As a preliminary way of 
investigating host toxicity, the 216 compounds were tested against cells from the 
HepG2 line, which is derived from a human hepatocellular carcinoma.
345
  This cell line 
is commonly used as an indicator of cytotoxicity due to the fact that the majority of 
drug metabolism occurs in the liver and hence the effect of both the parent compound 




 The assay was executed according to an established protocol.
347





 HepG2 cells were incubated with the compounds for 48 hours.  A 
dilution factor of ⅓ was used for each compound; this resulted in a concentration range 
of 100 µM to 1.7 nM with a total of 11 concentrations tested.  Compound toxicity 
following incubation was measured by the addition of CellTiter-Glo
®
 (Figure 4–4).  
This reagent allows the quantification of cell viability by producing a luminescent 
signal proportional to the quantity of adenosine triphosphate (ATP) present.  The 
luminescence output is therefore representative of cell viability, with a lower readout 























Figure 4–4: The conversion of luciferin to oxyluciferin by Ultra-
Glo™ recombinant luciferase accompanied by the production of light 
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 The results are shown in Figure 4–5.  In total, 148 of the 216 compounds tested 
demonstrated a pED50 less than or equal to 4.0 and hence were classed as non-toxic 
against the HepG2 cells.  However, comparison with the L. donovani axenic amastigote 
assay results was required in order to select compounds of interest. 
 
4.3.1.3 Compound Selection 
 
 The primary compound selection was achieved using two factors (criteria set 1): 
 
1. The pED50 against axenic L. donovani amastigotes was required to be greater than 
or equal to 5.0.  This is equivalent to an ED50 of less than or equal to 10 µM. 
2. The pSI (logarithm of the selectivity index, as discussed in section 3.3.6) over 
HepG2 cells was required to be greater than or equal to 1.0.  This is equivalent to 
the compound demonstrating at least 10 fold greater potency against the                 
L. donovani amastigotes than the HepG2 cells. 
 
 The application of this set of criteria is shown in Figure 4–6.  Compounds which 
were inactive against L. donovani amastigotes, or which were active but also cytotoxic 
to HepG2 cells, were filtered out.  Of the 216 compounds, 53 fulfilled both of the above 
















Figure 4–5: The pED50 values of the 216 compounds 




 HepG2 cells for 48 hours 




4.3.2 Secondary Compound Triage 
 
 The secondary stage of compound selection was achieved based on 
physicochemical properties.  As discussed in sections 1.4.2.5 and 3.3.4, smaller and 
more hydrophilic compounds are favoured for progression due to their tendency to 
result in more effective drugs.  As a result, the secondary compound selection was 
achieved using two factors (criteria set 2): 
 
1. The number of aromatic rings was required to be less than or equal to 4.  Aromatic 
rings increase hydrophobicity, hence compounds with fewer rings are more likely 
to possess favourable overall drug-like properties. 
2. The property forecast index (PFI), calculated as shown in equation 4.1, was 
required to be less than or equal to 8.0.  This term is a measure of the intrinsic 
hydrophobicity of a compound; high PFI is indicative of high hydrophobicity and is 








 Whilst PFI is sometimes calculated using the LogP value, this does not take into 
account the fact that ionisable compounds will be present in both the ionised and 


















pED50 against axenic L. donovani amastigotes 
Figure 4–6: The pSI for axenic L. donovani amastigotes over HepG2 
cells plotted against the pED50 against axenic L. donovani amastigotes 
for the 216 compounds, with the limits of criteria set 1 shown in green 
(4.1) PFI = LogD7.4 + #Ar 
where: PFI   = property forecast index 
 LogD7.4  = logarithm of the 1-octanol−water distribution coefficient 
 #Ar   = number of aromatic rings  
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LogD7.4, which is dependent upon the concentrations of both the ionised and unionised 
forms in octanol and water.  LogD is often measured pharmaceutically at pH 7.4, as this 
is the physiological pH of blood serum.  The LogD7.4 values of the 216 compounds, 
however, had not been determined and therefore PFI was predicted using cLogP values.  
 
 The application of this set of criteria is shown in Figure 4–7.  Of the 53 compounds 
studied, all possessed a maximum of 4 aromatic rings and therefore fulfilled the first 
criterion.  The suitability of the compounds for selection was therefore dependent upon 
the PFI, and 30 of the 53 compounds possessed a PFI value lower than or equal to the 
threshold and were therefore advanced for additional testing. 
 
4.3.3 Tertiary Compound Triage 
 
4.3.3.1 L. donovani Intramacrophage Screening 
 
 The 30 selected compounds were subsequently tested against intramacrophage      
L. donovani amastigotes.  This assay more accurately mimics the disease state than the 
previously utilised axenic assay and is therefore a better representation of how effective 
the compounds might prove to be in in vivo studies. 
 
 The assay was executed according to an established protocol.
341
  The human 
biological samples were sourced ethically and their research use was in accord with the 




 THP-1 derived macrophages 

























Figure 4–7: The number of aromatic rings plotted against the predicted 
PFI for the 53 compounds, with the limits of criteria set 2 shown in green 
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multiplicity of 10 and incubated prior to the addition of the test compounds.  A dilution 
factor of ⅓ was used for each compound resulting in a concentration range of 50 µM to 
0.85 nM with a total of 11 concentrations tested.  Following a 96 hour incubation the 
cells were fixed and stained.  Wells were imaged by microscopy (an example is shown 
in Figure 4–8) and analysed using Acapella
®
 High Content Imaging and Analysis 








  The results of this assay (Figure 4–9) were promising, with only 10 compounds 
being completely ineffective (pED50 less than or equal to 4.3) against the 
intramacrophage amastigotes.  The loss of activity for some compounds was expected 
given that, as discussed in section 1.4.2.2.1, they have to be capable of crossing multiple 
membranes.
266
  In addition, macrophages themselves express a range of drug 
transporters that control the uptake and efflux of the compounds being tested and hence 
will affect the concentration of the test compound that the parasites are exposed to.
349
  
Despite this, seven compounds displayed activity in the low µM range (pED50 greater 











Figure 4–8: The infection of macrophages, the nuclei of which have been stained 
red, with L. donovani amastigotes expressing eGFP.  Figure provided by Dr J. Martin 
Figure 4–9: The pED50 values of the 30 compounds tested 











40 µm  
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4.3.3.2 THP-1 Cytotoxicity Screening 
 
 In order to confirm the activities observed against intramacrophage L. donovani 
amastigotes, a second cytotoxicity assay was required against the macrophages 
themselves.  These were obtained by the differentiation of THP-1 premonocytes, a cell 
line derived from the blood of a human patient with acute monocytic leukaemia.
350
  
Differentiation is achieved by exposure to phorbol myristate acetate, which is an 
activator of protein kinase enzymes and a promoter of tumour growth.
351
  THP-1 
derived macrophages exhibit multiple advantages compared to those derived from 
commercially available peripheral blood mononuclear cells, including a faster growth 





 The assay was conducted as in section 4.3.3.1 with the modification that                
L. donovani amastigotes were not added; instead, compound inhibitory activity against 
the macrophages was determined using HCS CellMask™ Deep Red dye and the 
subsequent cell count.  The results (Figure 4–10) show that 19 of the 30 compounds 
exhibited no cytotoxic activity on the macrophages (pED50 less than or equal to 4.3).  
However, as with the HepG2 cytotoxicity assay, comparison with the L. donovani 















Figure 4–10: The pED50 values of the 30 compounds tested against THP-1 cells for 96 hours 
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4.3.3.3 Compound Selection 
 
 The tertiary compound selection was achieved using two factors (criteria set 3): 
 
1. The pED50 against intramacrophage L. donovani amastigotes was required to be 
greater than or equal to 5.0.  This is equivalent to an ED50 of less than or equal to 
10 µM. 
2. The pSI over THP-1 cells was required to be greater than or equal to 1.0.  This is 
equivalent to the compound demonstrating at least 10 fold greater potency against 
the L. donovani intramacrophage amastigotes than the THP-1 cells. 
 
 The application of this set of criteria is shown in Figure 4–11.  Compounds which 
were inactive against intramacrophage L. donovani amastigotes, or which were active 
but also cytotoxic, were filtered out.  Of the 30 compounds tested at this stage, six 
fulfilled both of the above criteria.  These compounds, which include two series and two 
















Figure 4–11: The pSI for intramacrophage L. donovani amastigotes over THP-1 
cells plotted against the pED50 against intramacrophage L. donovani amastigotes 
for the 30 compounds, with the limits of criteria set 3 shown in green.  10 
compounds are overlaid on the marker highlighted in yellow, 4 are overlaid on the 


















pED50 against intramacrophage L. donovani amastigotes 
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Table 4−1: The structures, properties and inhibition results 





  Compound 















































































74.1 5.3 5.7 4.0 4.3 4.7 2 
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 From the data shown above, the two series appear to be the most promising options 
for further development.  The benzazepane compounds (23 and 24) demonstrate the 
most potent antiparasitic activity, with both active in the nM range against axenic 
amastigotes and in the low µM range against intramacrophage parasites.  However, their 
physicochemical properties are at the upper end of the limits set by the selection criteria, 
which could result in a reduced potency in vivo. 
 
 By contrast, the dithiophene compounds (25 and 26) possess comparable 
antiparasitic activities against intramacrophage parasites to the benzazepanes whilst 
their PFI values are far more favourable and well within the permitted limits.  The basic 
chemical structure of the dithiophenes is also simpler than the benzazepanes, meaning 
they may lend themselves more favourably to a medicinal chemistry campaign.  The 
presence of the nitro group, however, is a possible cause for alarm given that this 
functional group can undergo enzymatic reduction and has been linked to a range of 
toxic issues including hepatotoxicity, carcinogenicity and immunosuppression.
353
  
Whilst the presence of a nitro group does not necessarily preclude a compound making 
it to market (Nifurtimox (10, Figure 1–7) being one such example) it remains a cause 
for concern. 
 
 The singleton 28 is the least potent of the six compounds in both L. donovani 
assays.  In addition, this compound also possesses a nitro group.  Singleton 27, on the 
other hand, was the only compound tested in the intramacrophage L. donovani assay 
that exhibited a potency in the nM range.  This was, however, offset by significant 
activity against THP-1 cells, resulting in a pSI of only 1.1. 
 
 Overall, the continued screening campaign was successful in significantly reducing 
the number of compounds of interest.  However, all of the screens described above were 
conducted at the cellular level and provide no information on the specific activities of 
the compounds against the IPCS enzyme; the only information regarding this so far 
were the dose-response results against yeast.  Additional screens were therefore required 
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4.4 Lead Selection 
 
 In order to permit dose-response testing, additional quantities of compounds 25, 26, 
27 and 28 were provided by GSK.  The benzazepane compounds 23 and 24 were 
resynthesised as the free base compounds 29 and 30 respectively (Figure 4–12) by the 
pharmaceutical services company Aptuit (www.aptuit.com).  Of the six compounds, 
these were the most attractive due to the fact that they are obviously part of a series 
rather than singletons, and they lack the concerning nitro group.  In addition, there was 
no competing interest with regards to these compounds from other drug development 
campaigns within GSK. 
 
4.4.1 L. major pED50 Determination 
 
 The six selected compounds, which all showed greater than 50% inhibition against 
L. major promastigotes at 10 µM (Figure 4–2), were subsequently tested in a dose-
response assay.  In order to allow comparison, it was decided to conduct experiments 
against both wild type L. major FV1 parasites and L. major lcb2Δ mutants, which lack 
subunit 2 of the serine palmitoyltransferase enzyme.
354, 355
  These mutants still produce 
the IPCS but the enzyme is redundant due to the lack of available in situ substrate.  This 
strain should therefore be resistant to inhibitors specific for IPCS. 
 
 Before screening could commence, the starting concentration of parasites in the 
assay needed to be checked as slower growth is observed with the sphingolipid-
deficient mutants.  The resulting growth curve for an incubation period of 72 hours 




, which was used 













SB-762123-AAA (29)  VAPT/8555/172/3 (30) 
Figure 4–12: The structures of the resynthesised free bases 
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fluorescence output even after 8 hours incubation with AlamarBlue
®
.  The decision was 
therefore made to increase the starting concentration for both wild type and mutant      




.  This resulted in the doubling of the 
fluorescence readout for the mutants in a consistent, reproducible manner, whilst 
remaining as close to the original assay parameters as possible. 
 
 The dose-response assay was conducted with a dilution factor of ½ for each 
compound; this resulted in a test concentration range of 10 µM to 78 nM with a total of 
8 concentrations tested.  The results are shown in Figure 4–13.  Compounds 26 and 28, 
despite demonstrating significant inhibition of growth of L. major FV1 parasites at      
10 µM, were weakly inhibitory at lower concentrations and the pED50 values were 
calculated at less than or equal to 5.0.  Of the remaining four compounds, only 25 
showed a significant difference in inhibition between the wild type and mutant 
parasites, with a t-test producing a P value of 0.033 (meaning that, if there was no 
significant difference between the results, there would be only a 3.3% probability of this 
observation occurring).  However, the fact that the compound was more effective 
against the L. major lcb2Δ mutants than the wild type, and that no significant difference 
was observed for any of the other compounds, suggests that either IPCS is not being 
inhibited or that the compounds have additional effects on targets other than IPCS.  In 











Figure 4–13: The pED50 values of the 6 selected compounds tested against wild 
type L. major FV1 and sphingolipid-deficient mutant L. major lcb2Δ for 72 
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4.4.2 Biochemical Screening 
 
4.4.2.1 Primary Screening 
 
 The biochemical assay, as described in section 2.4.2, involved incubating LmjIPCS-
enriched microsomal membranes with NBD-C6-ceramide, a fluorescent ceramide 
analogue, to produce the fluorescent product NBD-C6-IPC (Figure 2–6).  However, due 
to the low throughput possible with the HPTLC assay, screening was instead conducted 
in 96-well plate format.
320
  The separation of the product from the starting material was 
possible using an ion exchange resin. 
 
 The assay was initially conducted according to the protocol previously developed in 
the group.
320
  However, further optimisation proved to be necessary as the preliminary 
trial results were extremely inconsistent.  This was postulated to be predominantly due 
to the use of the vacuum manifold during the separation steps, which appeared to apply 
an uneven vacuum across the plates.  This issue was resolved by using a centrifuge for 
these steps, although the spin time had to be carefully controlled to prevent the ion 
exchange resin drying out.  In addition, the duration of the incubation steps was 
modified; the pre-incubation step was reduced to 15 minutes and the assay time 
shortened to 25 minutes as this was also found to improve consistency. 
 
 Prior to commencing the screening, a suitable positive control compound had to be 
identified.  Clemastine (21, Figure 3–8), which had previously displayed a pIC50 of 6.4 
in the biochemical assay, was tested alongside the three ceramide analogues         
(Figure 4–14 (a)) with the highest inhibitory activity from a library synthesised and 
tested by Dr J. Mina.
212
  The results (Figure 4–14 (b)) were unexpected, with clemastine 
showing the least inhibition compared to the DMSO control; this resulted in a Z′ of 0.28 
when tested at 25 µM.  This was postulated to be due to compound instability in 
solution, although this was not explored further.  The best of the compounds tested was 
JM222 (32) which reduced the mean fluorescence output from 11,900 to 595.  This was 
equivalent to a Z′ of 0.75, and this compound was consequently selected for use as the 
control. 

















 Whilst only six compounds fulfilled the selection criteria as described previously, 
the decision was made to run the assay against all 216.  This was in order to validate the 
compounds which, due to the nature of the HTS screening process described in the 
previous chapter, should all be inhibitors of LmjIPCS.  This assay, being the only one 
performed in vitro, was also orthogonal to all the assays utilised thus far and therefore 
may identify potent inhibitors of LmjIPCS which were not active in cellulo. 
 
 The 216 compounds, plus the two resynthesised benzazepanes, were tested at       
10 µM and the results are shown in Figure 4–15.  Whilst 12 of the 216 showed good 
activity (inhibition greater than 50%), the inhibition values obtained were, in general, 
significantly lower than in any of the parasite assays, or the original HTS assay, thus 
far.  One possible explanation for this is that the amount of biological material in this 
assay (0.6 enzyme units (U) per well, where 1 U = 1 pmol(product) min
−1
) is 
significantly greater than that used in the HTS assay (approximately 4.0 × 10
–5













































JM112 (31) JM222 (32) JM336 (33) 
b 
Figure 4–14: (a) The structures of the inhibitors tested in the biochemical 
assay and (b) the results of the inhibition testing at 25 µM.  Error bars 
show the standard error of the mean for a quadruplicate set of data 
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well); as discussed in section 4.2, this effectively reduces the relative concentration of 
the test compounds.  Whilst this variation is obviously not ideal, this is the minimum 
amount of microsomal material required in the biochemical assay to produce a 
measurable signal with sufficient signal to noise; the use of less also decreased result 
consistency.   
 
 One other factor that has to be considered is that the IPCS enzyme is membrane-
bound, and hence cannot be readily expressed in and purified from bacteria such as      
E. coli.  As a result, it is not pure enzyme that is being tested in the biochemical assay 
but microsomes which, whilst enriched in LmjIPCS, contain a variety of other proteins 
possibly including cytochrome P450s.
356
  These enzymes account for roughly 75% of 
drug metabolism,
357
 and it is possible that compound degradation could be occurring 
during the course of the assay despite the overall incubation time being reduced from 
the published protocol.  This hypothesis could be checked using a known cytochrome 
P450 inhibitor, such as quinidine,
358
 which would be incubated along with the test 
compounds in order to see if apparent inhibitory activity was improved. 
 
 Despite the inhibition values being lower than ideal, compound 27 along with both 
the original benzazepanes (23 and 24) and the free bases (29 and 20) showed greater 
than 25% inhibition, putting them in the top 15% of the compounds tested.  These 

















Figure 4–15: The inhibitory activities of the 216 compounds and the 
resynthesised benzazepanes tested at 10 µM against LmjIPCS microsomes.  
From left to right, compound 23 is highlighted in red, compound 24 in yellow, 
compound 28 in green, compound 27 in blue, compound 26 in orange, 
compound 25 in purple, compound 29 in turquoise and compound 30 in pink 
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4.4.2.2 pIC50 Determination 
 
 The three selected compounds were subsequently subjected to IC50 determination in 
a dose-response assay, which was conducted with a dilution factor of ⅓ for each 
compound.  This resulted in a test concentration range of 100 µM to 46 nM with a total 
of 8 concentrations tested.  Examples of the curves produced are shown in Figure 4–16.   
 
 Compound 27, which displayed the highest inhibition of the three compounds in the 
primary assay, was the least active at 100 µM and was calculated to have a pIC50 of 4.5.  
This level of activity was not sufficient to warrant further exploration as a potential 
IPCS inhibitor.  On the other hand, the two benzazepane compounds yielded excellent 
results, with 29 exhibiting a pIC50 of 6.1 and 30 exhibiting a pIC50 of 5.7.  These two 
compounds have therefore proven themselves to be potent inhibitors of LmjIPCS, with 
this translating into good antileishmanial activity against both L. major and L. donovani.  
As a result, it was decided to utilise the benzazepanes as starting points for a hit-to-lead 





























Figure 4–16: Example IC50 curves from a single experiment for (a) 
compound 29, (b) compound 30 and (c) compound 27.  The mean 
pIC50 values, calculated from a quadruplicate set of data, are shown 
pIC50 = 6.1 
pIC50 = 5.7 
pIC50 = 4.5 
c 
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 The work described in this chapter involved the further screening of 216 
compounds identified by HTS.  Six compounds with high antileishmanial activity, low 
mammalian cytotoxicity and favourable physicochemical properties were identified, and 
further biochemical testing identified two compounds from the same structural family as 
potent inhibitors of LmjIPCS.  Additional testing in order to determine whether this 
series was suitable for lead optimisation and subsequent progression to clinical trials 












Chapter 5  
 




 Having identified a compound series worthy of further investigation, attention 
turned to the exploration of SARs in order to determine whether the antiparasitic and 
biochemical properties of the two compounds studied thus far could be improved upon.  
With the core benzazepane structure identical between the two compounds, the primary 
variations explored were the left and right hand sides of the compounds.  The simplest 
examples, the mix and match compounds with the right hand sides of compounds 29 
and 30 exchanged (Figure 5–1), were prioritised for analysis. 
 
5.2 Pyrrole-Pyridine Benzazepane  
 
5.2.1 Antileishmanial and Biochemical Activity 
 
 Compound 34 was initially subjected to a range of assays as previously described in 
chapter 4.  As can be seen from Figure 5–2, the biochemical activity (pIC50 = 4.2) was 

















 Figure 5–1: The structures of the mix and match benzazepane compounds 
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biochemical activity is to a certain extent dependent on either the substituted indole ring 
on the left hand side of the molecule or the substituted benzene ring on the right hand 
side.  With little known about the structure of the IPCS protein, it is not clear why 
particular rings would be important, although they could either fit better into a pocket in 
the protein structure or be involved with π-stacking interactions with aromatic amino 
acids.
359
  This decrease in biochemical activity did not, however, result in a decrease in 
antileishmanial activity; on the contrary, pED50s of 5.6 and 6.3 were observed against   
L. major wild type promastigotes and intramacrophage L. donovani amastigotes 
respectively.  The high potency against intramacrophage L. donovani was particularly 
exciting given that the pED50 against THP-1 macrophages was only 5.0.  Whilst the 
physicochemical properties were not ideal – the PFI was 8.4, which would not have 
passed the selection criteria described in chapter 4 – the high potency against                
L. donovani intramacrophage amastigotes led to the decision to test the compound in 
vivo, which was carried out with the support of the London School of Hygiene and 





5.2.2 In vivo Activity 
 
 The use of animal models is crucial in drug discovery as it is the only way, save for 
human clinical trials, to determine factors such as distribution, metabolism and 
















L. major FV1    L. major lcb2Δ   L. don InMac           THP-1              Biochem 
Figure 5–2: The assay results for compound 34.  Note that due to assay restrictions, 
the lowest possible pED50 / pIC50 measurements are 5.0 for the L. major assays, 4.3 
for the L. donovani and THP-1 assays and 4.0 for the biochemical assay 
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hosts for VL are Syrian hamsters (Mesocricetus auratus) and mice (Mus musculus), 
although dogs and non-human primates are also occasionally used for testing.
360
  Whilst 
infected hamsters often exhibit clinical symptoms that closely mimic the human disease, 
their use in immunisation trials is precluded by a lack of reagents for immunological 
analysis.
361
  As a result, murine models are the most extensively used, although not all 
strains are equally susceptible to L. donovani infection.
362
  One of the most commonly 
used strains, due to the fact that it produces highly consistent levels of infection, is the 
BALB/c strain,
360
 and this was selected for the testing of compound 34. 
 
 Prior to in vivo activity determination, the compound was tested in a metabolic 
stability assay.  This involved incubating human and mouse liver microsomes with the 
compound and measuring the intrinsic clearance (CLint), with a higher value indicating a 
faster rate of clearance and hence greater metabolic instability.  The human biological 
samples were sourced ethically and their research use was in accordance with the terms 





 against human microsomes, implying a favourable low rate of 





which was outside of the desired range (above 15).
363
  Whilst a difference between 
microsomes from two different species is not unexpected and frequently observed,
364
 a 
high clearance in mouse microsomes prior to in vivo testing in mice was not ideal.  
 
 It was postulated that this high clearance level in mouse microsomes was due to the 
metabolically labile benzylic carbon; this atomic position is known to be readily 
oxidised to a benzylic alcohol by cytochrome P450 enzymes.
365
  This theory would 
support the speculation discussed in section 4.4.2.1 that drug metabolism, potentially 
due to cytochrome P450 activity, was responsible for the general low levels of activity 
observed.  In order to investigate this, the fact that cytochrome P450 oxidation of 
benzylic carbon atoms is known to exhibit a kinetic isotope effect, with the rate of 
oxidation for a carbon-hydrogen bond being 11 times greater than that for a carbon-
deuterium bond,
366
 was exploited.  The deuterated compound 36 (Figure 5–3) was 
therefore synthesised by Aptuit and provided for testing. This compound did not, 
however, display increased metabolic stability; the CLint values against human and 








 respectively.  This 
indicates that the benzyl position is not labile to cytochrome P450 oxidation, meaning 
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the reason for the instability in mouse microsomes remained unclear.  Despite this 
result, both compound 34 and compound 36 were progressed to in vivo testing.  
 
 The in vivo testing was executed according to an established protocol.
367
  All 
animal studies were ethically reviewed and carried out in accordance with the Animals 
(Scientific Procedures) Act 1986 and the GSK policy on the Care, Welfare and 
Treatment of Animals.  Briefly, BALB/c mice were infected with L. donovani 
amastigotes and the infection was allowed to develop over 7 days.  Half the mice were 
subsequently dosed orally at 50 mg kg
−1
 twice a day for 5 days, before all the mice were 
sacrificed 14 days post infection.  Counting the number of amastigotes per liver cell 
allowed any effect on parasite burden to be determined.     
 
 Whilst compound 34 disappointingly demonstrated a 0% reduction on liver 
parasitaemia, treatment with compound 36 resulted in a 32% reduction in parasite 
burden.  This was unexpected given the microsomal stability results discussed above, 
but could possibly be explained by the different pharmacokinetic profiles exhibited by 
the two compounds (Figure 5–4).  Compound 36 achieved a maximum concentration 
three times larger than compound 34 and reached that level in less than half the time.  In 
addition, the dose normalised area under the curve (DNAUC) measurement, which is an 
indication of total dug exposure, for compound 36 was more than twice as large as for 
compound 34.  All of these measurements suggest that the oral uptake and 
biodistribution of compound 36 is greater; this is possibly due to the fact that some 
deuterated drugs, such as amphetamines, have been shown to exhibit different transport 
processes than their non-deuterated counterparts, although the reasons for this 
phenomenon are unclear.
368, 369
  In addition, in some drugs deuteration leads to 
metabolic switching, whereby the site of metabolism is altered and the process occurs 
via a different pathway.  Therefore, whilst compound 36 may not be more active than 










  Figure 5–3: The structure of the deuterated analogue of compound 34 

















 Despite these differences, the compounds were less active than hoped for; as can be 
seen from the graphs, both were present at a concentration greater than the pED50 
against intramacrophage L. donovani amastigotes for several hours following dosing.  
One possible explanation for this was that the L. donovani strains used for the two 
assays were different; the intramacrophage testing utilised L. donovani 
MHOM/SD/62/1S-CL2D (LdBOB), whilst the in vivo testing utilised L. donovani 
MHOM/ET/67/L82.  These strains have different geographic origins (Sudan and 
Ethiopia respectively) and therefore may demonstrate slight variations in biochemistry.  
It is possible, for example, that MHOM/ET/67/L82 may possess more drug efflux 
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L. donovani InMac ED50 = 148 ng ml
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Figure 5–4: The pharmacokinetic profile of (a) compound 34 and (b) compound 36, 
where Cmax is the maximum blood concentration attained, tmax is the time after which 
the maximal concentration is reached, and DNAUC is a measure of total drug exposure 
over time.  The concentrations required to show 50% inhibition in the L. donovani 
intramacrophage assay are indicated.  Figure provided by DDW, GSK, Tres Cantos 
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Figure 5–5: The assay results for compound 35.  Note that due to assay restrictions, 
the lowest possible pED50 / pIC50 measurements are 5.0 for the L. major assays, 4.3 
for the L. donovani and THP-1 assays and 4.0 for the biochemical assay 
transporters or they may act at an increased rate, which would therefore decrease the 
susceptibility to drug compounds compared to LdBOB.   
 
 One other consideration is that whilst intramacrophage testing is the most 
biologically relevant assay possible in cellulo, it is still a very simplified model in 
comparison to in vivo testing.  The latter introduces a new range of factors to take into 
consideration, such as oral uptake, biodistribution, correct localisation and excretion.  
All of these affect the relative compound concentration the parasites are exposed to 
compared to in cellulo studies.  For example, if a compound acts as a prodrug and is 
metabolised into an active drug, this would remain present in the wells in an in cellulo 
assay but would face excretion in an in vivo model.  Irrespective of the reason for the 
results obtained, however, the potencies demonstrated by both compounds were 
insufficient to justify progressing them further towards clinical trials.   
 
5.3 Indole-Benzene Benzazepane  
 
 With compound 34 proving disappointing in the in vivo tests, attention turned to the 
other mix and match compound, 35.  This was subjected to the same range of assays as 
discussed in section 5.2.1, with the results being shown in Figure 5–5.  Whilst 
demonstrating a pED50 of only 4.7 against intramacrophage L. donovani amastigotes 
(and a pSI against THP-1 macrophages of 0.4), compound 35 produced a pIC50 of just 




























L. major FV1    L. major lcb2Δ   L. don InMac           THP-1              Biochem 
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Figure 5–6: The IC50 curves and mean pIC50 values against L. major FV1 and lcb2Δ 
promastigotes for (a) compound 35 and (b) compound 34.  Error bars show the standard 
error of the mean for a sextuplet set of data for 35 and a triplicate set of data for 34 
 Compound 35 did, however, produce a unique result in that it demonstrated a 
pED50 of 5.7 against L. major wild type promastigotes whilst being completely 
ineffective at 10 µM against L. major lcb2Δ promastigotes.  This is more clearly visible 
from the IC50 curves produced (Figure 5–6).  This therefore suggests that compound 35 












 In order to investigate this result further, compound 35 was tested alongside its two 
parent compounds, 29 and 30, in a metabolic labelling assay, which was undertaken 
using the L. major lcb2Δ mutants.  As discussed in section 4.4.1, these parasites are 
lacking subunit 2 of serine palmitoyltransferase, the first enzyme in the sphingolipid 
synthesis pathway.  Whilst this renders the rest of the enzymes in the pathway, 
including IPCS, redundant, they remain capable of performing their usual roles.  As a 
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analogue, such as BODIPY FL C5-ceramide, and monitoring the conversion to 
fluorescently-labelled IPC (Figure 5–7) in the presence or absence of test compounds.  
Given the absence of in situ ceramide to act upon, there is no substrate competition for 
IPCS and therefore fluorescence output is proportional to the amount of fluorescent 
product produced, and hence IPCS activity.  
 
 Initial experiments were conducted according to an established protocol.
370
  Briefly, 
the parasites were incubated with the test compound for 1 hour in serum-free media to 
ensure the absence of competing ceramide.  The cells were subsequently incubated with 
BODIPY FL C5-ceramide for 1 hour prior to the extraction and analysis of the cellular 
contents.  However, the samples all produced comparable fluorescence, and this was 
postulated to be due to the short incubation time with the test compounds.  The 
incubation time was subsequently increased from 1 hour to 18 hours and this adjustment 











































Figure 5–7: The conversion of BODIPY FL C5-ceramide to BODIPY FL C5-IPC by IPCS 
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Figure 5–8: (a) HPTLC of the metabolic labelling assay.  Lane allocation from left to 
right: media, DMSO control, compound 35, compound 30 and compound 29.  (b) The 
inhibition of L. major lcb2Δ promastigote growth in response to the test compounds at 












 Whilst compounds 29 and 30 both demonstrated approximately 30% inhibition 
compared to the media and DMSO controls, compound 35 inhibited BODIPY FL      
C5-IPC production by 80%.  This assay therefore verifies the results obtained in the in 
vitro biochemical assay and confirms compound 35 as a potent inhibitor of L. major 
IPCS in a cellular environment.   
 
 The low potency of compound 35 against intramacrophage L. donovani amastigotes 
coupled with a PFI of 12.8 suggests that the probability of developing this compound as 
an oral antileishmanial is low.  L. major, however, causes the cutaneous form of the 
disease, and it is therefore possible that this compound could be further developed as a 
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probe with the possibility of being utilised to further our understanding of Leishmania 
IPCS enzyme function and role. 
 
5.4 SARs of the Benzazepane Series  
 
 Having identified a potent and selective IPCS inhibitor but not an antileishmanial 
lead with in vivo activity, attention turned to the exploration of SARs in order to 
determine whether the IPCS inhibitory and, in particular, the antileishmanial properties 
of the benzazepanes studied thus far could be improved upon.  The compounds exhibit 
the same three structural features (Figure 5–9); the left hand side (LHS) of the molecule 
is a heteroaromatic ring attached via a sulphonyl linkage to the benzene ring of a 
benzazepane core group, whilst the right hand side (RHS) is an aromatic ring attached 
by a single carbon linker to the nitrogen of the benzazepane core group.  With only the 
two parents and the two mix and match compounds, however, it is impossible to draw 
any conclusions; the left and right hand side rings may not need to be aromatic, or they 
may not need to be rings at all.  Similarly, is the benzazepane core necessary or is this 
simply a means of connecting the LHS and RHS functional groups of the molecule?  
 
 
 In order to investigate this, the 1.8 million compound library previously screened 
was searched for molecules with structural similarity to the two known benzazepanes, 
and 63 compounds were identified for further investigation.  A number of additional 
compounds were synthesised by Aptuit (www.aptuit.com) with the majority containing 
a pyrrole ring on the LHS to allow comparison with compound 34, which demonstrated 
the better antileishmanial properties of the two mix and match compounds.  This 
resulted in a range of compound structures for further study; these compounds were 







LHS RHS Core 
Figure 5–9: The three separate structural features of the 
benzazepane compounds, indicated on compound 29 
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presented in Appendix C), although due to the overall aims of the project, the 
biochemical and intramacrophage L. donovani amastigote assays were prioritised. 
  
5.4.1 Right Hand Side SARs 
 
 Whilst many of the compounds identified from the GSK library possessed an indole 
ring on the LHS, like compound 30, a wide variety of substitution patterns were present 
which would render it difficult to draw accurate conclusions.  There were, however, 14 
compounds with unsubstituted pyrrole rings as seen in compound 29, so these were 
used alongside the Aptuit compounds as a starting point for SAR investigation.  
 
5.4.1.1 Steric Bulk 
  
 Whilst a degree of intramacrophage activity was retained when the RHS functional 
group was removed completely (compound 37), biochemical activity and activity 
against L. major was completely abolished (Figure 5–10).  This suggests that the RHS 
functional group is necessary for interaction with the IPCS enzyme; alternatively, the 
resulting N–H bond could result in novel hydrogen bonding with the protein leading to 
an alteration in binding and a loss of activity.  The addition of a small, single methyl 
group (compound 38) restored limited biochemical activity (pIC50 = 4.6), supporting the 
theory that H-bonding could be the reason for activity loss, although activity 
subsequently decreased with the 2,2-dimethylpentane RHS (compound 39).  This 
functional group is more sterically bulky (A-Value = 4.9) than either the benzene or 
pyridine rings (A-Values ~ 3.0) present in the parent compounds 29 and 30, meaning it 
may not fit into the same physical space as the parents and hence not be as active.  
Compound 39 does, on the other hand, display potent intramacrophage amastigote 
activity (pED50 = 6.1) whilst being non-toxic against THP-1 cells, suggesting it hits 
















5.4.1.2 Non-Aromatic Rings 
 
 The results for the three non-aromatic rings tested were somewhat surprising; 
whilst the cyclohexane (compound 40) and the piperidine (compound 42) demonstrated 
significant IPCS inhibition (pIC50s of 5.5 and 4.9 respectively), the tetrahydropyran 
(compound 41) was completely ineffective (Figure 5–11).  The reason for this striking 
difference is not clear, and this pattern was not observed with the antiparasitic activities.  
Whilst compounds 40 and 41 displayed modest activity against intramacrophage 
amastigotes (pED50 = 5.7), compound 42 displayed a pED50 of 6.9.  These results 
therefore suggest that H-bonding donor capability in the para ring position is critical for 
antiparasitic activity, at least in non-aromatic rings.  Future experiments on non-
aromatic rings of different sizes, and with the heteroatom in different positions, would 

































Figure 5–10: (a) The structures of the analogues tested 
and (b) the effect of steric bulk on benzazepane activity 










5.4.1.3 Aromatic Rings 
 
5.4.1.3.1 Benzene Rings 
 
 None of the three compounds with an oxy substituent (compounds 43, 44 and 45) 
demonstrated IPCS inhibitory activity or activity against L. major promastigotes.  In the 
L. donovani intramacrophage assay, however, a methoxy group in the ortho position 
resulted in a pED50 of 6.2 whilst activity in the meta position was significantly lower 
(Figure 5–12).  Exchanging the methoxy group for a hydroxyl group in the meta 
position subsequently restored activity against intramacrophage amastigotes; this could 
potentially be due to the H-bond donor capabilities of the hydroxyl group or its 
































Figure 5–11: (a) The structures of the analogues tested and 
(b) the effect of non-aromatic rings on benzazepane activity 
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of an ortho hydroxyl group and both hydroxyl and methoxy substituents in the para 
position, the lack of in vitro and L. major promastigote activity suggests that these 
compounds are acting off-target in L. donovani and they are therefore not a priority for 








 The other substituted benzene RHS groups tested are shown in Figure 5–13.  A 
meta nitro group (compound 46), whilst showing limited activity against LmjIPCS in 
vitro, only demonstrated a pED50 of 5.2 in the intramacrophage assay; this activity was 
the same as that obtained for the meta methoxy group (Figure 5–12).  A nitrile group, 
however, demonstrated potent antiparasitic activity against both L. major and               
L. donovani whether in the meta (compound 48) or para (compound 47) position.  
Nitriles are prevalent in pharmaceuticals due to their stability and biocompatibility; they 
also typically lower lipophilicity when used to replace groups such a hydrogen, methyl 
or halogen and hence result in more favourable pharmacokinetic properties.
371
































Figure 5–12: (a) The structures of the analogues tested and (b) the 
effect of oxy-substituted benzene rings on benzazepane activity 
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potential future strategy could therefore be based around the incorporation of the nitrile 
functionality into the parent and mix and match benzazepanes.  Finally, following 
continued speculation about the benzyl position, compound 49 demonstrated that 
introducing a carbonyl group into this position resulted in the loss of in vitro activity 
compared to the parent compound 29 (pIC50 = 6.1).  This therefore confirms that the 
benzyl position holds critical significance for compound function, although the nature 



















5.4.1.3.2 Pyridine Rings 
 
 The observation made above regarding the benzyl position was further verified by 
the results from compounds 50 and 51, which both differ from the mix and match 






























Figure 5–13: (a) The structures of the analogues tested and (b) 
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showed that substitution in this position also resulted in a loss of activity against 
intramacrophage L. donovani amastigotes; whilst compound 34 demonstrated a pED50 








 The additional pyridine compounds investigated are shown in Figure 5–15 (along 
with the mix and match compound 34 for comparison).  Compound 52, which contains 
a pyridine ring with a fluorine in the para position (relative to the benzazepane core), is 
a fusion of the RHS groups of the parent compounds.  This is reflected in the results; 
whilst lacking in vitro activity, its effectiveness against intramacrophage amastigotes 
was greater than compound 29 (benzene with fluorine substituent) but lower than 
compound 34 (unsubstituted pyridine).  This therefore suggests that the fluorine in the 
para position has a detrimental effect on compound efficacy; one possible explanation 
































Figure 5–14: (a) The structures of the analogues tested and (b) the 
effect of benzyl-substituted pyridine rings on benzazepane activity 
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Figure 5–15: (a) The structures of the analogues tested and (b) 
the effect of substituted pyridine rings on benzazepane activity 
aromatic amino acids could result in an offset in stacking geometry and hence hinder the 
ability of the compound to bind to that target.
372
  On the other hand, when the fluorine 
substituent was exchanged for a nitrile group (compound 53), intramacrophage activity 
was greatly improved.  This further solidifies the theory suggested in section 5.4.1.3.1 
that nitrile substituents could be an important route for further compound optimisation 
studies.  Finally, compound 54, in which the benzazepane core is ortho to the pyridine 
nitrogen rather than meta, demonstrated reduced antiparasitic activity compared to the 
other pyridine analogues.  It would not be possible to draw a definitive conclusion from 
this, however, given that the effect of the methyl substituent that has also been 
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Figure 5–16: (a) The structures of the analogues tested and 
(b) the effect of imidazole rings on benzazepane activity 
5.4.1.3.3 Imidazole Rings 
 
 In order to investigate whether a 6-membered ring was necessary, a small group of 
compounds containing imidazole rings were also investigated.  Those with a pyrrole 
LHS are shown in Figure 5–16; whilst neither demonstrated any activity against 
LmjIPCS, both compounds 55 and 56 proved to be potent in the intramacrophage assay 
with pED50s of 6.4 and 6.8 respectively.  This effectiveness was offset slightly in 
compound 56 by an increase in pED50 against THP-1 macrophages, but the difference in 

















 Four imidazole compounds with indole-based LHSs were also available for testing.  
Whilst high potency against intramacrophage amastigotes was maintained in compound 
57, substitution of the indole ring led to reductions in activity in the three other 
analogues tested (Figure 5–17).  As discussed above, this is possibly due to the effects 
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Figure 5–17: (a) The structures of the analogues tested and (b) the 
effect of imidazole rings and indole substituents on benzazepane activity 
the use of imidazole substituents on the RHS would definitely be worth further 
investigation, although this would have to be accompanied by the determination of 

























5.4.2 Left Hand Side SARs 
 
 The investigation of SARs of the LHS of the benzazepane core was limited due to 
the fact that RHS functionality was incredibly diverse and hence comparisons, in many 
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Figure 5–18: (a) The structure of the analogue tested and (b) 
the effect of no LHS functional group on benzazepane activity 
necessary; compound 61, which lacks any LHS functionality, was ineffective in vitro 
and non-toxic to both L. major promastigotes and intramacrophage L. donovani 
amastigotes (Figure 5–18).  Combined with the observations for compound 37, this 
suggests that both the LHS and RHS functional groups are integral to compound 
efficacy.  Furthermore, the low potency of compound 61 suggests that the role of the 
benzazepane core is likely to be structural – keeping the LHS and RHS in fixed 
positions relative to each other – rather than interaction with the enzyme, although 
further investigation would be needed to confirm this. 













 One analysis that was possible was the investigation of the effect of methyl 
substituents in every position of the indole ring (Figure 5–19).  The RHS for this 
analysis was a single methyl group, permitting comparison with compound 38 (methyl 
RHS with a pyrrole LHS).  The unsubstituted compound 62 was a full order of 
magnitude less active against intramacrophage L. donovani amastigotes than compound 
38 (pED50s of 4.7 and 5.7 respectively), which might suggest that the bicyclic ring 
system was unfavourable due to the increased steric bulk.  However, any substituent 
position resulted in an increase in activity against intramacrophage amastigotes 
compared to the unsubstituted compound 62; this was in contrast to the results shown in 
Figure 5–16 where the unsubstituted compound 57 demonstrated increased activity over 
the substituted compounds.  It is important to note, though, that the RHS functionalities 
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comparison to those studied in Figure 5–17, is non-polar and so would interact 
differently to the polar groups previously studied.  Strikingly, compound 67 was the 
only one to show any activity against LmjIPCS, and compound 68 was unique in 
demonstrating activity against L. major promastigotes.  These results therefore indicate 
extremely specific mechanisms of action, such as fitting into a tight binding pocket, or 
being more resistant to metabolism than the compounds with substituents in other 



















Figure 5–19: (a) The structures of the analogues tested and (b) the 
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Figure 5–20: (a) The structures of the analogues tested and 
(b) the effect of RHS functionality on benzazepane activity 
 The results discussed above must, however, be viewed cautiously.  As was 
observed in section 5.4.1.1, the methyl group was far from the best RHS functionality 
when combined with a pyrrole LHS (compound 38) and exchanging for an alternative 
has drastic effects, as shown in Figure 5–20.  Compound 69 demonstrated no efficacy 
against LmjIPCS at 100 µM whereas compound 38 demonstrated a pIC50 of 4.6; this 
single result implies that the substituted indole LHS is detrimental to activity against the 
enzyme.  However, the mix and match compound 35 demonstrated a high in vitro 
potency, which would suggest that this is not the case.  It is therefore possible that 
compound activity is not simply dependent upon the individual LHS and RHS 
functional groups, but on the combination of the two groups acting in tandem.  Testing 
of molecular fragments, both individually and in combination, could help confirm or 
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5.4.3 Benzazepane Core SARs 
 
 The final feature to consider was the benzazepane core.  Two possible alterations 
were considered: removing the azepane ring, and removing the benzene ring, to 
determine if either was necessary for function.  The results (Figure 5–21) were 
conclusive; in comparison to the mix and match compound 34, compound 70 lost all 
efficacy against both L. major promastigotes and L. donovani intramacrophage 
amastigotes at the concentrations tested.  On the other hand, the azepane compound 71 
maintained intramacrophage activity whilst displaying a slightly improved selectivity 
over THP-1 macrophages.  Therefore, the azepane ring appears to be necessary for 
antiparasitic activity but the benzene ring is not.  Compound 71 also has the additional 
benefit of having one less aromatic ring resulting in a much more favourable PFI than 
compound 34 (6.0 compared to 8.4).  It can therefore be predicted that compounds 
based on azepane cores would exhibit more favourable pharmacokinetic properties than 
their benzazepane counterparts, and this could potentially lead to compounds with more 
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Figure 5–21: (a) The structures of the analogues tested and (b) 








5.4.4 SAR Summary 
 
 Overall, it is difficult to draw definitive conclusions due to the fact that, as 
demonstrated above, both in vitro and in cellulo activity is dependent upon the LHS and 
RHS combination rather than being dependent upon the presence of a specific 
functional group.  The mix and match compounds originally tested at the beginning of 
this chapter remain two of the best; compound 35, along with the parent compounds 29 
and 30, remains the best LmjIPCS inhibitor with high potency being demonstrated both 
in vitro and in cellulo, with no compound studied in the SAR analysis being able to 
improve upon this.  Compound 34, on the other hand, has had its antileishmanial 
activity matched and even bettered, with two obvious trends being the high activities 
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with these two functionalities, and possibly combining them with the azepane core, 
could therefore potentially lead to antileishmanial compounds with greater potency than 
has been observed to date.  
 
5.5 Conclusion  
 
 The work described in this chapter initially involved the screening of the two mix 
and match benzazepane compounds.  Compound 35 proved to be a potent and selective 
inhibitor of the L. major IPCS enzyme.  Compound 34 demonstrated increased 
antileishmanial activity but lower biochemical activity compared to the parents and 
ultimately proved to be ineffective in vivo.  The determination of SARs for the 
benzazepanes show overall disconnection between the cell-based and biochemical 
activity, suggesting that compounds in this chemical family are promiscuous and are 
capable of hitting multiple cellular targets.  Despite this, selectivity for the 
intramacrophage L. donovani amastigotes over the THP-1 cells was frequently 
observed, meaning that this compound class still shows the potential to produce a lead 
compound in the future.  Several possible solutions for improving antileishmanial 















Chapter 6  
 




 The changing landscape of drug discovery for NTDs brought about by the London 
Declaration in 2012
162
 means that the ideal of effective, affordable treatments for a wide 
range of diseases is closer now than ever before.  The work presented in this thesis has 
contributed towards the overall goal of finding new therapeutic agents for the 
widespread, potentially fatal NTD leishmaniasis and the related disease HAT. 
 
 In order to characterise the SLS enzymes from L. major and T. brucei, existing 
methodology was adapted to engineer novel mutant S. cerevisiae strains dependent on 
the expression of a kinetoplastid SLS for viability.  The fact that all the complemented 
strains prepared were viable showed that all the kinetoplastid SLSs investigated thus far 
are functional orthologues of the yeast AUR1.  This supports previous work in the 
group
217
 and contradicts claims that TbSLS4 does not synthesise IPC.
322
  Furthermore, 
differential sensitivity to AbA was observed between isoforms 1 and 4 of TbSLS.  
Whilst this observation is unprecedented in the literature (to the best of the author’s 
knowledge), it is known that a single F158Y mutation in AUR1 confers resistance of         
S. cerevisiae to AbA.
201
  It can therefore be hypothesised that AbA has an extremely 
specific mechanism of action, resulting in differential sensitivity between the two highly 
similar TbSLS enzymes.  Additional investigation will be required to identify the source 
of this variation and determine the binding site of AbA.   
 
 The complemented yeast strains were subsequently utilised to develop and optimise 
a HTS-compatible assay to screen the 1.8 million compound library.  Whilst the 
initially-proposed multiplex assay was not robust enough to pursue, an alternative assay 
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based on conversion of FDGlu to fluorescein proved successful.  The primary assay 
progressed smoothly with a mean Z′ of 0.7 and, following confirmation and dose-
response testing, a total of 500 compounds demonstrated a selectivity ratio greater than 
1.5 log units. 
 
  Whilst yeast-based assays are not common place, they are increasing in popularity 
with many screens being undertaken in recent years.  However, the majority of these are 
on the order of magnitude of tens of thousands of compounds
373, 374
 to a few hundred 
thousand compounds.
375
  To the best of the author’s knowledge this is the largest screen 
utilising a yeast-based assay recorded in the literature, and is quite possible the largest 
scale screen undertaken to date by an academic research group.  Additionally, the 
genetic tractability of yeast has allowed an otherwise difficult target – a parasitic 
membrane protein – to be readily and extensively tested in a fashion that would have 
been difficult in the more commonly-utilised bacterial vector.  This assay therefore 
verifies the use of eukaryotic organisms, and yeast in particular, as suitable vectors for 
HTS.   
 
 Following the successful HTS assay, the screening programme was continued 
against Leishmania promastigote and amastigote parasites.  Testing against mammalian 
cells was also achieved and allowed the identification of six compounds with high 
antileishmanial activity, low mammalian toxicity and favourable physicochemical 
properties.  Further biochemical testing narrowed this down to two compounds with a 
common benzazepane core that acted as potent inhibitors of the L. major IPCS enzyme 
in vitro. 
 
 Additional investigation of benzazepane analogues identified one compound which 
was a highly potent enzyme inhibitor in both in vitro and in cellulo assay formats.  This 
compound could therefore be utilised in the future as a chemical probe to further 
investigate LmjIPCS; there is also the possibility of further development as a topically-
applied treatment for localised CL.  The majority of the additional analogues 
demonstrated low inhibitory activity against the L. major IPCS enzyme; however, many 
of these retained antileishmanial activity.  This disconnection between biochemical and 
antiparasitic activity suggests that the compounds are promiscuous and hit more than a 
single target.  Despite this fact, 21 of the 40 benzazepane compounds tested (53%) 
 6. Conclusions and Future Work 
139 
 
demonstrated greater potency against intramacrophage L. donovani parasites than 
macrophages (as defined by a SI greater than or equal to 1.0), suggesting that further 
lead optimisation could eventually result in a suitable candidate for clinical trials.   
 
 In summary, the work accomplished has fulfilled the original aims of the project 
and identified, from a library of 1.8 million compounds, a novel family of structurally-
related compounds which display high potency both in vitro and in cellulo.  This 
compound class forms the starting point for a future medicinal chemistry campaign, 
with the ultimate aim being the development of new treatments for leishmaniasis.  
 
6.2 Proposed Future Work 
 
 Building on the work achieved thus far, future work can be divided into two 
separate categories. 
 
6.2.1 Further Lead Optimisation 
 
 Perhaps the primary focus for future work would be the continuation of the SAR 
study described previously (Chapter 5).  Whilst a highly potent enzyme inhibitor was 
identified from this study, an active in vivo antileishmanial was not.  Given that this is 
the final stage before clinical trials, high in vivo potency is a necessity for compound 
progression.  Therefore, new benzazepane analogues with high potency against 
intramacrophage L. donovani amastigotes, low cytotoxicity against THP-1 cells and 
improved metabolic stability need to be identified.  From the SAR study, imidazole 
rings and aromatic rings with nitrile groups were both identified as resulting in high 
antileishmanial activity against intramacrophage L. donovani amastigotes, suggesting 
that a more focussed SAR study centred on these substituents could improve potency 
beyond what has been observed to date.  In addition, pairing these with the more 
physicochemically favourable azepane core could go some way towards improving oral 
absorption and biodistribution, and hence in vivo antileishmanial efficacy.   
 
 Also important is the determination of the mechanism of action by which the 
benzazepane compounds inhibit IPCS.  The ideal scenario would be to obtain a crystal 
structure of the IPCS protein which would then allow computational docking studies to 
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be undertaken.  This would provide information as to where the compounds bind to the 
enzyme and may allow further compound modification to be directed towards 
functional groups which would improve these interactions.  Unfortunately, membrane 
proteins remain one of the greatest challenges facing crystallographers; the number of 
entries in the Protein Data Bank (PDB, www.rcsb.org/pdb), an online repository for 
information about protein structures, topped 100,000 in 2014.  Of these, only 499 
(0.5%) were membrane proteins.
376
   
 
 One possibility, should crystallisation and structure determination prove 
unsuccessful, would be to attempt computational studies using LPP structures.  As 
discussed in section 1.3.4, this family of enzymes possess two domains similar to the 
fungal and Leishmania IPCS, with the residues of the catalytic triad located in these 
domains.  Whilst LPPs are also integral membrane proteins,
377
 the soluble enzyme 
epoxide hydrolase has been observed to possess LPP activity
378
 and structures for this 
enzyme have recently been published.
379
  It is therefore possible that computational 
docking experiments using these crystal structures could confirm or deny the binding of 
benzazepane compounds in the active site.   
 
6.2.2 Extension to Human African Trypanosomiasis and Chagas Disease 
 
 Much of the work discussed in this thesis has focussed on drug discovery for 
leishmaniasis, with only a limited analysis of the T. brucei SLS isoforms 1 and 4 
conducted as described in Chapter 2.  These basic experiments, however, generated 
interesting results with differential sensitivity to the fungal AUR1 inhibitor AbA being 
observed.  As discussed previously, the reason for this difference is not currently 
known; site-directed mutagenesis of the amino acid sequences of the two isoforms 
could therefore help to identify key residues involved in enzyme function and AbA 
sensitivity.  Furthermore, only two of the four T. brucei SLS isoforms have thus far 
been investigated.  The expansion of the analysis to include isoforms 2 and 3 could 
therefore aid the investigation into which amino acids are essential for function. 
 
 The project could also be extended further to include Chagas disease, the third 
disease caused by a trypanosomatid parasite.  Like Leishmania spp. and T. brucei,        
T. cruzi also synthesises IPC; the T. cruzi IPCS enzyme was first observed by 
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Figueiredo et al. in 2005,
380
 and the following year Denny et al. noted that two isoforms 
of the enzyme were present.
196
  The inclusion of these enzymes in the analysis, along 
with those from additional Leishmania species such as L. donovani, would result in a 
greater breadth of data that should facilitate the observation of trends between the 
enzymes from different species and allow more accurate, detailed conclusions to be 
drawn. 
 
 Finally, testing of any highly potent compounds from the further lead optimisation 
process against the variety of enzymes described above would allow the identification 
of any chemical entities with activity against a range of species.  If this is successful and 
a potential drug candidate is obtained, the future of the project lies with the 
pharmaceutical companies, or an organisation such as the DNDi, to ensure that the lead 
compound receives the best possible chance of succeeding in clinical trials and 
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 HD Cloning Kit with Cloning Enhancer and Herring Testes Carrier 
DNA were obtained from Clontech.  Phusion Flash PCR Master Mix, SmaI restriction 
enzyme, 10× Buffer Tango, T4 DNA Ligase, 100 bp DNA ladder, 1 kb DNA ladder,   
6× DNA Loading Dye, ethidium bromide, HCS CellMask™ Deep Red stain, RPMI 
media 1640, pyruvate, glutamine and HEPES were obtained from Thermo Scientific™.  
QIAquick PCR Purification kit and QIAprep Spin Miniprep kit were from Qiagen.  
Protein LoBind tubes were obtained from Eppendorf.  Miller’s LB broth powder was 
obtained from Melford.  Raffinose pentahydrate, galactose, yeast nitrogen base,            
5-Fluoroorotic acid monohydrate, amino acids and amino acid dropout packages were 
obtained from ForMedium™.  Acid-washed glass beads (425−600 µm), glycerol, 
sucrose, glucose, agarose, agar, glacial acetic acid, phenol red, adenosine, folic acid, 
resazurin, Hemin, MES hydrate, PEG3350, IGEPAL
®
 CA-630, MgCl2, LiAc, KCl, 
CaCl2, HCl, NaOH, DMSO, BSA, PBS, EDTA, CHAPS, PMA, Trizma
®
 base, KH2PO4, 
K2HPO4, (NH4)2SO4, NaHCO3, HCO2H, HCO2K, Giemsa stain, ampicillin, 
amphotericin B, cycloheximide, suloctidil, trypsin, 100× RPMI vitamin solution,       
50× RPMI amino acid solution, Eagle’s Minimum Essential Medium and Schneider’s 
Insect Medium were obtained from Sigma Aldrich.  MgSO4 was obtained from Panreac.  
Aureobasidin A was a generous gift from AureoGen.  AlamarBlue
®
, Na2CO3, 
Penicillin/Streptomycin, NBD-C6-ceramide and BODIPY
®
 FL C5-ceramide complexed 
to BSA were obtained from Invitrogen.  CellTiter-Glo
®
 reagent was from Promega.  
Complete
®
 EDTA-free Protease Inhibitor Cocktail Tablets were from Roche Applied 
Science.  HBSS buffer was obtained from Gibco.  FDGlu was obtained from Marker 
Gene Technologies Inc. or Invitrogen.  Clemastine was obtained from Tocris 
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Bioscience.  Bradford Reagent and AG 4-X4 ion exchange resin was obtained from 
Bio-Rad.  Heat-inactivated FCS was obtained from Labtech.  L-α-phosphatidyl inositol 
(sodium salt, bovine liver) was obtained from Avanti Polar Lipids.  Reactions and 
media were prepared using distilled, high purity water.  All other solvents used were of 
the highest purity available commercially. 
 
7.2 Instruments and Equipment 
 
 Centrifugation steps were carried out using Beckman Coulter centrifuges or 
ultracentrifuges.  Eppendorf tubes were centrifuged using a Sigma 1-14 microfuge.  
Eppendorf contents were dried using an Eppendorf Vacuum Concentrator 5301 from 
Brinkmann.  Disruption of cells was performed using an IKA
®
 Vortex Genius 3.  
Agarose gels were imaged using a Bio-Rad Gel Doc™ XR+ System and Quantity One 
1-D Analysis software (version 4.6.6).  HPTLC silica plates were from Merck Millipore 
and were imaged using a Fuji FLA−3000 plate reader and AIDA Image Analyser
®
 
software (version 3.52).  Media were filtered using a Corning
®
 1000 ml Vacuum 
Filter/Storage Bottle System, 0.22 µm pore CA membrane.  Multiwell plates were read 
using a PerkinElmer Opera
®
 High Content Screening System, an Ultramark Microplate 
Imaging System, a PerkinElmer ViewLux ultraHTS Microplate Imager or a BioTek 
FLx800 Fluorescence Microplate Reader.  Multiwell plate readouts were analysed using 
GSK-developed Statistical Online Data Analysis Software (SODA) or Gen5™ 1.08 
Data Analysis Software from BioTek.  Macrophage screening assays were imaged using 
an Opera QEHS high-content microscope and the readouts analysed using the 
automated Acapella
®
 High Content Imaging and Analysis Software (PerkinElmer).    









 cell culture plates 3595 (clear), Corning
®
 V-bottom 3897 (clear), MultiScreen
®
 
Solvinert filter plates from Merck Millipore or PerkinElmer OptiPlate-96 Black.      
384-well plates used were Greiner Bio-One FLUOTRAC™ 200 784076 (low volume, 
black base).  1,536-well plates used were either Greiner Bio-One FLUOTRAC™ 200 
782076 (non-sterile) or Greiner Bio-One FLUOTRAC™ 600 782077 (sterile).  Low 
volumes were dispensed using a Thermo Scientific™ Multidrop Combi Reagent 
Dispenser, a Thermo Scientific™ Multidrop Combi nL or a Labcyte Echo
®
 liquid 
handler.   
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Table 7−1: Buffer and solution compositions 
7.3 Buffers, Solutions and Media Compositions 
 
 Details of the buffers and solutions used are given in Table 7–1.  Media 
compositions are given in Table 7–2.  Solutions that are not sterilised prior to use, either 
by autoclaving or filtration, are indicated by an asterisk (*).  Components that must be 
sterilised by filtration and added after autoclaving are indicated by a hash (#). 
 
  Buffer/Solution Vol. / Mass Stock 
  TAE Buffer 








Glacial Acetic Acid 
EDTA (0.5 M, pH 8.0) 
Water 
  TE Buffer  




Tris−HCl (1 M, pH 7.4) 
EDTA (0.5 M, pH 8.0) 
Water 
  TE/LiAc Buffer  




LiAc (1 M) 
TE Buffer (10×) 
Water 
  PEG/LiAc 




LiAc (1 M) 
TE Buffer (10×) 
PEG 3350 (50%) 
  STE Buffer 






Sucrose (1 M) 
Tris−HCl (1 M, pH 7.4) 
EDTA (0.5 M, pH 8.0) 
Complete
®
 Protease Inhibitor Cocktail 
Water 
  Storage Buffer 






Tris−HCl (1 M, pH 7.4) 
Glycerol (80% w/v) 
MgCl2 (1 M) 
Complete
®
 Protease Inhibitor Cocktail 
Water 
  Tris/EDTA/BSA Buffer 





Tris−HCl (1 M, pH 7.4) 
EDTA (0.5 M) 
BSA (Fatty Acid Free) 
Water 
HCl (to pH 6.0) 
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  Phosphate Buffer 







  Phosphate Buffer 

















  Growth Media Vol. / Mass Stock 
  LB Broth 
  (1 L) 





±Agar (for solid media)  




  SD –W –URA 











Yeast Nitrogen Base −Amino Acids −Ammonium 
Sulphate 
(NH4)2SO4 
±Agar (for solid media) 




  SGR −W −L 












Yeast Nitrogen Base −Amino Acids −Ammonium 
Sulphate LoFlo 
(NH4)2SO4 
±Agar (for solid media) 
±5-Fluoroorotic Acid Monohydrate (#) 
Amino Acids Dropout Supplement −W −L (#) 
Water 
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  Schneider’s Insect 
  Medium (stock) 







Schneider’s Insect Medium 
NaHCO3 
CaCl2 
HCl (for pH adjustment) 
NaOH (for pH adjustment) 
Water 
  Schneider’s Insect 
  Medium 
  (50 ml, pH 7.0, 
  15% FCS) # 
42.5 ml 
7.5 ml 
Schneider’s Insect Medium (stock) 
Heat-inactivated FCS 
Amastigote Growth 






























100× RPMI Vitamin Solution 


















RPMI Media 1640 
THP-1 Growth 









RPMI Media 1640 
HepG2 Growth 





Eagle’s Minimum Essential Medium (with Earle’s 
salts, glutamine and non-essential amino acids) 
Heat-inactivated FCS 
Water 
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Table 7−3: Cycling conditions for PCR using Phusion Flash PCR Master Mix 
7.4 Protocols 
 
 All of the following biological procedures were carried out under sterile conditions 
unless otherwise stated. 
 




 PCR reactions were carried out using Phusion Flash PCR Master Mix according to 
the manufacturer’s protocol.  Each reaction typically contained 2× Phusion Flash PCR 
Master Mix (10 µl), sterile water (6 µl), forwards primer (10 µM, 1 µl), reverse primer 
(10 µM, 1 µl) and template DNA (5 ng µl
−1
, 2 µl).  The PCR reactions were cycled as 
shown in Table 7–3 before being purified using the QIAquick PCR Purification kit 










7.4.1.2 Agarose Gel Electrophoresis 
 
 The following protocol was carried out under non-sterile conditions.  0.8% w/v 
agarose in 1× TAE buffer was autoclaved prior to use.  Ethidium bromide (5 mg ml
−1
,   
3 µl) was added to the agarose solution (30 ml) and the gel allowed to set.  The DNA 
samples (5 µl) were mixed with 6× DNA Loading Dye (1 µl) prior to loading.  An 
appropriate DNA ladder (5 µl) was used as a reference.  Gels were run for 60 minutes at 
100 V using 1× TAE buffer as the running buffer.  
 
 
 Stage Time / s Temperature / °C Cycles  
  Initial denaturation  10 98 1  
  Denaturation 1 98   
  Annealing 5 Tm of lower Tm primer 30  
  Extension  15 kb
−1
 72   




hold 4  
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7.4.1.3 Enzymatic Digestion (SmaI) 
 
 SmaI restriction enzyme (10 U µl
−1
, 1 µl) (where 1U = 1 µmol(substrate) min
−1
) 
was mixed with water (16 µl), 10× Buffer Tango (3 µl) and DNA (10 µl).  Following 
incubation at 30 °C for 16 hours the mixture was either stored at 4 °C or used 
immediately for ligation. 
   
7.4.1.4 Ligation (In-Fusion Cloning) 
 
 The insert and plasmid DNA were quantified using agarose gel electrophoresis with 
an appropriate DNA ladder.  The linearised vector was mixed with the insert DNA   
(200 ng total, insert:vector mass ratio at 3:1) and 5× In-Fusion HD enzyme premix       
(2 µl) and the volume adjusted to 10 µl with water.  Following incubation at 50 °C for 
15 minutes the mixture was either stored at −20 °C or used immediately for 
transformation. 
 
7.4.1.5 Ligation (T4 Ligation) 
 
 The insert and plasmid DNA were quantified using agarose gel electrophoresis with 
an appropriate DNA ladder.  The linearised vector (30 ng) was mixed with the insert 
DNA (insert:vector molar ratios at both 1:1 and 3:1), T4 ligase enzyme (0.5 µl), T4 
ligase buffer (1.5 µl) and the volume adjusted to 15 µl with water.  Following 
incubation at room temperature overnight the mixture was either stored at −20 °C or 
used immediately for transformation. 
 
7.4.1.6 Preparation of Competent E. coli 
 
 The E. coli strain DH5α (stored at −80 °C) was inoculated onto LB agar medium 
and incubated at 37 °C for 16 hours.  This was used to inoculate LB broth (10 ml) which 
was then incubated with shaking at 37 °C until OD600 = 0.5.  The culture was incubated 
on ice for 15 minutes prior to centrifugation (3,000 × g for 10 minutes at 4 °C).  The 
supernatant was discarded and the pellet resuspended in CaCl2 (0.1 M, 30 ml).  The 
suspension was incubated on ice for 30 minutes prior to centrifugation (3,000 × g for   
10 minutes at 4 °C).  The supernatant was discarded and the pellet resuspended in CaCl2 
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(0.1 M, 6 ml) containing 15% v/v glycerol.  Aliquots were frozen on dry ice and stored 
at −80 °C. 
 
7.4.1.7 Transformation of Competent E. coli 
 
 DH5α competent cells (50 µl, stored at −80 °C) were thawed slowly on ice and 
gently mixed with the transforming DNA (4 µl, 7 µl and 9 µl for In-Fusion ligation mix, 
T4 ligation mix and purified plasmid respectively).  The mixture was incubated on ice 
for 60 minutes before being heat shocked at 42 °C for 60 seconds.  The mixture was 
chilled on ice for 2 minutes.  LB broth (1 ml) was added and the mixture incubated with 
shaking at 37 °C for 1 hour.  200 µl was plated onto LB-Amp agar medium and 
incubated at 37 °C for 20 hours prior to storage at 4 °C. 
 
7.4.1.8 Preparation of Purified Plasmid 
 
 LB-Amp broth (5 ml) was inoculated with a single colony and incubated with 
shaking at 37 °C for 16 hours.  Frozen stocks were prepared by adding the culture    
(800 µl) to 80% glycerol (400 µl) and storing at −80 °C.  The remaining culture was 
treated with the QIAprep Spin Miniprep kit according to the manufacturer’s protocol 
and the product analysed by agarose gel electrophoresis.   
 
7.4.1.9 Yeast Culture 
 












 (stored at 
−80 °C) was inoculated onto SD –W –URA agar medium and incubated at 30 °C for   
48 hours prior to storage at 4 °C.  This was used to inoculate SD –W –URA medium    
(5 ml) which was then incubated with shaking at 30 °C until OD600 = 0.5−0.6. 
 
7.4.1.10 Yeast Transformation 
 
 5 ml of cells at OD600 = 0.5−0.6 were centrifuged (1,000 × g for 5 minutes at room 
temperature).  The supernatant was discarded and the cells were resuspended in sterile 
TE buffer (5 ml).  The cells were recentrifuged (1,000 × g for 5 minutes at room 
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temperature) and the supernatant was discarded.  The cell pellet was resuspended in 
freshly prepared, sterile 1 × TE/LiAc buffer (1 ml) to form the competent yeast cells. 
 
 Herring testes carrier DNA (10 µl) was boiled at 95 °C for 10 minutes.  To this 
were added purified plasmid (30 µl) and competent yeast cells (100 µl), with mixing 
achieved by vortexing.  Freshly prepared, sterile PEG/LiAc (600 µl) was added and the 
mixture vortexed followed by incubation with shaking at 30 °C for 30 minutes.  DMSO 
(70 µl) was added followed by mixing by gentle inversion.  The mixture was heat 
shocked at 42 °C for 15 minutes before being chilled on ice for 2 minutes.  The cells 
were centrifuged (14,400 × g for 5 seconds at room temperature), the supernatant was 
discarded and the cell pellet was resuspended in 1× TE buffer (200 µl).  The cells were 
plated onto agar plates of permissive medium (SGR –W –L) and incubated at 30 °C 
until sufficient growth was observed, followed by storage at 4 °C. 
 
7.4.1.11 Plasmid Shuffle 
 
 SGR –W –L medium (5 ml) was inoculated with transformed yeast and incubated 
with shaking at 30 °C until OD600 = 0.5−0.6.  200 µl was plated onto SGR –W –L 
+5FOA agar medium and incubated at 30 °C for 4 days prior to storage at 4 °C. 
 
7.4.1.12 Colony PCR 
 
 Water (4 µl) was inoculated with a single colony.  DMSO (1 µl) was added and the 
mixture vortexed.  PCR was subsequently undertaken following the standard protocol 
(section 7.4.1.1) using the prepared mixture (2 µl) in the place of the template DNA.  
The PCR reactions were analysed by agarose gel electrophoresis. 
 
7.4.1.13 Yeast Culture Scale-Up 
 
 Plasmid-shuffled yeast cultures were propagated in SGR –W –L medium.  Liquid 
medium (5 ml) was inoculated and incubated with shaking at 30 °C until OD600 ≥ 0.8.  
Fresh medium (600 ml) was added and the culture incubated with shaking at 30 °C until 
OD600 ≥ 0.8.  The culture was diluted into fresh medium (12 L) and incubated with 
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shaking at 30 °C until OD600 = 0.5−0.6.  Frozen stocks were prepared by adding the 
culture (800 µl) to 80% glycerol (400 µl) and storing at −80 °C. 
 
7.4.1.14 Preparation of Crude Microsomal Membranes 
 
 The following protocol was adapted from a literature procedure
320
 and carried out 
under non-sterile conditions.  The cells grown in large scale culture were harvested by 
centrifugation (4,000 × g for 10 minutes at 4 °C) and washed with cold PBS (3 ×         
20 ml).  The cell pellet was weighed and resuspended in STE buffer (volume in ml     
1.5 times the mass of the pellet in g).  The cells were disrupted using pre-chilled, acid-
washed glass beads (mass 1.5 times the mass of the pellet) by vortexing.  Disruption 
involved 30 cycles of 1 minute vortexing followed by 1 minute resting on ice.  The 
mixture was centrifuged (1,500 × g for 15 minutes at 4 °C) and the cell extract 
(supernatant) removed and stored.  To the pellet was added a further measure of STE 
buffer (0.5 times the mass of the pellet) and disruption repeated, followed by further 
centrifugation (1,500 × g for 15 minutes at 4 °C).   
 
 The cell extracts were combined and centrifuged (23,000 × g for 30 minutes at       
4 °C) to initially remove large organelles and any remaining cell debris.  The 
supernatant was recentrifuged (150,000 × g for 90 minutes at 4 °C) to obtain a pellet 
enriched with microsomal membranes.  The supernatant was discarded and the pellet 
resuspended in the minimal amount of storage buffer.  The protein content was 
determined using the Bradford assay and the membranes stored at −80 °C. 
 
7.4.1.15 Determination of Protein Concentration (Bradford Assay)  
 
 The following protocol was adapted from a literature procedure
381
 and carried out 
under non-sterile conditions.  A stock solution of BSA at a concentration of 100 µg ml
−1
 
in water was prepared and used to create a standard curve ranging from 0.625 µg to     
20 µg.  The volumes were adjusted to 800 µl with water prior to the addition of 
Bradford reagent (200 µl).  Following mixing the absorbance at 595 nm was measured 
and a standard curve produced.  Samples of the microsomal membranes (from 1 µl to   
20 µl) were diluted with water to give a final volume of 800 µl prior to the addition of 
Bradford reagent (200 µl).  Following mixing the absorbance at 595 nm was measured.  
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Correlation with the standard curve allowed the protein content of the microsomal 




7.4.1.16 Preparation of Washed Microsomal Membranes 
 
 The following protocol was performed according to a literature procedure
320
 and 
carried out under non-sterile conditions.  The crude microsomal membranes were 
adjusted to a concentration of 10 mg ml
−1
 using STE buffer and a 5% CHAPS stock 
solution was diluted to 2.5% with STE buffer. Equal volumes of the membranes and 
2.5% CHAPS solution were mixed and chilled on ice for 1 hour. The mixture was 
centrifuged (150,000 × g for 90 minutes at 4 °C) and the pellet was resuspended in 
storage buffer.  The protein content was determined using the Bradford assay and the 
membranes stored at −80 °C. 
 
7.4.1.17 Determination of Protein Content in Enzyme Units 
 
 The following protocol was carried out under non-sterile conditions.  A stock 
solution of NBD-C6-ceramide at a concentration of 10 pmol µl
−1
 in DMSO was 
prepared and used to create a standard curve ranging from 0.2 pmol to 80 pmol.  The 
volumes were adjusted to 200 µl with 1 M potassium formate in methanol.  The 
fluorescence was read at Ex460/Em540 and a standard curve produced.  Samples of the 
washed microsomal membranes were incubated with NBD-C6-ceramide under assay 
conditions (section 7.4.2.1.2) and the product fluorescence read at Ex460/Em540.  
Correlation with the standard curve allowed the activity of the microsome preparation to 
be calculated in U µl
−1
 (where 1U = 1 pmol(product) min
−1
).  The membranes were 
adjusted to 1.5 U µl
−1
 and stored at −80 °C. 
 
7.4.1.18 Preparation of Samples for Confocal Microscopy 
 
 The following protocol was carried out under non-sterile conditions.  The frozen 
samples of transformed yeast (100 µl) were defrosted on ice and washed with HBSS 
buffer (900 µl).  Following centrifugation (660 × g for 3 minutes at room temperature) 
the pellets were resuspended in HBSS buffer (1 ml).  100 µl, 75 µl, 50 µl, 25 µl, 10 µl 
and 5 µl of each sample were loaded into separate wells in a 96-well plate and all the 
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volumes adjusted to 100 µl with HBSS buffer.  The plate was centrifuged (1,900 × g for 
5 minutes at 4 °C) and imaged using the confocal microscope. 
 
7.4.1.19 L. major Promastigote Culture 
 
 The frozen samples of L. major MHOM/IL/81/Friedlin promastigotes (1 ml) or     
L. major MHOM/IL/81/Friedlin/−/−lcb2 promastigotes (1 ml) were rapidly defrosted 
and added to Schneider’s Insect Medium (pH 7, 15% FCS, 5 ml).  Incubation was 
carried out at 26 °C and promastigotes maintained in Schneider’s Insect Medium (pH 7, 
15% FCS).  Frozen stocks were prepared by adding the culture (900 µl) to DMSO    
(100 µl) and cooling slowly to −140 °C. 
 
7.4.1.20 Differentiation of THP-1 Cells 
 
 This protocol was conducted by personnel at GSK, Tres Cantos.  THP-1 cells were 
added to THP-1 pre-differentiation growth medium (−PMA, 50 ml) to a concentration 




 and incubated at 37 °C for 72 hours.  This was used to seed a culture   




 in pre-differentiation growth medium (+PMA) 
which was incubated at 37 °C for 24 hours under 5% CO2.  Differentiation was 
confirmed by microscopy and the cells were washed with 2 × 50 ml pre-differentiation 
growth medium (+PMA). 
 
7.4.2 Biological Assay Protocols 
 
7.4.2.1 In vitro Assay Protocols 
 
7.4.2.1.1 HPTLC Assay 
 
 The following protocol was adapted from a literature procedure
320
 and carried out 
under non-sterile conditions.  PI (10 mM, 1 µl) was dried into each LoBind Eppendorf 
tube using the Eppendorf Concentrator.  To each tube was added Tris/EDTA/BSA 
buffer (20 µl) and the contents mixed by vortexing.  The tubes were centrifuged briefly 
to collect the material and the volume adjusted to 48 µl with water.  The test compounds 
(0.5 µl) were added followed by washed microsomal membranes (1.5 U µl
−1
, 0.5 µl) 
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and the tubes pre-incubated with shaking at 30 °C for 30 minutes.  The reaction was 
initiated by the addition of NBD-C6-ceramide (100 µM,  1 µl) and incubated with 
shaking at 30 °C for a further 25 minutes before being quenched with 
chloroform:methanol:water (10:10:3, 150 µl).  Following centrifugation (14,400 × g for 
5 minutes at room temperature), 20 µl of the organic layer were removed and loaded 
onto a HTPLC plate.  This was run using the solvent system 
chloroform:methanol:0.25% aqueous KCl (55:45:10) and the fluorescence was read at 
Ex475/Em520.   
 
7.4.2.1.2 96-Well Plate Assay 
 
 The following protocol was adapted from a literature procedure
320
 and carried out 
under non-sterile conditions.  All quantities are calculated for 96 reactions. 
 
 The test compounds and controls (1 µl) were dispensed into a 96 V-well plate.       
PI (10 mM, 40 µl) was dried into a LoBind Eppendorf tube using the Eppendorf 
Concentrator.  To the tube was added phosphate buffer (71.4 mM, pH 7.0, 1.4 ml) and 
the contents mixed by vortexing.  The contents were transferred to a glass vial and to 
this were added CHAPS (3 mM, 400 µl), storage buffer (160 µl) and CHAPS-washed 
microsomal membranes (1.5 U µl
−1
, 40 µl).  The solution (20 µl) was added to each 
well and the plate pre-incubated at 30 °C for 15 minutes.  CHAPS (3 mM, 450 µl),      
phosphate buffer (71.4 mM, 1575 µl) and NBD-C6-ceramide (200 µM, 112.5 µl) were 
mixed together by vortexing and the solution (19 µl) was added to each well.  The plate 
was incubated at 30 °C for 25 minutes before the reaction was quenched by the addition 
of methanol (200 µl). 
 
 Separation of the product and starting material was achieved using ion exchange 
resin in 96-well filter plates.  20% w/v AG 4-X4 resin in ethanol (100 µl) was added per 
well and sedimented by centrifugation (2,450 × g for 27 seconds at room temperature).  
The resin was incubated with formic acid (50 µl) for 5 minutes before being centrifuged 
(2,450 × g for 27 seconds at room temperature).  The resin was then washed with water 
(100 µl) and dried by centrifugation (2,450 × g for 27 seconds at room temperature).   
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 The reaction mixture (200 µl) was loaded onto the resin and the starting material 
removed by centrifugation (2,450 × g for 1 minute at room temperature).  The resin was 
washed with 5 × 200 µl methanol before the product was eluted into black plates using 
4 × 50 µl of potassium formate in methanol (1 M) (all centrifugations at 2,450 × g for      
1 minute at room temperature).  The fluorescence was read at Ex460/Em540. 
 
7.4.2.2 In cellulo Assay Protocols 
 
7.4.2.2.1 Diffusion Assay 
 
Agarose (280 mg) was added to SGR –W –L medium (14 ml) and autoclaved.  
To this was added liquid yeast culture to produce a solution of OD600 = 0.14, which was 
mixed by gentle inversion.  This was poured into a square plate and left to set.  A test 
compound and a control (DMSO) were spotted onto the surface of the agarose (1 µl,     
2 µl and 3 µl of each) and the plate incubated at 30 °C for 96 hours. 
 
7.4.2.2.2 HTS Assay 
  
 Cycloheximide (1 mM, 50 nl) was dispensed into the control wells of 1,536-well 
plates.  The frozen stock of the required strain(s) (OD600 = 10) was thawed on ice.  The 
required volume of assay mixture (10 µM FDGlu and α-Lmj or α-AUR1 of            
OD600 = 0.0625 in SGR –W –L) was subsequently prepared and dispensed (5 µl per 
well).  Plates were incubated at 30 °C for 25 hours prior to the addition of phosphate 
buffer (0.25 M, pH 7.0, 5 µl per well).  The fluorescence was read at Ex480/Em540. 
 
7.4.2.2.3 L. major Cytotoxicity Assay 
 
 The following protocol was adapted from a literature procedure.
320
  The test 
compounds and controls (1 µl) were dispensed into a sterile 96-well plate.  L. major 




 for the 




 for the dose-response assay and the plate incubated at 
26 °C for 72 hours.  AlamarBlue
®
 (10 µl) was added and the plate incubated at 26 °C 
for 4 hours for L. major FV1 promastigotes or 8 hours for L. major lcb2Δ mutant 
promastigotes.  The fluorescence was read at Ex540/Em600. 
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7.4.2.2.4 Metabolic Labelling Assay 
 
 L. major lcb2Δ mutant promastigotes were centrifuged (1,500 × g for 10 minutes at 
room temperature) and the pellet washed three times with stock Schneider’s Insect 
Medium (pH 7, no FCS).  The pellet was subsequently resuspended in Schneider’s 





dispensed into Eppendorf tubes (250 µl per tube).  Following a pre-incubation at 26 °C 
for 1 hour, the test compounds were added (1 µl) and the tubes incubated at 26 °C for 
18 hours. 
 
 The reaction was initiated by the addition of BODIPY
®
 FL C5-ceramide complexed 
to BSA (0.5 mM, 1.25 µl).  Following further incubation at 26 °C for 1 hour, the tubes 
were centrifuged (12,500 × g for 5 minutes at room temperature) and the pellets washed 
twice with PBS (250 µl).  The pellets were resuspended in chloroform:methanol:water 
(10:10:3, 200 µl) followed by sonication in a water bath for 15 minutes.  Water (25 µl) 
was added before centrifugation (14,400 × g for 10 seconds at room temperature).  20 µl 
of the organic layer were removed and loaded onto a HTPLC plate.  This was run using 
the solvent system chloroform:methanol:0.25% aqueous KCl (55:45:10) and the 
fluorescence was read at Ex475/Em520. 
 
7.4.2.2.5 Axenic L. donovani Cytotoxicity Assay 
 
 This protocol was conducted by personnel at GSK, Tres Cantos and was performed 
according to a literature procedure.
341
  The test compounds and controls (30 nl) were 
dispensed into a sterile 1,536-well plate.  L. donovani LdBOB amastigotes in amastigote 




 and the 
plate incubated at 37 °C for 72 hours under 5% CO2.  Resazurin solution (2 µl) was 
added and the plate incubated at room temperature for 4 hours.  The fluorescence was 
read at Ex528/Em590. 
 
7.4.2.2.6 HepG2 Cytotoxicity Assay 
 
 This protocol was conducted by personnel at GSK, Tres Cantos and was performed 
according to a literature procedure.
341
  The test compounds and controls (250 nl) were 
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dispensed into a sterile 384-well plate.  HepG2 cells in HepG2 growth medium (25 µl) 




 and the plate incubated at 37 °C 
for 48 hours under 5% CO2 and at 80% relative humidity.  The plate was incubated at 
room temperature for 30 minutes prior to the addition of CellTiter-Glo
®
 (25 µl).  The 
plate was incubated at room temperature for 10 minutes and the luminescent output 
measured. 
 
7.4.2.2.7 Intramacrophage L. donovani Cytotoxicity Assay 
 
  This protocol was conducted by personnel at GSK, Tres Cantos and was performed 
according to a literature procedure.
341





 (prepared using protocol 7.4.1.20, 50 ml) were infected with L. donovani 




 and the flask incubated 
overnight at 37 °C.  Remaining extracellular parasites were removed by washing with   
3 × 50 ml PBS before the cells were harvested with trypsin.   
 
 The test compounds and controls (250 nl) were dispensed into a sterile 384-well 
plate.  Infected macrophages in post-differentiation growth medium (50 µl) were added 




 and the plate incubated at 37 °C for 96 hours 
under 5% CO2.  Wells were fixed with 4% (v/v) formaldehyde in PBS at room 
temperature for 30 minutes before washing with 2 × 100 µl PBS.  Cells were stained 
with HCS CellMask™ Deep Red at room temperature for 30 minutes before washing 
with 2 × 50 µl PBS.  PBS (50 µl) was added to each well and the wells imaged at 
Ex405/Em460 and Ex488/Em509.  Images were analysed using the automated 
Acapella
®
 High Content Imaging and Analysis Software from PerkinElmer. 
 
7.4.2.3 In vivo Assay Protocol 
 
 This protocol was conducted by personnel at the London School of Hygiene and 
Tropical Medicine and was performed according to a literature procedure.
367
                 
L. donovani amastigotes were isolated from the spleen of an infected hamster and       
1.0 × 10
7
 parasites were intravenously injected into female BALB/c mice, which were 
randomly sorted into groups of 5.  The infection was allowed to develop over 7 days 
before the mice were dosed orally at 50 mg kg
−1
 twice a day for 5 days.  The mice were 
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sacrificed 14 days post infection and the livers and spleens were removed and weighed 
prior to the preparation of smears, which were fixed with methanol and stained with 
Giemsa.  The number of amastigotes per 500 liver or spleen cells × organ weight was 















1. WHO, Investing to overcome the global impact of neglected tropical diseases - 




 May, 2015). 
2. L. Manderson, J. Aagaard-Hansen, P. Allotey, M. Gyapong and J. Sommerfeld, 
PLoS Negl. Trop. Dis., 2009, 3, e332. 
3. K. Nussbaum, J. Honek, C. Cadmus and T. Efferth, Curr. Med. Chem., 2010, 17, 
1594-1617. 
4. H. C. Turner, M. Walker, M. D. French, I. M. Blake, T. S. Churcher and M. G. 
Basanez, Trends Parasitol., 2014, 30, 562-570. 
5. P. J. Hotez, M. Alvarado, M. G. Basanez, I. Bolliger, R. Bourne, M. Boussinesq, 
S. J. Brooker, A. S. Brown, G. Buckle, C. M. Budke, H. Carabin, L. E. Coffeng, 
E. M. Fevre, T. Furst, Y. A. Halasa, R. Jasrasaria, N. E. Johns, J. Keiser, C. H. 
King, R. Lozano, M. E. Murdoch, S. O'Hanlon, S. D. S. Pion, R. L. Pullan, K. D. 
Ramaiah, T. Roberts, D. S. Shepard, J. L. Smith, W. A. Stolk, E. A. Undurraga, 
J. Utzinger, M. R. Wang, C. J. L. Murray and M. Naghavi, PLoS Negl. Trop. 
Dis., 2014, 8, e2865. 
6. J. Noblick, R. Skolnik and P. J. Hotez, PLoS Negl. Trop. Dis., 2011, 5, e1022. 
7. K. Stuart, R. Brun, S. Croft, A. Fairlamb, R. E. Gurtler, J. McKerrow, S. Reed 
and R. Tarleton, J. Clin. Invest., 2008, 118, 1301-1310. 
8. D. A. Maslov, S. A. Podtipaev and J. Lukes, Mem. I. Oswaldo Cruz, 2001, 96, 
397-402. 
9. A. G. B. Simpson, J. R. Stevens and J. Lukes, Trends Parasitol., 2006, 22, 168-
174. 
10. P. A. Bates, Int. J. Parasitol., 2007, 37, 1097-1106. 




 May, 2015). 




 May, 2015). 
13. J. Alvar, I. D. Velez, C. Bern, M. Herrero, P. Desjeux, J. Cano, J. Jannin and M. 
den Boer, PLoS One, 2012, 7, e35671. 
14. H. W. Murray, J. D. Berman, C. R. Davies and N. G. Saravia, Lancet, 2005, 366, 
1561-1577. 
15. W. H. Markle and K. Makhoul, Am. Fam. Physician, 2004, 69, 1455-1460. 
16. R. Kubba, Y. Algindan, A. M. Elhassan, A. H. S. Omer, M. K. Kutty and M. B. 
M. Saeed, Int. J. Dermatol., 1988, 27, 702-706. 
  8. References 
160 
 
17. P. Desjeux, Comp. Immunol. Microbiol. Infect. Dis., 2004, 27, 305-318. 
18. E. D. Franke, A. Llanoscuentas, J. Echevarria, M. E. Cruz, P. Campos, A. A. 
Tovar, C. M. Lucas and J. D. Berman, Am. J. Trop. Med. Hyg., 1994, 51, 77-82. 
19. P. M. Woster, Comp. Med. Chem. II, 2007, 7, 815-843. 
20. WHO, Working to overcome the global impact of neglected tropical diseases - 




 May, 2015). 
21. J. D. Berman, Clin. Infect. Dis., 1997, 24, 684-703. 
22. I. L. Mauricio, J. R. Stothard and M. A. Miles, Parasitol. Today, 2000, 16, 188-
189. 
23. V. E. Miranda de Araujo, M. H. Franco Morais, I. A. Reis, A. Rabello and M. 
Carneiro, PLoS Negl. Trop. Dis., 2012, 6, e1511. 
24. F. R. Martins-Melo, M. D. Lima, A. N. Ramos, C. H. Alencar and J. 
Heukelbach, PLoS One, 2014, 9, e93770. 
25. E. E. Zijlstra, A. M. Musa, E. A. G. Khalil, I. M. el-Hassan and A. M. el-Hassan, 
Lancet Infect. Dis., 2003, 3, 87-98. 
26. P. Desjeux and J. Alvar, Ann. Trop. Med. Parasitol., 2003, 97, 3-15. 
27. CDC, Life Cycle of Leishmania spp, 
http://www.cdc.gov/dpdx/leishmaniasis/index.html, (accessed 24
th
 May, 2015). 
28. K. Leifso, G. Cohen-Freue, N. Dogra, A. Murray and W. R. McMaster, Mol. 
Biochem. Parasitol., 2007, 152, 35-46. 
29. A. T. Peterson and J. Shaw, Int. J. Parasitol., 2003, 33, 919-931. 
30. M. Rogers, P. Kropf, B. S. Choi, R. Dillon, M. Podinovskaia, P. Bates and I. 
Muller, PLoS Pathog., 2009, 5, e1000555. 
31. O. Brandonisio, R. Spinelli and M. Pepe, Microbes Infect., 2004, 6, 1402-1409. 
32. P. E. Kima, Int. J. Parasitol., 2007, 37, 1087-1096. 
33. M. J. McConville and E. Handman, Int. J. Parasitol., 2007, 37, 1047-1051. 
34. E. Gluenz, M. L. Ginger and P. G. McKean, Curr. Opin. Microbiol., 2010, 13, 
473-479. 
35. P. F. P. Pimenta, S. J. Turco, M. J. McConville, P. G. Lawyer, P. V. Perkins and 
D. L. Sacks, Science, 1992, 256, 1812-1815. 
36. J. Blum, P. Buffet, L. Visser, G. Harms, M. S. Bailey, E. Caumes, J. Clerinx, P. 
P. A. M. van Thiel, G. Morizot, C. Hatz, T. P. C. Dorlo and D. N. J. Lockwood, 
J. Travel Med., 2014, 21, 116-129. 
37. G. O. Vianna, Anais do VII Congresso Brasileiro de Medicina e Cirurgia, 1912, 
4, 426-428. 
38. G. Di Cristina and G. Caronia, Pathologica, 1915, 7, 82-83. 
39. U. N. Brahmachari, Ind. J. Med. Res., 1922, 10, 492-522. 
40. A. K. Haldar, P. Sen and S. Roy, Mol. Biol. Int., 2011, 2011, e571242. 
41. R. A. Gasser, A. J. Magill, C. N. Oster, E. D. Franke, M. Grogl and J. D. 
Berman, Clin. Infect. Dis., 1994, 18, 83-90. 
42. S. Sundar and J. Chakravarty, Int. J. Environ. Res. Publ. Health, 2010, 7, 4267-
4277. 
43. E. M. Andersen, M. Cruz-Saldarriaga, A. Llanos-Cuentas, M. Luz-Cjuno, J. 
Echevarria, C. Miranda-Verastegui, O. Colina and J. D. Berman, Am. J. Trop. 
Med. Hyg., 2005, 72, 133-137. 
44. P. Shaked-Mishan, N. Ulrich, M. Ephros and D. Zilberstein, J. Biol. Chem., 
2001, 276, 3971-3976. 
45. A. K. Chakraborty and H. K. Majumder, Biochem. Biophys. Res. Commun., 
1988, 152, 605-611. 
  8. References 
161 
 
46. S. Sundar, D. K. More, M. K. Singh, V. P. Singh, S. Sharma, A. Makharia, P. C. 
K. Kumar and H. W. Murray, Clin. Infect. Dis., 2000, 31, 1104-1107. 
47. G. Mandal, S. Mandal, M. Sharma, K. S. Charret, B. Papadopoulou, H. 
Bhattacharjee and R. Mukhopadhyay, PLoS Negl. Trop. Dis., 2015, 9, 
e0003500. 
48. A. N. Hazarika, Ind. Med. Gaz., 1949, 84, 140-145. 
49. T. P. C. Dorlo and P. A. Kager, PLoS Negl. Trop. Dis., 2008, 2, e225. 
50. A. Belehu and B. Naafs, Lancet, 1982, 1, 1463-1464. 
51. M. Sands, M. A. Kron and R. B. Brown, Rev. Infect. Dis., 1985, 7, 625-634. 
52. M. Basselin, H. Denise, G. H. Coombs and M. P. Barrett, Antimicrob. Agents 
Chemother., 2002, 46, 3731-3738. 
53. S. Sundar, Med. Microbiol. Immunol., 2001, 190, 89-92. 
54. A. S. Nagle, S. Khare, A. B. Kumar, F. Supek, A. Buchynskyy, C. J. N. 
Mathison, N. K. Chennamaneni, N. Pendem, F. S. Buckner, M. H. Gelb and V. 
Molteni, Chem. Rev., 2014, 114, 11305-11347. 
55. M. Roussel, M. Nacher, G. Fremont, B. Rotureau, E. Clyti, D. Sainte-Marie, B. 
Carme, R. Pradinaud and P. Couppie, Ann. Trop. Med. Parasitol., 2006, 100, 
307-314. 
56. R. Donovick, W. Gold, J. F. Pagano and H. A. Stout, Antibiot. Ann., 1955, 3, 
579-586. 
57. W. H. Trejo and R. E. Bennett, J. Bacteriol., 1963, 85, 436-439. 
58. A. Prata, Trans. R. Soc. Trop. Med. Hyg., 1963, 57, 266-268. 
59. J. Berman, Am. J. Trop. Med. Hyg., 2015, 92, 471-473. 
60. S. Sundar, H. Mehta, A. V. Suresh, S. P. Singh, M. Rai and H. W. Murray, Clin. 
Infect. Dis., 2004, 38, 377-383. 
61. C. P. Thakur, R. K. Singh, S. M. Hassan, R. Kumar, S. Narain and A. Kumar, 
Trans. R. Soc. Trop. Med. Hyg., 1999, 93, 319-323. 
62. B. E. Cohen, Int. J. Pharm., 1998, 162, 95-106. 
63. E. Castillo, M. A. Dea-Ayuela, F. Bolas-Fernandez, M. Rangel and M. E. 
Gonzalez-Rosende, Curr. Med. Chem., 2010, 17, 4027-4051. 
64. WHO, Report of a WHO informal consultation on liposomal amphotericin B in 
the treatment of visceral leishmaniasis, 
www.who.int/neglected_diseases/resources/AmBisomeReport.pdf, (accessed 
2nd July, 2015). 
65. Y. D. Paila, B. Saha and A. Chattopadhyay, Biochem. Biophys. Res. Commun., 
2010, 399, 429-433. 
66. S. L. Croft, S. Sundar and A. H. Fairlamb, Clin. Microbiol. Rev., 2006, 19, 111-
126. 
67. M. Baginski, H. Resat and J. A. McCammon, Mol. Pharmacol., 1997, 52, 560-
570. 
68. A. Chattopadhyay and M. Jafurulla, Biochem. Biophys. Res. Commun., 2011, 
416, 7-12. 
69. B. Purkait, A. Kumar, N. Nandi, A. H. Sardar, S. Das, S. Kumar, K. Pandey, V. 
Ravidas, M. Kumar, T. De, D. Singh and P. Das, Antimicrob. Agents 
Chemother., 2012, 56, 1031-1041. 
70. R. N. Davidson, M. den Boer and K. Ritmeijer, Trans. R. Soc. Trop. Med. Hyg., 
2009, 103, 653-660. 
71. R. A. Neal, S. Allen, N. McCoy, P. Olliaro and S. L. Croft, J. Antimicrob. 
Chemother., 1995, 35, 577-584. 
72. C. N. Chunge, J. Owate, H. O. Pamba and L. Donno, Trans. R. Soc. Trop. Med. 
Hyg., 1990, 84, 221-225. 
  8. References 
162 
 
73. A. Ben Salah, N. Ben Messaoud, E. Guedri, A. Zaatour, N. Ben Alaya, J. 
Bettaieb, A. Gharbi, N. B. Hamida, A. Boukthir, S. Chlif, K. Abdelhamid, Z. El 
Ahmadi, H. Louzir, M. Mokni, G. Morizot, P. Buffet, P. L. Smith, K. M. 
Kopydlowski, M. Kreishman-Deitrick, K. S. Smith, C. J. Nielsen, D. R. Ullman, 
J. A. Norwood, G. D. Thorne, W. F. McCarthy, R. C. Adams, R. M. Rice, D. 
Tang, J. Berman, J. Ransom, A. J. Magill and M. Grogl, New Engl. J. Med., 
2013, 368, 524-532. 
74. S. Sundar, T. K. Jha, C. P. Thakur, P. K. Sinha, S. K. Bhattacharya, B. Nguyen, 
E. Kwan, A. Oudin, K. Valcke, S. Mathie, C. Ley, M. Rosenberg, E. L. 
Gaithersburg, L. Muenz, D. He, L. J. Wei, B. Ballanchanda, E. Wrone, E. 
Mahmoud, R. Davidson, R. Sweetow, M. Valente, L. Sheiner, S. Beal, E. Lin, 
W. Gee, Y. Huang, H. Chang and X. Li, New Engl. J. Med., 2007, 356, 2571-
2581. 
75. M. M. Fernandez, E. L. Malchiodi and I. D. Algranati, Antimicrob. Agents 
Chemother., 2011, 55, 86-93. 
76. B. Chawla, A. Jhingran, A. Panigrahi, K. D. Stuart and R. Madhubala, PLoS 
One, 2011, 6, e26660. 
77. M. Maarouf, F. Lawrence, S. Brown and M. RobertGero, Parasitol. Res., 1997, 
83, 198-202. 
78. S. Teklemariam, A. G. Hiwot, D. Frommel, T. L. Miko, G. Ganlov and A. 
Bryceson, Trans. R. Soc. Trop. Med. Hyg., 1994, 88, 334-339. 
79. M. Maarouf, M. T. Adeline, M. Solignac, D. Vautrin and M. Robert-Gero, 
Parasite, 1998, 5, 167-173. 
80. P. Hilgard, T. Klenner, J. Stekar and C. Unger, Cancer Chemother. Pharmacol., 
1993, 32, 90-95. 
81. S. L. Croft, D. Snowdon and V. Yardley, J. Antimicrob. Chemother., 1996, 38, 
1041-1047. 
82. K. Ritmeijer, A. Dejenie, Y. Assefa, T. B. Hundie, J. Mesure, G. Boots, M. den 
Boer and R. N. Davidson, Clin. Infect. Dis., 2006, 43, 357-364. 
83. P. R. Machado, J. Ampuero, L. H. Guimaraes, L. Villasboas, A. T. Rocha, A. 
Schriefer, R. S. Sousa, A. Talhari, G. Penna and E. M. Carvalho, PLoS Negl. 
Trop. Dis., 2010, 4, e912. 
84. S. Sundar and P. L. Olliaro, Ther. Clin. Risk Manag., 2007, 3, 733-740. 
85. T. P. C. Dorlo, P. van Thiel, A. D. R. Huitema, R. J. Keizer, H. J. C. de Vries, J. 
H. Beijnen and P. J. de Vries, Antimicrob. Agents Chemother., 2008, 52, 2855-
2860. 
86. N. K. Verma and C. S. Dey, Antimicrob. Agents Chemother., 2004, 48, 3010-
3015. 
87. T. P. C. Dorlo, M. Balasegaram, J. H. Beijnen and P. J. de Vries, J. Antimicrob. 
Chemother., 2012, 67, 2576-2597. 
88. K. Seifert, S. Matu, F. J. Perez-Victoria, S. Castanys, F. Gamarro and S. L. 
Croft, Int. J. Antimicrob. Agents, 2003, 22, 380-387. 
89. S. Cojean, S. Houze, D. Haouchine, F. Huteau, S. Lariven, V. Hubert, F. 
Michard, C. Bories, F. Pratlong, J. Le Bras, P. M. Loiseau and S. Matheron, 
Emerg. Infect. Dis., 2012, 18, 704-706. 
90. K. Seifert and S. L. Croft, Antimicrob. Agents Chemother., 2006, 50, 73-79. 
91. R. E. Saenz, H. Paz and J. D. Berman, Am. J. Med., 1990, 89, 147-155. 
92. S. Sundar, P. K. Sinha, S. A. Dixon, R. Buckley, A. K. Miller, K. Mohamed and 
M. Al-Banna, Am. J. Trop. Med. Hyg., 2011, 84, 892-900. 
93. J. Dogra, B. B. Lal and S. N. Misra, Int. J. Dermatol., 1986, 25, 398-400. 
  8. References 
163 
 
94. I. Arevalo, B. Ward, R. Miller, T. C. Meng, E. Najar, E. Alvarez, G. 
Matlashewski and A. Llanos-Cuentas, Clin. Infect. Dis., 2001, 33, 1847-1851. 
95. DNDi, DNDi R&D Project Portfolio, http://www.dndi.org/diseases-
projects/portfolio.html, (accessed 29
th
 May 2015). 
96. DNDi, Target Product Profile for CL, http://www.dndi.org/diseases-
projects/diseases/vl/tpp/tpp-cl.html, (accessed 17
th
 July, 2015). 
97. DNDi, Target Product Profile for VL, http://www.dndi.org/diseases-
projects/diseases/vl/tpp/tpp-vl.html, (accessed 17
th
 July, 2015). 
98. C. I. de Oliveira, I. P. Nascimento, A. Barral, M. Soto and M. Barral-Netto, 
Parasitol. Int., 2009, 58, 319-324. 
99. J. R. Baker, Parasite, 1995, 2, 3-12. 





 June, 2015). 





 June, 2015). 
102. P. G. E. Kennedy, J. Clin. Invest., 2004, 113, 496-504. 





 June, 2015). 
104. S. C. Welburn, E. M. Fevre, P. G. Coleman, M. Odiit and I. Maudlin, Trends 
Parasitol., 2001, 17, 19-24. 
105. J. R. Franco, P. P. Simarro, A. Diarra and J. G. Jannin, Clin. Epidemiol., 2014, 
6, 257-275. 
106. P. G. E. Kennedy, Pract. Neurol., 2005, 5, 260-267. 
107. J. Rodgers, A. Jones, S. Gibaud, B. Bradley, C. McCabe, M. P. Barrett, G. 
Gettinby and P. G. E. Kennedy, PLoS Negl. Trop. Dis., 2011, 5, e1308. 
108. A. J. Duggan and M. P. Hutchinson, J. Trop. Med. Hyg., 1966, 69, 124-131. 





110. E. M. Fevre, K. Picozzi, J. Jannin, S. C. Welburn and I. Maudlin, in Advances in 
Parasitology, Vol 61: Control of Human Parasitic Diseases, ed. D. H. 
Molyneux, Elsevier Academic Press Inc., San Diego, 2006, vol. 61, pp. 167-221. 
111. H. Belete, G. Tikubet, B. Petros, W. A. Oyibo and I. N. Otigbuo, Trop. Med. Int. 
Health, 2004, 9, 710-714. 
112. M. Becker, N. Aitcheson, E. Byles, B. Wickstead, E. Louis and G. Rudenko, 
Genome Res., 2004, 14, 2319-2329. 
113. J. R. Seed and S. J. Black, J. Parasitol., 1997, 83, 656-662. 
114. B. Reuner, E. Vassella, B. Yutzy and M. Boshart, Mol. Biochem. Parasitol., 
1997, 90, 269-280. 
115. J. R. Seed and M. A. Wenck, Kinetoplastid Biol. Dis., 2003, 2, 3. 
116. J. Van den Abbeele, Y. Claes, D. van Bockstaele, D. Le Ray and M. Coosemans, 
Parasitology, 1999, 118, 469-478. 
117. M. D. Urbaniak, M. L. S. Guther and M. A. J. Ferguson, PLoS One, 2012, 7, 
e36619. 
118. D. Steverding, Parasite. Vector., 2008, 1, 3. 
119. N. Baker, H. P. de Koning, P. Maser and D. Horn, Trends Parasitol., 2013, 29, 
110-118. 
  8. References 
164 
 
120. P. Babokhov, A. O. Sanyaolu, W. A. Oyibo, A. F. Fagbenro-Beyioku and N. C. 
Iriemenam, Pathog. Glob. Health, 2013, 107, 242-252. 
121. F. Doua, T. W. Miezan, J. R. S. Singaro, F. B. Yapo and T. Baltz, Am. J. Trop. 
Med. Hyg., 1996, 55, 586-588. 
122. B. Bouteille, O. Oukem, S. Bisser and M. Dumas, Fundam. Clin. Pharmacol., 
2003, 17, 171-181. 
123. H. P. de Koning, Mol. Pharmacol., 2001, 59, 586-592. 
124. D. Kayembe and M. Wery, Ann. Soc. Belg. Med. Trop., 1972, 52, 1-8. 
125. E. L. M. Vansterkenburg, I. Coppens, J. Wilting, O. J. M. Bos, M. J. E. Fischer, 
L. H. M. Janssen and F. R. Opperdoes, Acta Trop., 1993, 54, 237-250. 
126. M. P. Barrett, D. W. Boykin, R. Brun and R. R. Tidwell, Br. J. Pharmacol., 
2007, 152, 1155-1171. 
127. R. Brun, J. Blum, F. Chappuis and C. Burri, Lancet, 2010, 375, 148-159. 
128. A. J. Nok, Parasitol. Res., 2003, 90, 71-79. 
129. M. Willson, M. Callens, D. A. Kuntz, J. Perie and F. R. Opperdoes, Mol. 
Biochem. Parasitol., 1993, 59, 201-210. 
130. H. Dixon, C. D. Ginger and Williams.J, Comp. Biochem. Physiol., 1971, 39, 
247-266. 
131. S. N. Kibona, L. Matemba, J. S. Kaboya and G. W. Lubega, Trop. Med. Int. 
Health, 2006, 11, 144-155. 
132. A. G. Scott, A. Tait and C. M. R. Turner, Acta Trop., 1996, 60, 251-262. 
133. E. A. H. Friedheim, Am. J. Trop. Med. Hyg., 1949, 29, 173-180. 
134. D. Steverding, Parasite. Vector., 2010, 3, 15. 
135. C. Burri, S. Nkunhu, A. Merolle, T. Smith, J. Blum and R. Brun, Lancet, 2000, 
355, 1419-1425. 
136. I. Kuepfer, C. Schmid, M. Allan, A. Edielu, E. P. Haary, A. Kakembo, S. 
Kibona, J. Blum and C. Burri, PLoS Negl. Trop. Dis., 2012, 6, e1695. 
137. S. Kappagoda, U. Singh and B. G. Blackburn, Mayo Clin. Proc., 2011, 86, 561-
583. 
138. J. Blum, S. Nkunku and C. Burri, Trop. Med. Int. Health, 2001, 6, 390-400. 
139. J. Keiser, O. Ericsson and C. Burri, Clin. Pharmacol. Ther., 2000, 67, 478-488. 
140. M. L. Cunningham, M. Zvelebil and A. H. Fairlamb, Eur. J. Biochem., 1994, 
221, 285-295. 
141. A. H. Fairlamb, G. B. Henderson and A. Cerami, Proc. Natl. Acad. Sci. USA, 
1989, 86, 2607-2611. 
142. R. Brun, R. Schumacher, C. Schmid, C. Kunz and C. Burri, Trop. Med. Int. 
Health, 2001, 6, 906-914. 
143. J. Robays, G. Nyamowala, C. Sese, V. Kande, P. Lutumba, W. Van der Veken 
and M. Boelaert, Emerg. Infect. Dis., 2008, 14, 966-967. 
144. P. Pyana Pati, N. Van Reet, D. Mumba Ngoyi, I. Ngay Lukusa, S. Karhemere 
Bin Shamamba and P. Buscher, PLoS Negl. Trop. Dis., 2014, 8, e3212. 
145. C. J. Bacchi, H. C. Nathan and S. H. Hutner, Science, 1980, 210, 332-334. 
146. B. F. Giffin, P. P. McCann, A. J. Bitonti and C. J. Bacchi, J. Protozool., 1986, 
33, 238-243. 
147. M. Iten, H. Mett, A. Evans, J. C. K. Enyaru, R. Brun and R. Kaminsky, 
Antimicrob. Agents Chemother., 1997, 41, 1922-1925. 
148. G. Priotto, L. Pinoges, I. B. Fursa, B. Burke, N. Nicolay, G. Grillet, C. Hewison 
and M. Balasegaram, BMJ, 2008, 336, 705-708. 
149. C. Burri and R. Brun, Parasitol. Res., 2003, 90, S49-S52. 
150. J. Pepin, F. Milord, B. Mpia, F. Meurice, L. Ethier, D. Degroof and H. Bruneel, 
Trans. R. Soc. Trop. Med. Hygiene, 1989, 83, 514-517. 
  8. References 
165 
 
151. S. M. Townson, P. F. L. Boreham, P. Upcroft and J. A. Upcroft, Acta Trop., 
1994, 56, 173-194. 
152. S. Bisser, F. X. N'Siesi, V. Lejon, P. M. Preux, S. Van Nieuwenhove, C. M. M. 
Bilenge and P. Buscher, J. Infect. Dis., 2007, 195, 322-329. 
153. G. Priotto, S. Kasparian, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri and 
U. Karunakara, Clin. Infect. Dis., 2007, 45, 1435-1442. 
154. P. P. Simarro, A. Diarra, J. A. R. Postigo, J. R. Franco and J. G. Jannin, PLoS 
Negl. Trop. Dis., 2011, 5, e1007. 
155. F. Checchi, P. Piola, H. Ayikoru, F. Thomas, D. Legros and G. Priotto, PLoS 
Negl. Trop. Dis., 2007, 1, e64. 
156. G. Priotto, S. Kasparian, W. Mutombo, D. Ngouama, S. Ghorashian, U. Arnold, 
S. Ghabri, E. Baudin, V. Buard, S. Kazadi-Kyanza, M. Ilunga, W. Mutangala, G. 
Pohlig, C. Schmid, U. Karunakara, E. Torreele and V. Kande, Lancet, 2009, 
374, 56-64. 
157. E. Alirol, D. Schrumpf, J. A. Heradi, A. Riedel, C. de Patoul, M. Quere and F. 
Chappuis, Clin. Infect. Dis., 2013, 56, 195-203. 




 June, 2015). 
159. M. Kaiser, L. Maes, L. P. Tadoori, T. Spangenberg and J. R. Ioset, J. Biomol. 
Screen., 2015, 20, 634-645. 
160. P. Trouiller, P. Olliaro, E. Torreele, J. Orbinski, R. Laing and N. Ford, Lancet, 
2002, 359, 2188-2194. 
161. B. Pedrique, N. Strub-Wourgaft, C. Some, P. Olliaro, P. Trouiller, N. Ford, B. 
Pecoul and J. H. Bradol, Lancet Glob. Health, 2013, 1, e371-e379. 




 June, 2015). 
163. P. H. Jakobsen, M. W. Wang and S. Nwaka, PLoS Negl. Trop. Dis., 2011, 5, 
e1221. 
164. J. L. W. Thudichum, Treatise on the Chemical Constitution of the Brain, 
Bailliere, Tindall and Cox, London, 1884. 
165. A. H. Merrill, M. D. Wang, M. Park and M. C. Sullards, Trends Biochem. Sci., 
2007, 32, 457-468. 
166. K. A. Karlsson, Lipids, 1970, 5, 878-891. 
167. C. Bure, J. L. Cacas, S. Mongrand and J. M. Schmitter, Anal. Bioanal. Chem., 
2014, 406, 995-1010. 
168. A. H. Merrill, J. Biol. Chem., 2002, 277, 25843-25846. 
169. A. H. Merrill, Chem. Rev., 2011, 111, 6387-6422. 
170. E. Fahy, S. Subramaniam, H. A. Brown, C. K. Glass, A. H. Merrill, R. C. 
Murphy, C. R. H. Raetz, D. W. Russell, Y. Seyama, W. Shaw, T. Shimizu, F. 
Spener, G. van Meer, M. S. VanNieuwenhze, S. H. White, J. L. Witztum and E. 
A. Dennis, J. Lipid Res., 2005, 46, 839-861. 
171. Y. Hirabayashi, Y. Igarashi and A. H. Merrill, Sphingolipid Biology, Springer 
Science & Business Media, 2007. 
172. W. Godchaux, III and E. R. Leadbetter, J. Bacteriol., 1980, 144, 592-602. 
173. A. A. Hicks, P. P. Pramstaller, A. Johansson, V. Vitart, I. Rudan, P. Ugocsai, Y. 
Aulchenko, C. S. Franklin, G. Liebisch, J. Erdmann, I. Jonasson, I. V. 
Zorkoltseva, C. Pattaro, C. Hayward, A. Isaacs, C. Hengstenberg, S. Campbell, 
C. Gnewuch, A. C. J. W. Janssens, A. V. Kirichenko, I. R. Koenig, F. Marroni, 
O. Polasek, A. Demirkan, I. Kolcic, C. Schwienbacher, W. Igl, Z. Biloglav, J. C. 
  8. References 
166 
 
M. Witteman, I. Pichler, G. Zaboli, T. I. Axenovich, A. Peters, S. Schreiber, H. 
E. Wichmann, H. Schunkert, N. Hastie, B. A. Oostra, S. H. Wild, T. Meitinger, 
U. Gyllensten, C. M. van Duijn, J. F. Wilson, A. Wright, G. Schmitz and H. 
Campbell, PLoS Genetics, 2009, 5, e1000672. 
174. J. T. Hannich, K. Umebayashi and H. Riezman, Cold Spring Harb. Perspect. 
Biol., 2011, 3, a004762. 
175. W. H. Wilson, D. C. Schroeder, M. J. Allen, M. T. G. Holden, J. Parkhill, B. G. 
Barrell, C. Churcher, N. Harnlin, K. Mungall, H. Norbertczak, M. A. Quail, C. 
Price, E. Rabbinowitsch, D. Walker, M. Craigon, D. Roy and P. Ghazal, 
Science, 2005, 309, 1090-1092. 
176. D. A. Brown and E. London, J. Biol. Chem., 2000, 275, 17221-17224. 
177. B. Ramstedt and J. P. Slotte, FEBS Lett., 2002, 531, 33-37. 
178. F. J. Alvarez, L. M. Douglas and J. B. Konopka, Eukaryot. Cell, 2007, 6, 755-
763. 
179. D. A. Brown and E. London, J. Memb. Biol., 1998, 164, 103-114. 
180. K. Simons and E. Ikonen, Nature, 1997, 387, 569-572. 
181. M. D. Ledesma, K. Simons and C. G. Dotti, Proc. Natl. Acad. Sci. USA, 1998, 
95, 3966-3971. 
182. D. A. Brown, Int. J. Med. Microbiol., 2002, 291, 433-437. 
183. D. W. Shi, X. D. Lv, Z. Zhang, X. F. Yang, Z. C. Zhou, L. Zhang and Y. Zhao, 
J. Biol. Chem., 2013, 288, 12605-12614. 
184. I. A. Prior and J. F. Hancock, J. Cell Sci., 2001, 114, 1603-1608. 
185. E. E. Prieschl and T. Baumruker, Immunol. Today, 2000, 21, 555-560. 
186. Y. Li, S. Li, X. Qin, W. Hou, H. Dong, L. Yao and L. Xiong, Cell Death Dis., 
2014, 5, e1245. 
187. A. Huwiler, T. Kolter, J. Pfeilschifter and K. Sandhoff, Biochim. Biophys. Acta, 
2000, 1485, 63-99. 
188. Y. A. Hannun and L. M. Obeid, Nat. Rev. Mol. Cell Biol., 2008, 9, 139-150. 
189. N. Bartke and Y. A. Hannun, J. Lipid Res., 2009, 50, S91-S96. 
190. R. Tidhar and A. H. Futerman, Biochim. Biophys. Acta Mol. Cell Res., 2013, 
1833, 2511-2518. 
191. M. F. Rutti, S. Richard, A. Penno, A. von Eckardstein and T. Hornemann, J. 
Lipid Res., 2009, 50, 1237-1244. 
192. R. Berkey, D. Bendigeri and S. Y. Xiao, Front. Plant Sci., 2012, 3, a22. 
193. L. A. Cowart and L. M. Obeid, Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 
2007, 1771, 421-431. 
194. Z. Li, T. K. Hailemariam, H. Zhou, Y. Li, D. C. Duckworth, D. A. Peake, Y. 
Zhang, M.-S. Kuo, G. Cao and X.-C. Jiang, Biochim. Biophys. Acta Mol. Cell 
Biol. Lipids, 2007, 1771, 1186-1194. 
195. M. Koval and R. E. Pagano, Biochim. Biophys. Acta, 1991, 1082, 113-125. 
196. P. W. Denny, H. Shams-Eldin, H. P. Price, D. F. Smith and R. T. Schwarz, J. 
Biol. Chem., 2006, 281, 28200-28209. 
197. R. L. Lester and R. C. Dickson, Adv. Lipid Res., 1993, 26, 253-274. 
198. N. H. Georgopapadakou, Exp. Opin. Invest. Drugs, 2000, 9, 1787-1796. 
199. K. Takesako, K. Ikai, F. Haruna, M. Endo, K. Shimanaka, E. Sono, T. 
Nakamura, I. Kato and H. Yamaguchi, J. Antibiot., 1991, 44, 919-924. 
200. S. A. Heidler and J. A. Radding, Antimicrob. Agents Chemother., 1995, 39, 
2765-2769. 
201. T. Hashida-Okado, A. Ogawa, M. Endo, R. Yasumoto, K. Takesako and I. Kato, 
Mol. Gen. Genet., 1996, 251, 236-244. 
  8. References 
167 
 
202. M. M. Nagiec, E. E. Nagiec, J. A. Baltisberger, G. B. Wells, R. L. Lester and R. 
C. Dickson, J. Biol. Chem., 1997, 272, 9809-9817. 
203. S. A. Heidler and J. A. Radding, Biochim. Biophys. Acta Mol. Basis Dis., 2000, 
1500, 147-152. 
204. D. W. Waggoner, J. Xu, I. Singh, R. Jasinska, Q. X. Zhang and D. N. Brindley, 
Biochim. Biophys. Acta Mol. Cell Biol. Lipids, 1999, 1439, 299-316. 
205. S. M. Mandala, R. A. Thornton, J. Milligan, M. Rosenbach, M. Garcia-Calvo, H. 
G. Bull, G. Harris, G. K. Abruzzo, A. M. Flattery, C. J. Gill, K. Bartizal, S. 
Dreikorn and M. B. Kurtz, J. Biol. Chem., 1998, 273, 14942-14949. 
206. S. M. Mandala, R. A. Thornton, M. Rosenbach, J. Milligan, M. Garcia-Calvo, H. 
G. Bull and M. B. Kurtz, J. Biol. Chem., 1997, 272, 32709-32714. 
207. S. A. Young, J. G. Mina, P. W. Denny and T. K. Smith, Biochem. Res. Int., 
2012, 2012, a248135. 
208. P. G. M. Wuts, L. J. Simons, B. P. Metzger, R. C. Sterling, J. L. Slightom and A. 
P. Elhammer, ACS Med. Chem. Lett., 2015, 6, 645-649. 
209. K. Huitema, J. van den Dikkenberg, J. Brouwers and J. C. M. Holthuis, EMBO 
J., 2004, 23, 33-44. 
210. V. Mandlik, S. Shinde, A. Chaudhary and S. Singh, Integr. Biol., 2012, 4, 1130-
1142. 
211. M. A. Goren, B. G. Fox and J. D. Bangs, Biochemistry, 2011, 50, 8853-8861. 
212. J. G. M. Mina, PhD Thesis, Durham University, 2010. 
213. Y. J. Sigal, M. I. McDermott and A. J. Morris, Biochem. J., 2005, 387, 281-293. 
214. J. G. Mina, J. A. Mosely, H. Z. Ali, P. W. Denny and P. G. Steel, Org. Biomol. 
Chem., 2011, 9, 1823-1830. 
215. F. G. Tafesse, P. Ternes and J. C. M. Holthuis, J. Biol. Chem., 2006, 281, 
29421-29425. 
216. A. K. Tanaka, V. B. Valero, H. K. Takahashi and A. H. Straus, J. Antimicrob. 
Chemother., 2007, 59, 487-492. 
217. J. G. Mina, S.-Y. Pan, N. K. Wansadhipathi, C. R. Bruce, H. Shams-Eldin, R. T. 
Schwarz, P. G. Steel and P. W. Denny, Mol. Biochem. Parasitol., 2009, 168, 16-
23. 
218. P. M. Adcock, P. Pastor, F. Medley, J. E. Patterson and T. V. Murphy, J. Infect. 
Dis., 1998, 178, 577-580. 
219. S. Buffet-Bataillon, P. Tattevin, M. Bonnaure-Mallet and A. Jolivet-Gougeon, 
Int. J. Antimicrob. Ag., 2012, 39, 381-389. 
220. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. 
Lindborg and A. L. Schacht, Nat. Rev. Drug Disc., 2010, 9, 203-214. 
221. J. Y. Chien, S. Friedrich, M. A. Heathman, D. P. de Alwis and V. Sinha, AAPS 
J., 2005, 7, e544-e559. 
222. M. Hay, D. W. Thomas, J. L. Craighead, C. Economides and J. Rosenthal, Nat. 
Biotechnol., 2014, 32, 40-51. 
223. J. Bibette, Proc. Natl. Acad. Sci. USA, 2012, 109, 649-650. 
224. G. Takatsky, Kiserl. Orvostud., 1950, 5, 393-397. 
225. J. W. Noah, Int. J. High Throughput Screen., 2010, 1, 141-149. 
226. BioTek, BioTek History Timeline, http://www.biotek.com/about/timeline.html, 
(accessed 13
th
 June, 2015). 
227. T. Ferragamo and M. J. Wildey, J. Biomol. Screen., 1999, 4, 175. 




 June, 2015). 
  8. References 
168 
 




 June, 2015). 




 June, 2015). 




 June, 2015). 
232. B. Lloyd, J. Burrin, P. Smythe and K. Alberti, Clin. Chem., 1978, 24, 1724-
1729. 
233. E. W. Holmes, J. Fareed and E. W. Bermes, Clin. Chem., 1981, 27, 816-818. 
234. P. Hodder, R. Mull, J. Cassaday, K. Berry and B. Strulovici, J. Biomol. Screen., 
2004, 9, 417-426. 
235. L. M. Mayr and D. Bojanic, Curr. Opin. Pharmacol., 2009, 9, 580-588. 
236. R. P. Hertzberg and A. J. Pope, Curr. Opin. Chem. Biol., 2000, 4, 445-451. 
237. J. A. Frearson and I. T. Collie, Drug Disc. Today, 2009, 14, 1150-1158. 
238. R. Brenk, A. Schipani, D. James, A. Krasowski, I. H. Gilbert, J. Frearson and P. 
G. Wyatt, ChemMedChem, 2008, 3, 435-444. 
239. J. A. Frearson, S. Brand, S. P. McElroy, L. A. T. Cleghorn, O. Smid, L. 
Stojanovski, H. P. Price, M. L. S. Guther, L. S. Torrie, D. A. Robinson, I. 
Hallyburton, C. P. Mpamhanga, J. A. Brannigan, A. J. Wilkinson, M. 
Hodgkinson, R. Hui, W. Qiu, O. G. Raimi, D. M. F. van Aalten, R. Brenk, I. H. 
Gilbert, K. D. Read, A. H. Fairlamb, M. A. J. Ferguson, D. F. Smith and P. G. 
Wyatt, Nature, 2010, 464, 728-732. 
240. J. Inglese, R. L. Johnson, A. Simeonov, M. Xia, W. Zheng, C. P. Austin and D. 
S. Auld, Nat. Chem. Biol., 2007, 3, 466-479. 
241. G. M. Keseru and G. M. Makara, Nat. Rev. Drug Disc., 2009, 8, 203-212. 
242. C. Delvecchio, J. Tiefenbach and H. M. Krause, Assay Drug Dev. Technol., 
2011, 9, 354-361. 
243. J. Lee, D. W. Jung, W. H. Kim, J. I. Um, S. H. Yim, W. K. Oh and D. R. 
Williams, ACS Chem. Biol., 2013, 8, 1803-1814. 
244. S. C. Baraban, M. T. Dinday and G. A. Hortopan, Nat. Comm., 2013, 4, a2410. 
245. J. L. Shepard, J. F. Amatruda, H. M. Stern, A. Subramanian, D. Finkelstein, J. 
Ziai, K. R. Finley, K. L. Pfaff, C. Hersey, Y. Zhou, B. Barut, M. Freedman, C. 
Lee, J. Spitsbergen, D. Neuberg, G. Weber, T. R. Golub, J. N. Glickman, J. L. 
Kutok, J. C. Aster and L. I. Zon, Proc. Natl. Acad. Sci. USA, 2005, 102, 13194-
13199. 
246. I. Gashaw, P. Ellinghaus, A. Sommer and K. Asadullah, Drug Disc. Today, 
2011, 16, 1037-1043. 
247. R. Macarron and R. P. Hertzberg, Mol. Biotechnol., 2011, 47, 270-285. 
248. J. A. Frearson, P. G. Wyatt, I. H. Gilbert and A. H. Fairlamb, Trends Parasitol., 
2007, 23, 589-595. 
249. A. C. Cheng, R. G. Coleman, K. T. Smyth, Q. Cao, P. Soulard, D. R. Caffrey, A. 
C. Salzberg and E. S. Huang, Nat. Biotechnol., 2007, 25, 71-75. 
250. P. Schmidtke and X. Barril, J. Med. Chem., 2010, 53, 5858-5867. 
251. T. Liu and R. B. Altman, CPT Pharmacometrics Syst. Pharmacol., 2014, 3, e93. 
252. T. A. Halgren, J. Chem. Inf. Model., 2009, 49, 377-389. 
253. I. Moraes, G. Evans, J. Sanchez-Weatherby, S. Newstead and P. D. S. Stewart, 
Biochim. Biophys. Acta Biomembranes, 2014, 1838, 78-87. 
254. W. Faulkner and L. Borella, J. Immunol., 1970, 105, 786-790. 
  8. References 
169 
 
255. N. Miyazaki, H. Ohkura, N. Kajimura and N. Okazaki, Human Cell, 1993, 6, 
114-120. 
256. K. Steger, J. Brady, W. L. Wang, M. Duskin, K. Donato and M. Peshwa, J. 
Biomol. Screen., 2015, 20, 545-551. 
257. J. H. Toney, A. Ogawa, M. Blair and Y. W. Park, Assay Drug Dev. Technol., 
2003, 1, 521-525. 
258. E. England, P. Newton, F. Neal, L. Kitching, C. Colley and C. J. Rossant, J. 
Biomol. Screen., 2015, 20, 536-544. 
259. C. Eggeling, L. Brand, D. Ullmann and S. Jager, Drug Disc. Today, 2003, 8, 
632-641. 
260. R. Sink, S. Gobec, S. Pecar and A. Zega, Curr. Med. Chem., 2010, 17, 4231-
4255. 
261. N. Thorne, D. S. Auld and J. Inglese, Curr. Opin. Chem. Biol., 2010, 14, 315-
324. 
262. A. Simeonov, A. Jadhav, C. J. Thomas, Y. H. Wang, R. L. Huang, N. T. 
Southall, P. Shinn, J. Smith, C. P. Austin, D. S. Auld and J. Inglese, J. Med. 
Chem., 2008, 51, 2363-2371. 
263. R. Hopkins, D. Esposito and W. Gillette, J. Struct. Biol., 2010, 172, 14-20. 
264. S. Schlegel, A. Hjelm, T. Baumgarten, D. Vikstrom and J. W. de Gier, Biochim. 
Biophys. Acta Mol. Cell Res., 2014, 1843, 1739-1749. 
265. S. L. McGovern, E. Caselli, N. Grigorieff and B. K. Shoichet, J. Med. Chem., 
2002, 45, 1712-1722. 
266. R. M. Reguera, E. Calvo-Alvarez, R. Alvarez-Velilla and R. Balana-Fouce, Int. 
J. Parasitol. Drugs Drug Resist., 2014, 4, 355-357. 
267. D. C. Swinney and J. Anthony, Nat. Rev. Drug Disc., 2011, 10, 507-519. 
268. K. S. Schroeder and B. D. Neagle, J. Biomol. Screen., 1996, 1, 75-80. 
269. P. Coward, S. D. H. Chan, H. G. Wada, G. M. Humphries and B. R. Conklin, 
Anal. Biochem., 1999, 270, 242-248. 
270. K. L. Whiteaker, S. M. Gopalakrishnan, D. Groebe, C. C. Shieh, U. Warrior, D. 
J. Burns, M. J. Coghlan, V. E. Scott and M. Gopalakrishnan, J. Biomol. Screen., 
2001, 6, 305-312. 
271. S. M. Gopalakrishnan, B. Mammen, M. Schmidt, B. Otterstaetter, W. Amberg, 
W. Wernet, J. L. Kofron, D. J. Burns and U. Warrior, J. Biomol. Screen., 2005, 
10, 46-55. 
272. J. Qian, C. H. Zhou, Z. Qian, F. J. Nan and Q. Z. Ye, Acta Pharmacol. Sin., 
2001, 22, 821-826. 
273. F. M. Balis, J. Natl. Cancer Inst., 2002, 94, 78-79. 
274. J. Drewe and S. X. Cai, Exp. Opin. Drug Disc., 2010, 5, 583-596. 
275. T. Spangenberg, J. N. Burrows, P. Kowalczyk, S. McDonald, T. N. C. Wells and 
P. Willis, PLoS One, 2013, 8, e62906. 
276. I. Pena, M. P. Manzano, J. Cantizani, A. Kessler, J. Alonso-Padilla, A. I. 
Bardera, E. Alvarez, G. Colmenarejo, I. Cotillo, I. Roquero, F. de Dios-Anton, 
V. Barroso, A. Rodriguez, D. W. Gray, M. Navarro, V. Kumar, A. Sherstnev, D. 
H. Drewry, J. R. Brown, J. M. Fiandor and J. J. Martin, Sci. Rep., 2015, 5, 
a8771. 
277. J. Oeljeklaus, F. Kaschani and M. Kaiser, Angew. Chem. Int. Ed., 2013, 52, 
1368-1370. 
278. W. Zheng, N. Thorne and J. C. McKew, Drug Disc. Today, 2013, 18, 1067-
1073. 
279. Y. Fang, A. G. Frutos and R. Verklereen, Comb. Chem. High Throughput 
Screen., 2008, 11, 357-369. 
  8. References 
170 
 
280. R. Zhang and X. Xie, Acta Pharmacol. Sin., 2012, 33, 372-384. 
281. A. E. Eakin, R. Nievesalicea, R. Tosadoacevedo, M. S. Chin, C. C. Wang and S. 
P. Craig, Antimicrob. Agents Chemother., 1995, 39, 620-625. 
282. W. J. Netzer and F. U. Hartl, Nature, 1997, 388, 343-349. 
283. P. W. Denny and P. G. Steel, J. Biomol. Screen., 2015, 20, 56-63. 
284. T. Munder and A. Hinnen, Appl. Microbiol. Biotechnol., 1999, 52, 311-320. 
285. R. D. Klein, M. A. Favreau, S. J. AlexanderBowman, S. C. Nulf, L. Vanover, C. 
A. Winterrowd, N. Yarlett, M. Martinez, J. S. Keithly, M. R. Zantello, E. M. 
Thomas and T. G. Geary, Exp. Parasitol., 1997, 87, 171-184. 
286. E. Bilsland, P. Pir, A. Gutteridge, A. Johns, R. D. King and S. G. Oliver, PLoS 
Negl. Trop. Dis., 2011, 5, e1320. 
287. E. Bilsland, A. Sparkes, K. Williams, H. J. Moss, M. de Clare, P. Pir, J. 
Rowland, W. Aubrey, R. Pateman, M. Young, M. Carrington, R. D. King and S. 
G. Oliver, Open Biol., 2013, 3, a120158. 
288. S. Kurtz, G. X. Luo, K. M. Hahnenberger, C. Brooks, O. Gecha, K. Ingalls, K. I. 
Numata and M. Krystal, Antimicrob. Agents Chemother., 1995, 39, 2204-2209. 
289. O. Middendorp, C. Ortler, U. Neumann, P. Paganetti, U. Luthi and A. Barberis, 
Biochim. Biophys. Acta, 2004, 1674, 29-39. 
290. J. L. Norcliffe, E. Alvarez-Ruiz, J. J. Martin-Plaza, P. G. Steel and P. W. Denny, 
Parasitology, 2014, 141, 8-16. 
291. M. Klumpp, A. Boettcher, D. Becker, G. Meder, J. Blank, L. Leder, M. Forstner, 
J. Ottl and L. M. Mayr, J. Biomol. Screen., 2006, 11, 617-633. 
292. L. M. Mayr and P. Fuerst, J. Biomol. Screen., 2008, 13, 443-448. 
293. O. Motabar, Z. Shi, E. Goldin, K. Liu, N. Southall, E. Sidransky, C. P. Austin, 
G. L. Griffiths and W. Zheng, Anal. Biochem., 2009, 390, 79-84. 
294. S. Isken, A. Derks, P. F. G. Wolffs and J. A. M. de Bont, Appl. Environ. 
Microbiol., 1999, 65, 2631-2635. 
295. I. Coma, L. Clark, E. Diez, G. Harper, J. Herranz, G. Hofmann, M. Lennon, N. 
Richmond, M. Valmaseda and R. Macarron, J. Biomol. Screen., 2009, 14, 66-76. 
296. C. B. Maddox, L. Rasmussen and E. L. White, J. Assoc. Lab. Autom., 2008, 13, 
168-173. 
297. Shayne, Cox and Gad, Development of Therapeutic Agents Handbook, Wiley, 
2011. 
298. D. J. Urban, W. Zheng, O. Goker-Alpan, A. Jadhav, M. E. LaMarca, J. Inglese, 
E. Sidransky and C. P. Austin, Comb. Chem. High Throughput Screen., 2008, 
11, 817-824. 
299. J. H. Zhang, T. D. Y. Chung and K. R. Oldenburg, J. Biomol. Screen., 1999, 4, 
67-73. 
300. M. S. Rogers, L. M. Cryan, K. A. Habeshian, L. Bazinet, T. P. Caldwell, P. C. 
Ackroyd and K. A. Christensen, PLoS One, 2012, 7, e39911. 
301. PerkinElmer, Scintillation Proximity Assay (SPA): Custom Assay Development 




 June, 2015). 
302. P. J. Brescia Jr. and P. Banks, Automation of a Generic Fluorescent 




 June, 2015). 
303. B. Neumann, M. Held, U. Liebel, H. Erfle, P. Rogers, R. Pepperkok and J. 
Ellenberg, Nat. Methods, 2006, 3, 385-390. 
  8. References 
171 
 
304. J. H. Zhang, T. D. Y. Chung and K. R. Oldenburg, J. Comb. Chem., 2000, 2, 
258-265. 
305. Z. Wu, D. Liu and Y. Sui, J. Biomol. Screen., 2008, 13, 159-167. 
306. C. Brideau, B. Gunter, B. Pikounis and A. Liaw, J. Biomol. Screen., 2003, 8, 
634-647. 
307. T. Y. Shun, J. S. Lazo, E. R. Sharlow and P. A. Johnston, J. Biomol. Screen., 
2011, 16, 1-14. 
308. F. Parham, C. Austin, N. Southall, R. Huang, R. Tice and C. Portier, J. Biomol. 
Screen., 2009, 14, 1216-1227. 
309. R. Hamid, Y. Rotshteyn, L. Rabadi, R. Parikh and P. Bullock, Toxicol. In Vitro, 
2004, 18, 703-710. 
310. W. M. Lee, New Engl. J. Med., 2003, 349, 474-485. 
311. B. K. Park, N. R. Kitteringham, J. L. Maggs, M. Pirmohamed and D. P. 
Williams, Annu. Rev. Pharmacol. Toxicol., 2005, 45, 177-202. 
312. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Adv. Drug Del. 
Rev., 1997, 23, 3-25. 
313. T. I. Oprea, A. M. Davis, S. J. Teague and P. D. Leeson, J. Chem. Inf. Comp. 
Sci., 2001, 41, 1308-1315. 
314. R. W. Spencer, Biotechnol. Bioeng., 1998, 61, 61-67. 
315. R. Macarron, Drug Disc. Today, 2006, 11, 277-279. 
316. J. Hert, J. J. Irwin, C. Laggner, M. J. Keiser and B. K. Shoichet, Nat. Chem. 
Biol., 2009, 5, 479-483. 
317. S. Fox, S. Farr-Jones, L. Sopchak, A. Boggs and J. Comley, J. Biomol. Screen., 
2004, 9, 354-358. 
318. A. M. Davis, D. J. Keeling, J. Steele, N. P. Tomkinson and A. C. Tinker, Curr. 
Top. Med. Chem., 2005, 5, 421-439. 
319. F. E. Koehn, Prog. Drug Res., 2008, 65, 210. 
320. J. G. Mina, J. A. Mosely, H. Z. Ali, H. Shams-Eldin, R. T. Schwarz, P. G. Steel 
and P. W. Denny, Int. J. Biochem. Cell Biol., 2010, 42, 1553-1561. 
321. J. G. Mina, Y. Okada, N. K. Wansadhipathi-Kannangara, S. Pratt, H. Shams-
Eldin, R. T. Schwarz, P. G. Steel, T. Fawcett and P. W. Denny, Plant Mol. Biol., 
2010, 73, 399-407. 
322. E. S. Sevova, M. A. Goren, K. J. Schwartz, F. F. Hsu, J. Turk, B. G. Fox and J. 
D. Bangs, J. Biol. Chem., 2010, 285, 20580-20587. 




 August, 2015). 
324. W. M. Wang, X. H. Yang, S. Tangchaiburana, R. Ndeh, J. E. Markham, Y. 
Tsegaye, T. M. Dunn, G. L. Wang, M. Bellizzi, J. F. Parsons, D. Morrissey, J. E. 
Bravo, D. V. Lynch and S. Y. Xiao, Plant Cell, 2008, 20, 3163-3179. 
325. J. D. Boeke, J. Trueheart, G. Natsoulis and G. R. Fink, Methods Enzymol., 1987, 
154, 164-175. 
326. N. Wansadhipathi-Kannangara, PhD Thesis, Durham University, 2011. 
327. K. Sato, Y. Noda and K. Yoda, Mol. Biol. Cell, 2009, 20, 4444-4457. 
328. P. A. Aeed, C. L. Young, M. M. Nagiec and A. P. Elhammer, Antimicrob. 
Agents Chemother., 2009, 53, 496-504. 
329. V. J. Cid, A. M. Alvarez, A. I. Santos, C. Nombela and M. Sanchez, Yeast, 
1994, 10, 747-756. 
330. F. del Rey, T. Santos, I. Garciaacha and C. Nombela, J. Bacteriol., 1979, 139, 
924-931. 
331. US Pat., US20060293354A1, 2006. 
  8. References 
172 
 
332. US Pat., US20100048639A1, 2010. 
333. P. G. Lord and A. E. Wheals, J. Cell Sci., 1981, 50, 361-376. 
334. T. Schneider-Poetsch, J. H. Ju, D. E. Eyler, Y. J. Dang, S. Bhat, W. C. Merrick, 
R. Green, B. Shen and J. O. Liu, Nature Chem. Biol., 2010, 6, 209-217. 
335. D. A. Abbott, R. M. Zelle, J. T. Pronk and A. J. A. van Maris, FEMS Yeast Res., 
2009, 9, 1123-1136. 
336. J. M. Alvarez-Pez, L. Ballesteros, E. Talavera and J. Yguerabide, J. Phys. Chem. 
A, 2001, 105, 6320-6332. 




 July, 2015). 
338. P. D. Leeson and B. Springthorpe, Nat. Rev. Drug Disc., 2007, 6, 881-890. 
339. D. Butina, J. Chem. Inf. Comput. Sci., 1999, 39, 747-750. 
340. B. Page, M. Page and C. Noel, Int. J. Oncol., 1993, 3, 473-476. 
341. M. De Rycker, I. Hallyburton, J. Thomas, L. Campbell, S. Wyllie, D. Joshi, S. 
Cameron, I. H. Gilbert, P. G. Wyatt, J. A. Frearson, A. H. Fairlamb and D. W. 
Gray, Antimicrob. Agents Chemother., 2013, 57, 2913-2922. 
342. R. H. Glew, A. K. Saha, S. Das and A. T. Remaley, Microbiol. Rev., 1988, 52, 
412-432. 
343. J. J. Castilla, M. Sanchezmoreno, C. Mesa and A. Osuna, Mol. Cell. Biochem., 
1995, 142, 89-97. 
344. W. W. Zhang, L. I. McCall and G. Matlashewski, Eukaryot. Cell, 2013, 12, 70-
77. 
345. D. P. Aden, A. Fogel, S. Plotkin, I. Damjanov and B. B. Knowles, Nature, 1979, 
282, 615-616. 
346. J. Sahi, S. Grepper and C. Smith, Curr. Drug Disc. Technol., 2010, 7, 188-198. 
347. L. Ballell, R. H. Bates, R. J. Young, D. Alvarez-Gomez, E. Alvarez-Ruiz, V. 
Barroso, D. Blanco, B. Crespo, J. Escribano, R. Gonzalez, S. Lozano, S. Huss, 
A. Santos-Villarejo, J. J. Martin-Plaza, A. Mendoza, M. J. Rebollo-Lopez, M. 
Remuinan-Blanco, J. L. Lavandera, E. Perez-Herran, F. J. Gamo-Benito, J. F. 
Garcia-Bustos, D. Barros, J. P. Castro and N. Cammack, ChemMedChem, 2013, 
8, 313-321. 
348. R. J. Young, D. V. S. Green, C. N. Luscombe and A. P. Hill, Drug Disc. Today, 
2011, 16, 822-830. 
349. A. Moreau, M. Le Vee, E. Jouan, Y. Parmentier and O. Fardel, Fundam. Clin. 
Pharmacol., 2011, 25, 743-752. 
350. S. Tsuchiya, M. Yamabe, Y. Yamaguchi, Y. Kobayashi, T. Konno and K. Tada, 
Int. J. Cancer, 1980, 26, 171-176. 
351. M. Castagna, Y. Takai, K. Kaibuchi, K. Sano, U. Kikkawa and Y. Nishizuka, J. 
Biol. Chem., 1982, 257, 7847-7851. 
352. W. Chanput, J. J. Mes and H. J. Wichers, Int. Immunopharmacol., 2014, 23, 37-
45. 
353. S. Patterson and S. Wyllie, Trends Parasitol., 2014, 30, 289-298. 
354. K. Zhang, M. Showalter, J. Revollo, F. F. Hsu, J. Turk and S. M. Beverley, 
EMBO J., 2003, 22, 6016-6026. 
355. P. W. Denny, D. Goulding, M. A. J. Ferguson and D. F. Smith, Mol. Microbiol., 
2004, 52, 313-327. 
356. E. P. A. Neve, E. Eliasson, M. A. Pronzato, E. Albano, U. Marinari and M. 
Ingelman-Sundberg, Arch. Biochem. Biophys., 1996, 333, 459-465. 
357. F. P. Guengerich, Chem. Res. Toxicol., 2008, 21, 70-83. 
  8. References 
173 
 
358. L. A. McLaughlin, M. J. I. Paine, C. A. Kemp, J. D. Marechal, J. U. Flanagan, 
C. J. Ward, M. J. Sutcliffe, G. C. K. Roberts and C. R. Wolf, J. Biol. Chem., 
2005, 280, 38617-38624. 
359. C. Bissantz, B. Kuhn and M. Stahl, J. Med. Chem., 2010, 53, 5061-5084. 
360. S. Gupta and Nishi, Ind. J. Med. Res., 2011, 133, 27-39. 
361. A. Nieto, G. Dominguez-Bernal, J. A. Orden, R. De La Fuente, N. Madrid-Elena 
and J. Carrion, Vet. Res., 2011, 42, e13. 
362. D. J. Bradley and J. Kirkley, Trans. R. Soc. Trop. Med. Hyg., 1972, 66, 527-528. 
363. S. Brand, N. R. Norcross, S. Thompson, J. R. Harrison, V. C. Smith, D. A. 
Robinson, L. S. Torrie, S. P. McElroy, I. Hallyburton, S. Norval, P. Scullion, L. 
Stojanovski, F. R. C. Simeons, D. van Aalten, J. A. Frearson, R. Brenk, A. H. 
Fairlamb, M. A. J. Ferguson, P. G. Wyatt, I. H. Gilbert and K. D. Read, J. Med. 
Chem., 2014, 57, 9855-9869. 
364. J. K. Singh, A. Solanki and V. S. Shirsath, J. Drug. Metab. Toxicol., 2012, 3, 
e1000126. 
365. P. R. O. de Montellano, Chem. Rev., 2010, 110, 932-948. 
366. L. M. Hjelmeland, L. Aronow and J. R. Trudell, Biochem. Biophys. Res. Comm., 
1977, 76, 541-549. 
367. V. Yardley and S. L. Croft, Int. J. Antimicrob. Agents, 2000, 13, 243-248. 
368. M. Wenzel, J. Label. Compd. Radiopharm., 1989, 27, 1143-1155. 
369. D. J. Kushner, A. Baker and T. G. Dunstall, Can. J. Phys. Pharmacol., 1999, 77, 
79-88. 
370. H. Z. Ali, C. R. Harding and P. W. Denny, Biochem. Res. Int., 2012, 2012, 
691363-691363. 
371. F. F. Fleming, L. H. Yao, P. C. Ravikumar, L. Funk and B. C. Shook, J. Med. 
Chem., 2010, 53, 7902-7917. 
372. S. L. Cockroft, J. Perkins, C. Zonta, H. Adams, S. E. Spey, C. M. R. Low, J. G. 
Vinter, K. R. Lawson, C. J. Urch and C. A. Hunter, Org. Biomol. Chem., 2007, 
5, 1062-1080. 
373. E. Couplan, R. S. Aiyar, R. Kucharczyk, A. Kabala, N. Ezkurdia, J. Gagneur, R. 
P. St Onge, B. Salin, F. Soubigou, M. Le Cann, L. M. Steinmetz, J.-P. di Rago 
and M. Blondel, Proc. Natl. Acad. Sci. USA, 2011, 108, 11989-11994. 
374. X. Q. Zhang, D. L. Smith, A. B. Merlin, S. Engemann, D. E. Russel, M. Roark, 
S. L. Washington, M. M. Maxwell, J. L. Marsh, L. M. Thompson, E. E. Wanker, 
A. B. Young, D. E. Housman, G. P. Bates, M. Y. Sherman and A. G. Kazantsev, 
Proc. Natl. Acad. Sci. USA, 2005, 102, 892-897. 
375. O. Ceyhan, K. Birsoy and C. S. Hoffman, Chem. Biol., 2012, 19, 155-163. 
376. Y. G. Shi, Cell, 2014, 159, 995-1014. 
377. Y. J. Jia, M. Kai, I. Wada, F. Sakane and H. Kanoh, FEBS Lett., 2003, 552, 240-
246. 
378. J. W. Newman, C. Morisseau, T. R. Harris and B. D. Hammock, Proc. Natl. 
Acad. Sci. USA, 2003, 100, 1558-1563. 
379. L. Oster, S. Tapani, Y. Xue and H. Kack, Drug Disc. Today, 2015, 20, 1104-
1111. 
380. J. M. Figueiredo, W. B. Dias, L. Mendonca-Previato, J. O. Previato and N. 
Heise, Biochem. J., 2005, 387, 519-529. 











Assay Optimisation Matrices 
 
1. Galactose Concentration 
  
  
Sugar Concentrations / % 
 
 
Raffinose: 1 1 1 1 1 1 1 1 1 0 0 0 
 
 
Galactose: 10 5 2.5 1.25 0.63 0.31 0.16 0.08 0 0 0 0 
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 The layout of the 96-well plates used to determine the optimal galactose 
concentration, with sugar concentration gradients across the columns and compound 
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2. FDGlu and Culture Concentration (12 by 12) 
 
  
FDGlu Concentration / µM 
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 The layout of the matrix to determine the optimal FDGlu and starting yeast culture 
concentrations, with an FDGlu gradient across the columns and a starting culture 
concentration down the rows.  The matrix was prepared in duplicate in low volume 384-
well plates, with the matrix in A1−L12 and repeated in A13−L24. 
 














 The layout of the second matrix to determine the optimal FDGlu and starting yeast 
culture concentrations, with an FDGlu gradient across the columns and a starting culture 
concentration down the rows.  The matrix was prepared in duplicate in low volume 384-
well plates, with the matrix in A1−E5 and repeated in A11−E15. 
  
FDGlu Concentration / µM 
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 The layout of the plates to determine which conditions produced the optimal Z′ for 
the HTS assay.  Each set of conditions was tested across 4 rows, resulting in 192 data 
points.  Each plate was tested using both fresh and frozen yeast culture.  AmB and 
cycloheximide were tested at 10 µM, as this was shown to be effective in the assay to 
determine optimal galactose concentration, whilst suloctidil and clemastine, which were 
previously untested against yeast, were tested at 100 µM. 
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L. major Growth Curves 
 
1. L. major FV1 24 hours 
 
 The fluorescence readout produced by various starting concentrations of L. major 
FV1 parasites following a 24 hour incubation period and 4 hours treatment with 
AlamarBlue
®
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2. L. major FV1 48 hours 
 
 The fluorescence readout produced by various starting concentrations of L. major 
FV1 parasites following a 48 hour incubation period and 4 hours treatment with 
AlamarBlue
®
.  Error bars show the standard error of the mean for an octuplet set of 
data. 
 
3. L. major FV1 72 hours 
 
 The fluorescence readout produced by various starting concentrations of L. major 
FV1 parasites following a 72 hour incubation period and 4 hours treatment with 
AlamarBlue
®
.  Error bars show the standard error of the mean for an octuplet set of 
data. 
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4. L. major lcb2Δ 72 hours 
 
 The fluorescence readout produced by various starting concentrations of L. major 
lcb2Δ parasites following a 72 hour incubation period and 8 hours treatment with 
AlamarBlue
®
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